 AGREEMENT AND PLAN OF MERGER        

 

       

  

  |  

  **Exhibit 2.1 
  
  EXECUTION COPY**

    
---|--- 
  

  

  

  



  

  AGREEMENT AND PLAN OF MERGER

  

by  and among

  

  BRACCO DIAGNOSTICS, INC.,

  

  EAGLE ACQUISITION SUB, INC.,

  

  E-Z-EM, INC.

  

  and

  

  BRACCO IMAGING S.P.A.

  

(for  the limited purposes specified herein)

  



  

  Dated as of October 30, 2007

  

  

    



  

  ** **  

  

       

**TABLE OF  CONTENTS**

    
--- 
      

  ** Page **

    
      

  ARTICLE 1 THE MERGER

     |  

  1

    
   

  

       



     |  

  SECTION 1.01

     |  

  The Merger

     |  

  1

    
---|---|---|--- 
   

  

       



     |  

  SECTION 1.02

     |  

  Closing

     |  

  2

    
---|---|---|--- 
   

  

       



     |  

  SECTION 1.03

     |  

  Effective Time

     |  

  2

    
---|---|---|--- 
   

  

       



     |  

  SECTION 1.04

     |  

  Effect of the Merger

     |  

  2

    
---|---|---|--- 
   

  

       



     |  

  SECTION 1.05

     |  

  Certificate of  Incorporation

     |  

  2

    
---|---|---|--- 
   

  

       



     |  

  SECTION 1.06

     |  

  Bylaws

     |  

  2

    
---|---|---|--- 
   

  

       



     |  

  SECTION 1.07

     |  

  Directors; Officers

     |  

  2

    
---|---|---|--- 
   

  

       



     |  

  SECTION 1.08

     |  

  Effect on Capital Stock

     |  

  2

    
---|---|---|--- 
   

  

       



     |  

  SECTION 1.09

     |  

  Treatment of Options.

     |  

  4

    
---|---|---|--- 
   

  

       

  ARTICLE 2 EXCHANGE OF  CERTIFICATES

     |  

  4

    
---|--- 
   

  

       



     |  

  SECTION 2.01

     |  

  Exchange Fund

     |  

  4

    
---|---|---|--- 
   

  

       



     |  

  SECTION 2.02

     |  

  Exchange Procedures

     |  

  5

    
---|---|---|--- 
   

  

       



     |  

  SECTION 2.03

     |  

  No Further Ownership Rights in Company  Common Stock

     |  

  5

    
---|---|---|--- 
   

  

       



     |  

  SECTION 2.04

     |  

  Termination of Exchange  Fund

     |  

  5

    
---|---|---|--- 
   

  

       



     |  

  SECTION 2.05

     |  

  No Liability

     |  

  6

    
---|---|---|--- 
   

  

       



     |  

  SECTION 2.06

     |  

  Lost Certificates

     |  

  6

    
---|---|---|--- 
   

  

       



     |  

  SECTION 2.07

     |  

  Withholding Rights

     |  

  6

    
---|---|---|--- 
   

  

       



     |  

  SECTION 2.08

     |  

  Further Assurances

     |  

  6

    
---|---|---|--- 
   

  

       



     |  

  SECTION 2.09

     |  

  Stock Transfer Books

     |  

  6

    
---|---|---|--- 
   

  

       

  ARTICLE 3 REPRESENTATIONS AND WARRANTIES  OF THE COMPANY

     |  

  7

    
---|--- 
   

  

       



     |  

  SECTION 3.01

     |  

  Corporate Organization

     |  

  7

    
---|---|---|--- 
   

  

       



     |  

  SECTION 3.02

     |  

  Qualification to Do  Business

     |  

  7

    
---|---|---|--- 
   

  

       



     |  

  SECTION 3.03

     |  

  No Conflict or Violation

     |  

  7

    
---|---|---|--- 
   

  

       



     |  

  SECTION 3.04

     |  

  Consents and Approvals

     |  

  8

    
---|---|---|--- 
   

  

       



     |  

  SECTION 3.05

     |  

  Authorization and Validity of  Agreement

     |  

  8

    
---|---|---|--- 
   

  

       



     |  

  SECTION 3.06

     |  

  Capitalization and Related  Matters

     |  

  9

    
---|---|---|--- 
   

  

       



     |  

  SECTION 3.07

     |  

  Subsidiaries

     |  

  10

    
---|---|---|--- 
   

  

       



     |  

  SECTION 3.08

     |  

  Company SEC Reports

     |  

  11

    
---|---|---|--- 
   

  

       



     |  

  SECTION 3.09

     |  

  Absence of Certain Changes or  Events

     |  

  11

    
---|---|---|--- 
   

  

       



     |  

  SECTION 3.10

     |  

  Tax Matters.

     |  

  12

    
---|---|---|--- 
   

  

       



     |  

  SECTION 3.11

     |  

  Absence of Undisclosed  Liabilities

     |  

  13

    
---|---|---|--- 
   

  

       



     |  

  SECTION 3.12

     |  

  Company Property

     |  

  14

    
---|---|---|--- 
   

  

       



     |  

  SECTION 3.13

     |  

  Assets of the Company and its  Subsidiaries

     |  

  14

    
---|---|---|--- 
   

  

       



     |  

  SECTION 3.14

     |  

  Intellectual Property

     |  

  14

    
---|---|---|--- 
   

  

       



     |  

  SECTION 3.15

     |  

  Licenses and Permits.

     |  

  16

    
---|---|---|--- 
   

  

       



     |  

  SECTION 3.16

     |  

  Regulatory Matters

     |  

  17

    
---|---|---|--- 
   

  

       



     |  

  SECTION 3.17

     |  

  Certifications; Product  Safety

     |  

  19

    
---|---|---|--- 
    
 

  

        

i

    
---     



    

       



     |  

  SECTION 3.18

     |  

  Compliance with Law; Sarbanes-Oxley  Act

     |  

  20

    
---|---|---|--- 
   

  

       



     |  

  SECTION 3.19

     |  

  Litigation

     |  

  20

    
---|---|---|--- 
   

  

       



     |  

  SECTION 3.20

     |  

  Material Contracts

     |  

  21

    
---|---|---|--- 
   

  

       



     |  

  SECTION 3.21

     |  

  Employee Plans

     |  

  23

    
---|---|---|--- 
   

  

       



     |  

  SECTION 3.22

     |  

  Insurance

     |  

  26

    
---|---|---|--- 
   

  

       



     |  

  SECTION 3.23

     |  

  Affiliate Transactions

     |  

  26

    
---|---|---|--- 
   

  

       



     |  

  SECTION 3.24

     |  

  GPOs, Distributors and Independent  Hospital Networks

     |  

  26

    
---|---|---|--- 
   

  

       



     |  

  SECTION 3.25

     |  

  Labor Matters

     |  

  26

    
---|---|---|--- 
   

  

       



     |  

  SECTION 3.26

     |  

  Environmental Matters

     |  

  27

    
---|---|---|--- 
   

  

       



     |  

  SECTION 3.27

     |  

  No Brokers

     |  

  28

    
---|---|---|--- 
   

  

       



     |  

  SECTION 3.28

     |  

  State Takeover Statutes

     |  

  28

    
---|---|---|--- 
   

  

       



     |  

  SECTION 3.29

     |  

  Opinion of Financial  Advisor

     |  

  28

    
---|---|---|--- 
   

  

       



     |  

  SECTION 3.30

     |  

  Information Supplied

     |  

  28

    
---|---|---|--- 
   

  

       



     |  

  SECTION 3.31

     |  

  Board Approval

     |  

  28

    
---|---|---|--- 
   

  

       



     |  

  SECTION 3.32

     |  

  Vote Required

     |  

  28

    
---|---|---|--- 
   

  

       



     |  

  SECTION 3.33

     |  

  Foreign Corrupt Practices and  International Trade Sanctions

     |  

  29

    
---|---|---|--- 
   

  

       



     |  

  SECTION 3.34

     |  

  Products

     |  

  29

    
---|---|---|--- 
   

  

       



     |  

  SECTION  3.35

     |  

  No  Other Representations or  Warranties

     |  

  29

    
---|---|---|--- 
   

  

        ARTICLE 4 REPRESENTATIONS AND WARRANTIES OF  PARENT AND MERGER
SUB    |   30  
---|--- 
          |      |      |     
      



     |  

  SECTION 4.01

     |  

  Organization

     |  

  30

    
   

  

       



     |  

  SECTION 4.02

     |  

  No Conflict or Violation

     |  

  30

    
---|---|---|--- 
   

  

       



     |  

  SECTION 4.03

     |  

  Consents and Approvals

     |  

  30

    
---|---|---|--- 
   

  

       



     |  

  SECTION 4.04

     |  

  Authorization and Validity of  Agreement

     |  

  30

    
---|---|---|--- 
   

  

       



     |  

  SECTION 4.05

     |  

  No Brokers

     |  

  31

    
---|---|---|--- 
   

  

       



     |  

  SECTION 4.06

     |  

  Information Supplied

     |  

  31

    
---|---|---|--- 
   

  

       



     |  

  SECTION 4.07

     |  

  Merger Sub

     |  

  31

    
---|---|---|--- 
   

  

       



     |  

  SECTION 4.08

     |  

  Sufficiency of Funds

     |  

  31

    
---|---|---|--- 
   

  

       



     |  

  SECTION 4.09

     |  

  Ownership of Shares

     |  

  31

    
---|---|---|--- 
   

  

       



     |  

  SECTION 4.10

     |  

  Vote/Approval Required

     |  

  31

    
---|---|---|--- 
   

  

       



     |  

  SECTION 4.11

     |  

  No Other Representations or  Warranties

     |  

  32

    
---|---|---|--- 
   

  

       

  ARTICLE 5 COVENANTS OF THE  COMPANY

     |  

  32

    
---|--- 
   

  

       



     |  

  SECTION 5.01

     |  

  Conduct of Business Before the Closing  Date.

     |  

  32

    
---|---|---|--- 
   

  

       



     |  

  SECTION 5.02

     |  

  Notice of Breach

     |  

  35

    
---|---|---|--- 
   

  

       



     |  

  SECTION 5.03

     |  

  FDA Correspondence

     |  

  35

    
---|---|---|--- 
   

  

       



     |  

  SECTION 5.04

     |  

  Section 409A

     |  

  35

    
---|---|---|--- 
   

  

       



     |  

  SECTION 5.05

     |  

  Exemption from Liability Under SECTION  16(b)

     |  

  35

    
---|---|---|--- 
   

  

       

  ARTICLE 6 COVENANTS OF PARENT AND MERGER  SUB

     |  

  35

    
---|--- 
   

  

       



     |  

  SECTION 6.01

     |  

  Employee Benefits.

     |  

  35

    
---|---|---|--- 
   

  

       



     |  

  SECTION 6.02

     |  

  Directors' and Officers'  Indemnification and Insurance

     |  

  36

    
---|---|---|--- 
    
 

  

        

ii
     

       

  ARTICLE 7 ADDITIONAL COVENANTS OF THE  PARTIES

     |  

  38

    
---|--- 
   

  

       



     |  

  SECTION 7.01

     |  

  Preparation of Proxy Statement, Company  Stockholders Meeting

     |  

  38

    
---|---|---|--- 
   

  

       



     |  

  SECTION 7.02

     |  

  Access to Information; Preparation of  December 31 Financial Statements; 
Confidentiality   ;    
        

     | 39  
---|---|---|--- 
   

  

       



     |  

  SECTION 7.03

     |  

  Commercially Reasonable  Efforts

     |  

  40

    
---|---|---|--- 
   

  

       



     |  

  SECTION 7.04

     |  

  Acquisition Proposal

     |  

  43

    
---|---|---|--- 
   

  

       



     |  

  SECTION 7.05

     |  

  Stockholder Litigation

     |  

  45

    
---|---|---|--- 
   

  

       



     |  

  SECTION 7.06

     |  

  Public Announcements

     |  

  45

    
---|---|---|--- 
   

  

       



     |  

  SECTION 7.07

     |  

  Tyco LitigationM

     |  

  46

    
---|---|---|--- 
   

  

       



     |  

  SECTION 7.08

     |  

  J.D. Edwards ERP Implementation  Project

     |  

  46

    
---|---|---|--- 
   

  

       



     |  

  SECTION 7.09

     |  

  Credit Facility

     |  

  46

    
---|---|---|--- 
   

  

       



     |  

  SECTION 7.10

     |  

  Cimbar Agreement

     |  

  46

    
---|---|---|--- 
   

  

       

  ARTICLE 8 CONDITIONS  PRECEDENT

     |  

  47

    
---|--- 
   

  

       



     |  

  SECTION 8.01

     |  

  Conditions to the Merger

     |  

  47

    
---|---|---|--- 
   

  

       



     |  

  SECTION 8.02

     |  

  Conditions to the Obligations of Parent  and Merger Sub

     |  

  48

    
---|---|---|--- 
   

  

       



     |  

  SECTION 8.03

     |  

  Conditions to the Obligations of the  Company

     |  

  49

    
---|---|---|--- 
   

  

       



     |  

  SECTION 8.04

     |  

  Frustration of Closing  Conditions

     |  

  49

    
---|---|---|--- 
   

  

       

  ARTICLE 9 TERMINATION

     |  

  49

    
---|--- 
   

  

       



     |  

  SECTION 9.01

     |  

  Termination

     |  

  49

    
---|---|---|--- 
   

  

       



     |  

  SECTION 9.02

     |  

  Effect of Termination

     |  

  51

    
---|---|---|--- 
   

  

       



     |  

  SECTION 9.03

     |  

  Fees and Expenses

     |  

  52

    
---|---|---|--- 
   

  

       



     |  

  SECTION 9.04

     |  

  Amendment

     |  

  53

    
---|---|---|--- 
   

  

       



     |  

  SECTION 9.05

     |  

  Extension; Waiver

     |  

  53

    
---|---|---|--- 
   

  

       

  ARTICLE 10 MISCELLANEOUS

     |  

  53

    
---|--- 
   

  

       



     |  

  SECTION 10.01

     |  

  Non-Survival of Representations,  Warranties and Agreements

     |  

  53

    
---|---|---|--- 
   

  

       



     |  

  SECTION 10.02

     |  

  Successors and Assigns

     |  

  53

    
---|---|---|--- 
   

  

       



     |  

  SECTION 10.03

     |  

  Governing Law; Jurisdiction;  Remedies

     |  

  53

    
---|---|---|--- 
   

  

       



     |  

  SECTION 10.04

     |  

  Severability;  Construction

     |  

  55

    
---|---|---|--- 
   

  

       



     |  

  SECTION 10.05

     |  

  Notices

     |  

  55

    
---|---|---|--- 
   

  

       



     |  

  SECTION 10.06

     |  

  Entire Agreement

     |  

  57

    
---|---|---|--- 
   

  

       



     |  

  SECTION 10.07

     |  

  Parties in Interest

     |  

  57

    
---|---|---|--- 
   

  

       



     |  

  SECTION 10.08

     |  

  _Section and Paragraph Headings_

     |  

  57

    
---|---|---|--- 
   

  

       



     |  

  SECTION 10.09

     |  

  Counterparts

     |  

  57

    
---|---|---|--- 
   

  

       



     |  

  SECTION 10.10

     |  

  Company Disclosure  Schedule

     |  

  57

    
---|---|---|--- 
   

  

       



     |  

  SECTION 10.11

     |  

  Bracco Imaging

     |  

  57

    
---|---|---|--- 
   

  

       



     |  

  SECTION 10.12

     |  

  Definitions

     |  

  58

    
---|---|---|--- 
   

  



  

        

iii

    
--- 
    
  

     



  

  AGREEMENT AND PLAN OF MERGER

  

  AGREEMENT AND PLAN OF MERGER, dated as of October 30, 2007 (this  "
_Agreement_ "), by and  among BRACCO DIAGNOSTICS, INC., a Delaware
corporation  (" _Parent_ "), EAGLE  ACQUISITION SUB, INC., a Delaware
corporation and a wholly owned Subsidiary of Parent  (" _Merger Sub_ "), E-Z-
EM,  INC., a Delaware corporation (the  " _Company_ "), and, for the 
limited purposes specified herein, Bracco Imaging S.p.A., a corporation
organized under  the laws of the Republic of Italy (" _Bracco  Imaging_ ").

  

  RECITALS

  

  WHEREAS, the respective Boards of Directors of Parent and the Company 
have each approved and declared advisable the merger of Merger Sub with and
into the  Company (the " _Merger_ "),  upon the terms and subject to the
conditions set forth in this Agreement, pursuant to  which each outstanding
share of common stock, par value $0.10 per share, of the Company  (" _Company
Common Stock_ ")  issued and outstanding immediately prior to the Effective
Time, other than shares to be  cancelled pursuant to Section 1.08(b) and,
except as provided in  Section 1.08(e), Appraisal Shares, will be converted
into the right to receive  $21.00 per share in cash, without interest (the "
_Merger  Consideration_ ");

  

  WHEREAS, concurrently with the execution and delivery of this Agreement, 
certain stockholders of the Company, who collectively ownapproximately 33.8%
of the  Company Common Stock outstanding on the date hereof(collectively,
the  " _Stockholders_ "), have  entered into an agreement with Parent and
the Company pursuant to which each  Stockholder has agreed to vote and give a
proxy with respect to the shares of Company  Common Stock beneficially owned
by such Stockholder in favor of this Agreement and the  transactions
contemplated hereby (including the Merger) and against any transaction or 
other action that would interfere with this Agreement or any of the
transactions  contemplated hereby (including the Merger) (the " _Voting 
Agreement_ "); and

  

  WHEREAS, Parent, Merger Sub and the Company desire to make certain 
representations, warranties, covenants and agreements in connection with the 
transactions contemplated hereby and also to prescribe various conditions to
the  transactions contemplated hereby.

  

  NOW, THEREFORE, in consideration of the foregoing and the respective 
representations, warranties, covenants and agreements set forth herein, and
intending  to be legally bound hereby, the parties hereto agree as follows:

  

  ARTICLE 1

  

THE  MERGER

  

  SECTION  1.01 _The  Merger_. Upon the terms and subject to the
conditions hereof,  and in accordance with the Delaware General Corporation
Law (the  " _DGCL_ "), at the  Effective Time, Merger Sub shall be merged
with and into the Company and the separate  existence of Merger Sub shall
thereupon cease by virtue of the Merger, and the Company,  as the surviving
corporation in the Merger (the  " _Surviving  Corporation_ "), shall by
virtue of the Merger continue  its existence under the Laws of the State of
Delaware.

  



    

       

  

     |  

  1

    
---|--- 
   

  



     

  SECTION  1.02   _Closing_. Unless this Agreement shall have  been
terminated pursuant to the provisions of Section 9.01, the closing of the
Merger  (the " _Closing_ ") will  take place on the third Business Day after
the satisfaction or waiver (subject to  applicable Law) of the conditions
(excluding conditions that, by their terms, cannot be  satisfied until the
Closing Date, but subject to the satisfaction or, where permitted,  waiver of
those conditions as of the Closing) set forth in Article 8, unless another 
time or date is agreed to in writing by the parties hereto (the date of the
Closing,  the " _Closing Date_ "). The  Closing shall be held at the offices
of Greenberg Traurig, LLP, The Met Life Building,  200 Park Avenue, New York,
New York, unless another place is agreed to in writing by  the parties
hereto.

  

  SECTION  1.03 _Effective  Time_. Upon the Closing, the parties
shall file with the  Secretary of State of the State of Delaware a
certificate of merger (the  " _Certificate of  Merger_ "). The Merger shall
become effective at such  time as the Certificate of Merger is duly filed
with and accepted by the Secretary of  State of the State of Delaware or at
such subsequent date and time as Parent and the  Company shall agree and as
shall be specified in the Certificate of Merger (the date  and time the
Merger becomes effective being the  " _Effective  Time_ ").

  

  SECTION  1.04 _Effect of the  Merger_. From and after the
Effective Time, the effect of the  Merger shall be as provided in the
applicable provisions of the DGCL. Without limiting  the generality of the
foregoing, and subject thereto, at the Effective Time, all of the 
properties, rights, privileges, powers and franchises of the Company and
Merger Sub  shall vest entirely in the Surviving Corporation, and all debts,
liabilities,  obligations, restrictions, disabilities and duties of each of
the Company and Merger  Sub shall become the debts, liabilities, obligations,
restrictions, disabilities and  duties of the Surviving Corporation.

  

  SECTION  1.05 _Certificate of  Incorporation_. At the Effective
Time, the certificate of  incorporation of the Company shall be amended to
read in its entirety as the  certificate of incorporation of Merger Sub as in
effect immediately prior to the  Effective Time, and, as so amended, shall be
the certificate of incorporation of the  Surviving Corporation after the
Effective Time, and thereafter may be amended as  provided therein or by
applicable Law.

  

  SECTION  1.06   _Bylaws_. The bylaws of Merger Sub as in  effect
at the Effective Time shall be the bylaws of the Surviving Corporation, and 
thereafter may be amended as provided therein or by applicable Law.

  

  SECTION  1.07 _Directors;  Officers_. The directors of Merger Sub
immediately prior to  the Effective Time shall be the directors of the
Surviving Corporation and, unless  otherwise directed by Parent in writing
prior to the Effective Time, the officers of  the Company immediately prior
to the Effective Time shall be the officers of the  Surviving Corporation, in
each case until their respective successors are duly elected  and qualified
or until their death, resignation or removal in accordance with the DGCL  and
the certificate of incorporation and bylaws of the Surviving  Corporation.

  

  SECTION  1.08 _Effect on  Capital Stock_. At the Effective Time,
by virtue of the Merger  and without any action on the part of Parent, Merger
Sub, the Company or the holders of  any of the following securities:

  



    

       

  

     |  

  2

    
---|--- 
   

  



     

  (a)   Each share of Company Common Stock issued and outstanding
immediately  prior to the Effective Time (other than shares to be cancelled
pursuant to  Section 1.08(b) and, except as provided in Section 1.08(e),
Appraisal Shares)  shall be converted into the right to receive the Merger
Consideration, without interest  and subject to any required Tax withholding.
At the Effective Time, all such shares of  Company Common Stock shall cease
to be outstanding and shall be canceled and retired  and shall cease to
exist, and each holder of a certificate which immediately prior to  the
Effective Time represented any such shares of Company Common Stock (a  "
_Certificate_ ") shall  thereafter cease to have any rights with respect to
such shares of Company Common  Stock, except the right to receive the Merger
Consideration, without interest and  subject to any required Tax withholding.

  

  (b)   Each share of Company Common Stock held in the treasury of
the Company  and each share of Company Common Stock owned by Merger Sub,
Parent or any direct or  indirect wholly-owned Subsidiary of Parent, Merger
Sub or the Company, in each case  immediately prior to the Effective Time,
shall be canceled without any conversion  thereof and no payment or
distribution shall be made with respect thereto.

  

  (c)   Each share of common stock, par value $0.01 per share, of
Merger Sub  issued and outstanding immediately prior to the Effective Time
shall be converted into  one share of common stock, par value $0.01 per
share, of the Surviving  Corporation.

  

  (d)   If prior to the Effective Time, the Company should split,
combine or  otherwise reclassify the Company Common Stock, or pay a stock
dividend or other stock  distribution in Company Common Stock, or otherwise
change the Company Common Stock into  any other securities, or make any other
such stock dividend or distribution in capital  stock of the Company in
respect of the Company Common Stock, then the Merger  Consideration will be
appropriately adjusted to reflect such split, combination,  dividend or other
distribution or change.

  

  (e)   Notwithstanding anything in this Agreement to the contrary,
shares (the  " _Appraisal Shares_ ") of  Company Common Stock issued and
outstanding immediately prior to the Effective Time  that are held by any
holder who has not voted in favor of the adoption of this  Agreement or
consented thereto and who has properly exercised appraisal pursuant to and 
in accordance with, and who has otherwise complied with, the provisions of
Section 262  of the DGCL (" _Section  262_ "), shall not be converted into
the right to receive  the Merger Consideration as provided in Section
1.08(a), but instead such holder shall  be entitled only to payment of the
appraised value of such Appraisal Shares in  accordance with the provisions
of Section 262 unless and until any such holder fails to  perfect or
effectively withdraws or loses his, her or its rights to appraisal and 
payment under the DGCL. At the Effective Time, the Appraisal Shares shall no
longer be  outstanding and shall automatically be canceled and shall cease to
exist, and each  holder of a certificate that immediately prior to the
Effective Time represented  Appraisal Shares shall cease to have any rights
with respect thereto, except the right  to receive the appraised value of
such shares in accordance with the provisions of  Section 262.
Notwithstanding the foregoing, if any such holder shall fail to perfect or 
otherwise shall waive, withdraw or lose the right to appraisal under Section
262 or a  court of competent jurisdiction shall determine that such holder is
not entitled to the  relief provided by Section 262, then the right of such
holder to be paid the appraised  value of such holder's Appraisal Shares
under Section 262 shall cease and such  Appraisal Shares shall be deemed to
have been converted at the Effective Time into, and  shall

  



    

       

  

     |  

  3

    
---|--- 
   

  



     

have  become, the right to receive the Merger Consideration as provided in
Section 1.08(a).  The Company shall serve prompt written notice to Parent of
any demands for appraisal of  any shares of Company Common Stock, withdrawals
of any such demands and any other  related instruments served pursuant to the
DGCL received by the Company, and Parent  shall have the right to participate
in and direct all negotiations and proceedings with  respect to such demands.
Unless required by a final and non-appealable order, decree,  ruling or
injunction of a court of competent jurisdiction, the Company shall not, 
without the prior written consent of Parent (which shall not be unreasonably
withheld  or delayed), make any payment with respect to, or settle or offer
to settle, any such  demands, or agree to do or commit to do any of the
foregoing.

  

       

  

     |  

  Section 1.09

     |  

  _Treatment of  Options_.

    
---|---|--- 
   

  

  (a)   Each option to purchase shares of Company Common Stock
(individually a  " _Company Option_ " and  collectively, the " _Company 
Options_ ") outstanding immediately prior to the  Effective Time pursuant to
any Company Option Plan or otherwise will at the Effective  Time be cancelled
and the holder of such Company Option will, in full settlement of  such
Company Option, receive from the Company an amount (without interest and
subject  to any required Tax withholding), if any, in cash equal to the
product of (i) the  excess, if any, of the Merger Consideration over the
exercise price per share of  Company Common Stock underlying such Company
Option multiplied by (ii) the number of  shares of Company Common Stock
subject to such Company Option, whether or not vested or  exercisable;
_provided_ that the  aggregate amount of such payment shall be rounded down
to the nearest whole cent. If  the applicable exercise price of any Company
Option equals or exceeds the Merger  Consideration, such Company Option shall
be cancelled without payment of additional  consideration, and all rights
with respect to such Company Option shall terminate as of  the Effective
Time. Parent shall pay, or shall cause the Surviving Corporation to pay,  the
amount of cash payable in respect of each Company Option as soon as
practicable  following the Effective Time (but in no event later than ten
(10) Business Days after  the Effective Time). The holders of Company Options
shall have no further rights in  respect of any Company Options from and
after the Effective Time.

  

  (b)   Prior to the Effective Time, the Company shall adopt such
resolutions  and take such other actions as are necessary in order to (i)
effectuate the actions  contemplated by this Section 1.09 or to otherwise
cancel the Company Options prior to  the Effective Time and (ii) terminate
each Company Plan, including providing notice to,  or obtaining the consent
of, each holder of a Company Option necessary or desirable to  effect the
provisions of this Section 1.09, in each case without paying any 
consideration or incurring any debts or obligations on behalf of the Company,
Parent or  the Surviving Corporation other than as contemplated by Section
1.09(a);  _provided_ that such resolutions and actions  shall expressly be
conditioned upon the consummation of the Merger and the other  transactions
contemplated hereby and shall be of no effect if this Agreement is 
terminated.

  

  ARTICLE 2

  

  EXCHANGE OF CERTIFICATES

  

  SECTION  2.01 _Exchange  Fund_. At or prior to the Effective Time,
Parent shall deposit  with a bank or trust company designated by Parent and
reasonably satisfactory to the  Company (the " _Exchange  Agent_ "), in
trust for the benefit of holders of shares  of Company Common Stock,

  



    

       

  4

    
--- 
   

  



     

for  exchange in accordance with Section 1.08, the cash to be paid pursuant
to this  Agreement in exchange for outstanding Company Common Stock. Any cash
deposited with the  Exchange Agent, and any interest or other distributions
thereon, shall hereinafter be  referred to as the " _Exchange  Fund_." The
Exchange Fund shall be invested by the  Exchange Agent, as directed by Parent
or the Surviving Corporation, only in obligations  of or guaranteed by the
United States of America or obligations of an agency of the  United States of
America which are backed by the full faith and credit of the United  States
of America, or in deposit accounts, certificates of deposit or banker's 
acceptances of, repurchase or reverse repurchase agreements with, or
Eurodollar time  deposits purchased from, commercial banks, each of which has
capital, surplus and  undivided profits aggregating more than $500 million
(based on the most recent  financial statements of the banks which are then
publicly available at the Securities  and Exchange Commission (the  " _SEC_
") or  otherwise); _provided_ that no such  investment or losses thereon
shall affect the Merger Consideration payable to former  stockholders of the
Company, and Parent shall promptly provide, or cause the Surviving 
Corporation to promptly provide, additional funds to the Exchange Agent for
the benefit  of the former holders of Company Common Stock in the amount of
any such  losses.

  

  SECTION  2.02 _Exchange  Procedures_. As promptly as practicable
after the Effective  Time, Parent shall cause the Exchange Agent to send to
each record holder of a  Certificate, (a) a letter of transmittal (which
shall specify that delivery shall be  effected, and risk of loss and title to
the Certificates shall pass, only upon delivery  of the Certificates to the
Exchange Agent and shall be in customary form and have such  other provisions
as Parent may reasonably specify) and (b) instructions for use in  effecting
the surrender of the Certificates in exchange for the payment of the Merger 
Consideration. As soon as reasonably practicable after the Effective Time,
each holder  of a Certificate, upon surrender of a Certificate to the
Exchange Agent together with  such letter of transmittal, duly executed, and
such other documents as may reasonably  be required by the Exchange Agent,
shall be entitled to receive in exchange therefor a  check in the amount
equal to the per share cash amount of the Merger Consideration  (after giving
effect to any required Tax withholdings), which such holder has the right  to
receive pursuant to Section 1.08. The Exchange Agent shall accept such
Certificates  upon compliance with such reasonable terms and conditions as
the Exchange Agent may  impose to effect an orderly exchange thereof in
accordance with normal exchange  practices. No interest will be paid or will
accrue on any cash payable upon due  surrender of the Certificates. In the
event of a transfer of ownership of Company  Common Stock that is not
registered in the transfer records of the Company, the Merger  Consideration
with respect to such Company Common Stock shall be paid to such a  transferee
only if the Certificate representing such shares of Company Common Stock is 
presented to the Exchange Agent, accompanied by all documents required to
evidence and  effect such transfer and to evidence that any applicable stock
transfer Taxes have been  paid.

  

  SECTION  2.03 _No Further  Ownership Rights in Company Common
Stock_. The Merger  Consideration paid upon conversion of shares of Company
Common Stock in accordance with  the terms of Article 1 and this Article 2
shall be deemed to have been paid in full  satisfaction of all rights
pertaining to the shares of Company Common Stock.

  

  SECTION  2.04 _Termination of  Exchange Fund_. Any portion of the
Exchange Fund that remains  undistributed to the holders of Certificates for
six (6) months after the Effective  Time shall be delivered to the Surviving
Corporation or otherwise on the instruction of  the

  



    

       

  

     |  

  5

    
---|--- 
   

  



     

  Surviving Corporation, and any holders of Certificates who have not 
theretofore complied with this Article 2 shall thereafter look only to the
Surviving  Corporation and Parent (subject to abandoned property, escheat or
other similar laws)  for the Merger Consideration with respect to the shares
of Company Common Stock  formerly represented thereby to which such holders
are entitled pursuant to Section  1.08.

  

  SECTION  2.05 _No  Liability_. None of Parent, Merger Sub, the
Company, the  Surviving Corporation or the Exchange Agent shall be liable to
any Person in respect of  any Merger Consideration from the Exchange Fund
delivered to a public official pursuant  to any applicable abandoned
property, escheat or similar Law.

  

  SECTION  2.06 _Lost  Certificates_. If any Certificate shall have
been lost, stolen  or destroyed, upon the making of an affidavit of that fact
by the Person claiming such  Certificate to be lost, stolen or destroyed and,
if required by the Surviving  Corporation, the posting by such Person of a
bond in such reasonable amount as the  Surviving Corporation may direct as
indemnity against any claim that may be made  against it with respect to such
Certificate or other documentation (including an  indemnity in customary
form) reasonably requested by Parent, the Exchange Agent will  deliver in
exchange for such lost, stolen or destroyed Certificate the applicable 
Merger Consideration with respect to the shares of Company Common Stock
formerly  represented thereby.

  

  SECTION  2.07 _Withholding  Rights_. Each of the Exchange Agent,
the Surviving Corporation  and Parent shall be entitled to deduct and
withhold from the consideration otherwise  payable pursuant to this Agreement
to any holder of shares of Company Common Stock and  any holder of Company
Options such amounts as it is required to deduct and withhold  with respect
to the making of such payment under the Internal Revenue Code of 1986, as 
amended (the " _Code_ "),  and the rules and regulations promulgated
thereunder  (" _Treasury  Regulations_ "), or any provision of state, local
or  foreign Tax Law. To the extent that amounts are so withheld by the
Surviving  Corporation or Parent, as the case may be, such withheld amounts
shall be treated for  all purposes of this Agreement as having been paid to
the holder of the shares of  Company Common Stock in respect of which such
deduction and withholding was made by the  Surviving Corporation or Parent,
as the case may be.

  

  SECTION  2.08 _Further  Assurances_. At and after the Effective
Time, the officers and  directors of the Surviving Corporation will be
authorized to execute and deliver, in  the name and on behalf of the Company
or Merger Sub, any deeds, bills of sale,  assignments or assurances and to
take and do, in the name and on behalf of the Company  or Merger Sub, any
other actions and things to vest, perfect or confirm of record or  otherwise
in the Surviving Corporation any and all right, title and interest in, to
and  under any of the rights, properties or assets acquired or to be acquired
by the  Surviving Corporation as a result of, or in connection with, the
Merger.

  

  SECTION  2.09 _Stock Transfer  Books_. At the close of business,
New York time, on the day  the Effective Time occurs, the stock transfer
books of the Company shall be closed and  there shall be no further
registration of transfers of shares of Company Common Stock  thereafter on
the records of the Company. From and after the Effective Time, the  holders
of Certificates shall cease to have any rights with respect to such shares
of  Company Common Stock formerly represented thereby, except as otherwise
provided herein  or by applicable Law. On or after the

  



    

       

  

     |  

  6

    
---|--- 
   

  



     

  Effective Time, any Certificates presented to the Exchange Agent or 
Parent for any reason shall be converted into the Merger Consideration with
respect to  the shares of Company Common Stock formerly represented thereby.

  

  ARTICLE 3

  

  REPRESENTATIONS AND WARRANTIES OF THE COMPANY

  

  Except as disclosed in (a) the Company Disclosure Schedule delivered by 
the Company to Parent prior to the execution of this Agreement (the  "
_Company Disclosure  Schedule_ ") (provided that (i) information disclosed
in  any section or subsection of the Company Disclosure Schedule shall be
deemed to qualify  all other sections and subsections of this Agreement to
which such information relates,  but only to the extent (x) such relationship
is reasonably apparent or (y) such  disclosure is cross-referenced in such
other section or subsection of the Company  Disclosure Schedule (or a
reference to any attachments to such cross-referenced section  or subsection)
and (ii) all information disclosed in any subsection of Section 3.20 of  the
Company Disclosure Schedule shall be deemed to qualify for all purposes all
other  subsections of Section 3.20 of the Company Disclosure Schedule) or (b)
any Company SEC  Report filed with the SEC on or after August 17, 2006 and
prior to the date of this  Agreement (to the extent such disclosure does not
constitute a "risk  factor" or forward-looking statement and such disclosure
is reasonably apparent  on its face to pertain to such section or subsection
of Article 3 below, and provided  that any statement in any such Company SEC
Report shall not be deemed disclosed for  purposes of this Article 3 to the
extent such statement has been modified or superseded  or is otherwise
inconsistent with the disclosure contained in any such subsequently  filed
Company SEC Report, in which case such statement, as so modified or
superseded,  shall be deemed to be disclosed for the purposes of this Article
III), the Company  hereby represents and warrants to Parent and Merger Sub as
follows:

  

  SECTION  3.01 _Corporate  Organization_. Each of the Company and
its Subsidiaries is  duly organized, validly existing and in good standing
under the laws of the  jurisdiction of its organization and has all requisite
corporate power to own its  properties and assets and to conduct its business
as now conducted. Copies of the  Company's Restated Certificate of
Incorporation and Amended and Restated By-laws,  together with all amendments
thereto to the date hereof (the  " _Company Organizational  Documents_ ")
and the organizational documents of each  Subsidiary of the Company as
currently in effect, with all amendments thereto to the  date hereof, have
been made available to Parent, and such copies are accurate and  complete as
of the date hereof.

  

  SECTION  3.02 _Qualification  to Do Business_. Each of the Company
and its Subsidiaries is  duly qualified to do business as a foreign
corporation and is in good standing in every  jurisdiction in which the
character of the properties owned or leased by it or the  nature of the
business conducted by it makes such qualification necessary, except where 
the failure to be so qualified or in good standing individually or in the
aggregate has  not had and would not reasonably be expected to have a Company
Material Adverse  Effect.

  

  SECTION  3.03 _No Conflict or  Violation_. The execution, delivery
and performance by the  Company of this Agreement does not and will not (a)
violate or conflict with any  provision of any Company Organizational
Documents or any of the organizational  documents of the Subsidiaries of the
Company as currently in effect, (b) assuming  compliance with the matters

  



    

       

  

     |  

  7

    
---|--- 
   

  



     

  referenced in Section 3.04 and receipt of the Company Stockholder 
Approval, violate any provision of applicable Law, or (c) other than as set
forth in  Section 3.03 of the Company Disclosure Schedule, violate or result
in a breach of  or constitute (with due notice or lapse of time or both) a
default under any note,  bond, mortgage, indenture, lease, license, contract
or other agreement, instrument or  obligation to which the Company or any of
its Subsidiaries is a party or to which any  of their respective properties
or assets is subject or result in the creation or  imposition of any Lien
(other than any Permitted Lien) upon any of the assets,  properties or rights
of either the Company or any of its Subsidiaries or result in or  give to
others any rights of cancellation, modification, amendment, acceleration, 
revocation or suspension of any of such note, bond, mortgage, indenture,
lease,  license, contract, agreement, instrument or obligation thereunder, or
of any Licenses  and Permits, except with respect to clauses (b) and (c), for
any violations, breaches,  defaults, conflicts or other occurrences that
individually or in the aggregate have not  had and would not reasonably be
expected to have a Company Material Adverse  Effect.

  

  SECTION  3.04 _Consents and  Approvals_. No consent, waiver,
authorization or approval of  any Governmental Entity, and no declaration or
notice to or filing or registration with  any Governmental Entity, is
required in connection with the execution and delivery of  this Agreement by
the Company or the performance by the Company or its Subsidiaries of  their
obligations hereunder, except for: (a) any antitrust, competition or other 
regulatory approvals and/or notifications required by or of any Governmental
Entity in  connection with the transactions contemplated by this Agreement,
including under (i)  the Hart-Scott-Rodino Antitrust Improvements Act of
1976, as amended (the  " _HSR Act_ "), (ii) the  German Act Against
Restraints of Competition, (iii) notice to the Committee on Foreign 
Investment in the United States  (" _CFIUS_ ") pursuant to  the provisions
of Section 721 of Title VII of the Defense Production Act of  1950, as
amended, and the regulations promulgated thereunder (the  " _Exon-Florio 
Provision_ "), (iv) notices to the Directorate of Defense  Trade Controls,
U.S. Department of State  (" _DDTC_ ") pursuant to  Section 122.4 of the
International Traffic in Arms Regulations (22 C.F.R. Parts  120-130) ("
_ITAR_ ") and  (v) the amendment of Establishment Registrations and Product
Listings under the United  States Food and Drug Administration's  (" _FDA_
") Establishment  Registration and Product Listing regulations, as set forth
in 21 C.F.R. Part 207 and  Part 807 (all approvals under this Section 3.04(a)
being the  " _Required Approvals_ ");  (b) applicable requirements of the
Securities Act of 1933, as amended, and the rules  and regulations
promulgated thereunder (the " _Securities  Act_ ") and of the Securities
Exchange Act of 1934, as  amended, and the rules and regulations promulgated
thereunder (the  " _Exchange Act_ ") and the  rules and regulations of
NASDAQ; (c) state securities, takeover and "blue  sky" laws; (d) the filing
of the Certificate of Merger with the Secretary of  State of the State of
Delaware; and (e) such other consents, waivers, authorizations, 
declarations, notices, filings and registrations the failure of which to be
obtained or  made individually or in the aggregate (i) has not had and would
not reasonably be  expected to have a Company Material Adverse Effect or (ii)
would not reasonably be  expected to prevent or materially delay the
consummation of the transactions  contemplated by this Agreement.

  

  SECTION  3.05 _Authorization  and Validity of Agreement_. The
Company has the necessary  corporate power and authority to execute, deliver
and perform its obligations under  this Agreement and to consummate the
transactions contemplated hereby. The execution  and delivery of this
Agreement by the Company and the performance by the Company of its 
obligations hereunder and the consummation of the transactions contemplated
hereby have  been

  



    

       

  

     |  

  8

    
---|--- 
   

  



     

duly  authorized by the Board of Directors of the Company (the  " _Company
Board_ ") and all  other necessary corporate action on the part of the
Company, other than the Company  Stockholder Approval and the actions
contemplated by Section 1.09(b), and, other than  the Company Stockholder
Approval and the actions contemplated by Section 1.09(b), no  other corporate
proceedings on the part of the Company are necessary to authorize this 
Agreement and the transactions contemplated hereby. This Agreement has been
duly and  validly executed and delivered by the Company and, assuming due
execution and delivery  by Parent and Merger Sub, shall constitute a legal,
valid and binding obligation of the  Company, enforceable against it in
accordance with its terms, subject to (a) the effect  of bankruptcy,
fraudulent conveyance, reorganization, moratorium and other similar Laws 
relating to or affecting the enforcement of creditors' rights generally, (b) 
general equitable principles (whether considered in a proceeding in equity or
at Law)  and (c) an implied covenant of good faith and fair dealing.

  

       

  

     |  

  SECTION 3.06

     |  

  _Capitalization and Related  Matters_.

    
---|---|--- 
   

  

  (a)   The authorized capital stock of the Company consists of
16,000,000  shares of Company Common Stock and 1,000,000 shares of preferred
stock, par value $.10  per share, of the Company (the " _Preferred  Stock_
"). At the close of business on October 26,  2007:

  

  (i)   10,976,549 shares of Company Common Stock are issued and
outstanding,  including no restricted shares of Company Common Stock,

  

       

  

     |  

  (ii)

     |  

  no shares of Preferred Stock are issued and  outstanding,

    
---|---|--- 
   

  

  (iii)   89,205 shares of Company Common Stock are held by the
Company as  treasury shares,

  

  (iv)   an aggregate of 1,974,994 shares of Company Common Stock
are reserved  and available for issuance pursuant to the Company's 2004 Stock
and Incentive  Award Plan, 1983 Stock Option Plan and 1984 Stock Option Plan
(the  " _Company Option Plans_ "),  and of such shares, 1,278,819 shares of
Company Common Stock are subject to issuance  pursuant to outstanding Company
Options and

  

  (v)   an aggregate of 104,395 shares of Company Common Stock are
reserved and  available for issuance pursuant to the Company's 1985 Employee
Stock Purchase  Plan (together with the Company Option Plans, the  "
_Company  Plans_ ").

  

Other  than the Company Plans and as set forth in Section 3.06(a) of the
Company Disclosure  Schedule, there is no plan or other Contract providing
for the grant of options,  securities or other rights exercisable or
exchangeable for or into shares of Company  Common Stock by the Company or
any of its Subsidiaries. No shares of Company Common  Stock are owned by any
Subsidiary of the Company. Section 3.06(a) of the Company  Disclosure
Schedule sets forth a true and complete list as of the date hereof, of all 
outstanding Company Options, the number of shares of Company Common Stock (or
other  capital stock) subject thereto, the grant dates, expiration dates,
exercise prices and  vesting schedules thereof, the names of the holders
thereof and whether or not each  holder is a current employee of the Company
or any of its Subsidiaries and whether or  not such Company Option is
intended to qualify as an "incentive stock  option" under Section 422 of the
Code.

  



    

       

  

     |  

  9

    
---|--- 
   

  



     

  (b)   On the date hereof, except for the Company Options and as
set forth in  Section 3.06(a) of the Company Disclosure Schedule, no shares
of capital stock of, or  other equity or voting interests in, the Company, or
any securities convertible into,  or exchangeable for, any such stock,
interests or securities, or any options, warrants,  shares of deferred stock,
restricted stock awards, restricted stock units, stock  appreciation or
depreciation rights, performance stock awards and performance stock  units,
dividend equivalent rights, "phantom" stock awards or other  agreements (to
which the Company or any of its Subsidiaries is a party) or calls or  rights
to acquire or receive any such stock, interests or securities, or other
rights  that are linked in any way to the value of the Company Common Stock
or the value of the  Company or any part thereof, were issued, reserved for
issuance or  outstanding.

  

  (c)   All outstanding shares of capital stock of the Company are,
and all  shares which are issuable pursuant to the Company Plans shall be,
when issued in  accordance with the terms thereof, duly authorized, validly
issued, fully paid and  non-assessable and not subject to or issued in
violation of any purchase option, call  or put option, right of first offer
or refusal, preemptive right, subscription right or  any similar right under
any provision of the DGCL, the Company Organizational Documents  or any
Contract to which the Company is a party or otherwise bound. Except as set
forth  in Section 3.06(a), there are no (i) bonds, debentures, notes or other
evidences of  indebtedness of the Company or any of its Subsidiaries and (ii)
securities or other  instruments or obligations of the Company or any of its
Subsidiaries, in each case, the  value of which is based upon or derived from
any capital stock of, or other equity or  voting interest in, the Company or
which has or which by its terms may have at any time  (whether actual or
contingent) the right to vote (or which is convertible into, or  exchangeable
or exercisable for, securities having the right to vote) on any matters on 
which holders of Company Common Stock may vote whether generally in the
election of  Company directors or in respect of any other matter for which
holders of Company Common  Stock are entitled to vote as a matter of Law or
pursuant to the Company Organizational  Documents. With respect to the
Company Options, (A) each Company Option intended to  qualify as an
"incentive stock option" under Section 422 of the Code so  qualifies, (B)
each grant of a Company Option was duly authorized no later than the  date on
which the grant of such Company Option was by its terms to be effective by
all  necessary corporate action, including, as applicable, approval by the
Company Board (or  a duly constituted and authorized committee thereof) and
any required stockholder  approval by the necessary number of votes or
written consents, and the award agreement  governing such grant (if any) was
duly executed and delivered by each party thereto,  (C) each such grant was
made in accordance with the terms of the Company Plans, the  Exchange Act and
all other applicable Laws and regulatory rules or requirements,  including
the rules of NASDAQ, (D) the per share exercise price of each Company Option 
was not less than the fair market value of a share of Company Common Stock on
the  applicable date of grant of such Company Option and (E) each such grant
was properly  accounted for in accordance with U.S. GAAP in the financial
statements (including the  related notes) of the Company and disclosed in the
Company SEC Reports in accordance  with the Exchange Act and all other
applicable Laws. The provisions of the Company  Option Plans and the grant
agreements governing the Company Options permit the Company  Options to be
treated in accordance with Section 1.09.

  

  SECTION  3.07   _Subsidiaries_. Except as set forth in  Section
3.07 of the Company Disclosure Schedule, each Subsidiary of the Company is 
listed on Exhibit 21 of the Company's

  



    

       

  

     |  

  10

    
---|--- 
   

  



     

Annual  Report on Form 10-K for the fiscal year ended June 2, 2007. Other
than those  Subsidiaries, neither the Company nor any of its Subsidiaries,
directly or indirectly,  owns, or holds any rights to acquire, any capital
stock or any other securities,  interests or investments in any other Person.

  

       

  

     |  

  SECTION 3.08

     |  

  _Company SEC  Reports_.

    
---|---|--- 
   

  

  (a)   Since June 3, 2004, the Company has filed or otherwise
transmitted each  registration statement, prospectus, definitive proxy
statement or information  statement, form, report, schedule and other
document (together with all amendments  thereof and supplements thereto)
required to be filed by the Company pursuant to the  Exchange Act or the
Securities Act, each as in effect as of the date of the respective  filing
(as such documents have since the time of their filing been amended or 
supplemented, the " _Company SEC  Reports_ "). As of their respective dates,
after giving  effect to any amendments or supplements thereto filed prior to
the date hereof, the  Company SEC Reports (i) complied in all material
respects with the applicable  requirements of the Exchange Act, the
Securities Act and the Sarbanes-Oxley Act of 2002  and any rules and
regulations promulgated thereunder (the  " _Sarbanes-Oxley Act_ "),  each as
in effect as of the date of the respective filing, and (ii) did not contain
any  untrue statement of a material fact or omit to state a material fact
required to be  stated therein or necessary in order to make the statements
therein, in light of the  circumstances under which they were made, not
misleading (other than to the extent such  statement or fact was provided to
the Company by, or on behalf of, Parent specifically  for inclusion in the
Proxy Statement). Each of the Company SEC Reports, if not yet  filed, when so
filed will comply in all material respects with the applicable  requirements
of the Exchange Act, the Securities Act and the Sarbanes-Oxley Act, each  as
in effect as of the date of the respective filing. As of the date of this
Agreement,  (i) there are no outstanding or unresolved comments in comment
letters received from  the SEC staff with respect to the Company SEC Reports
and (ii) to the Knowledge of the  Company, none of the Company SEC Reports is
the subject of ongoing review, comment or  investigation by the SEC. None of
the Subsidiaries of the Company are, or have been,  subject to the reporting
requirements of Section 13(a) or 15(d) of the Exchange  Act.

  

  (b)   The audited consolidated financial statements and unaudited
interim  consolidated financial statements (including, in each case, the
notes, if any, thereto)  included in the Company SEC Reports complied as to
form in all material respects with  the published rules and regulations of
the SEC with respect thereto, were prepared in  accordance with U.S. GAAP
applied on a consistent basis during the periods involved  (except as may be
indicated therein or in the notes thereto and except with respect to 
unaudited statements as permitted by Form 10-Q of the SEC) and fairly present
(subject,  in the case of the unaudited interim financial statements included
therein, to normal  year-end adjustments and the absence of complete
footnotes) the consolidated financial  position of the Company and its
consolidated Subsidiaries as of the respective dates  thereof and the
consolidated results of their operations and cash flows for the  respective
periods then ended.

  

  SECTION  3.09 _Absence of  Certain Changes or Events_. Except as
disclosed in Section  3.09 of the Company Disclosure Schedule, since June 3,
2007, (a) the Company and its  Subsidiaries have conducted their respective
businesses in all material respects in the  ordinary course of business
consistent with past practice, (b) there has not been any  Company Material

  



    

       

  

     |  

  11

    
---|--- 
   

  



     

  Adverse Effect and (c) none of the Company or any of its Subsidiaries  has
taken any action that if taken after the date of this Agreement, would have 
required the consent of Parent under Section 5.01.

  

  

  

       

  

     |  

  SECTION 3.10

     |  

  _Tax Matters_.

    
---|---|--- 
   

  (a) (i) The  Company and each of its Subsidiaries has filed when
due with the appropriate  governmental entities all Tax Returns it was
required by applicable Law to file; (ii)  all such Tax Returns are true,
correct and complete in all material respects; (iii) the  Company and each of
its Subsidiaries has timely paid all material Taxes (except for  Taxes which
are being contested in good faith by appropriate proceedings) due with 
respect to the taxable periods covered by such Tax Returns and all other
material Taxes  due and owing by the Company and its Subsidiaries (whether or
not shown on any tax  return); and (iv) any liability of the Company or any
of its Subsidiaries for Taxes not  yet due and payable, or which are being
contested in good faith, has been provided for  on the financial statements
of the Company in accordance with U.S. GAAP. 
  
  

  (b)   The Company has delivered or made available to Parent
correct and  complete copies of all federal, state, local and foreign Income
Tax Returns filed by  the Company or any of its Subsidiaries since May 31,
2002.

  

  (c)   There is no material action, suit, proceeding,
investigation, audit or  claim now pending with respect to the Company or any
of its Subsidiaries in respect of  any Tax, nor has any material claim for
additional Tax been asserted in writing by any  taxing authority since May
31, 2002. Since May 31, 2002, no claim has been made in  writing by any
taxing authority in a jurisdiction where the Company or any of its 
Subsidiaries has not filed a Tax Return that it is or may be subject to Tax by
such  jurisdiction.

  

  (d)   (i) There is no outstanding request for any extension of
time for the  Company or any of its Subsidiaries to pay any Taxes or file any
Tax Returns; (ii) there  has been no waiver or extension of any applicable
statute of limitations for the  assessment or collection of any Taxes of the
Company or any of its Subsidiaries that is  currently in force; and (iii)
neither the Company nor any of its Subsidiaries is a  party to or bound by
any Tax-sharing, Tax indemnity, Tax allocation, pre-filing, or  advance
pricing agreement or similar arrangements, whether written or unwritten, 
providing for the payment of Taxes, payment for Tax losses, entitlements to
refunds or  similar Tax matters.

  

  (e)   The Company and each of its Subsidiaries has withheld and
paid all  material Taxes required to be withheld in connection with any
amounts paid or owing to  any employee, creditor, independent contractor or
other third party.

  

  (f)   The Company has not been a United States real property
holding  corporation within the meaning of Section 897(c)(2) of the Code
during the applicable  period specified in Section 897(c)(1)(A)(ii) of the
Code.

  

  (g)   Neither the Company nor any of its Subsidiaries has elected
at any time  to be treated as an S corporation within the meaning of Sections
1361 or 1362 of the  Code or under any comparable state or local Tax
provision.

  



    

       

  

     |  

  12

    
---|--- 
   

  



     

  (h)   Except as set forth in Section 3.10 of the Company
Disclosure Schedule,  none of the Company nor any of its Subsidiaries shall
be required to include in a  taxable period ending after the Closing taxable
income attributable to income that  accrued in a prior taxable period as a
result of the installment method of accounting,  the completed contract
method of accounting, the long-term contract method of  accounting, the cash
method of accounting or Section 481 of the Code or comparable  provisions of
state or local Tax law, or for any other reason.

  

  (i)   Other than with respect to the Company's spin-off of
AngioDynamics  in 2004, neither the Company nor any of its Subsidiaries has
distributed stock of  another Person, or has had its stock distributed by
another Person, in a transaction  that was purported or intended to be
governed in whole or in part by Section 355 or  Section 361 of the Code.

  

  (j)   There is no material Lien, other than a Permitted Lien,
affecting any of  the assets, properties or rights of the Company and its
Subsidiaries that arose in  connection with any failure or alleged failure to
pay any Tax.

  

  (k)   Neither the Company nor any of its Subsidiaries (i) has
been a member of  an affiliated group (within the meaning of Code  1504(a))
filing a consolidated  federal income Tax Return (other than a group the
common parent of which is the  Company) or (ii) except as set forth in
Section 3.10 of the Company Disclosure  Schedule, has any liability for the
Taxes of any Person (other than any of the Company  and its Subsidiaries)
under Treasury Regulations  1.1502-6 (or any similar  provision of state,
local, or foreign law), as a transferee or successor, by contract,  or
otherwise.

  

  (l)   Neither the Company nor any of its Subsidiaries is or ever
has been a  partner for Tax purposes with respect to any joint venture,
partnership, or other  arrangement or contract which is treated as a
partnership for Tax purposes.

  

  (m)   Neither the Company nor any of its Subsidiaries has entered
into any  transaction identified as a "reportable transaction" or "listed 
transaction" for purposes of Code Section 6707A(c) or Treasury Regulations 
Sections 1.6011-4(b)(2) or 301.6111-2(b)(2).

  

  SECTION  3.11 _Absence of  Undisclosed Liabilities_. Neither the
Company nor any of its  Subsidiaries has any liability or obligation of any
nature (whether accrued, absolute,  contingent or otherwise), except for
liabilities and obligations that (i) are accrued  or reserved against in the
most recent financial statements included in the Company SEC  Reports filed
prior to the date hereof or are reflected in the notes thereto, (ii) were 
incurred in the ordinary course of business consistent with past practice
since the  date of such financial statements, (iii) are incurred as expressly
provided in this  Agreement, (iv) have been discharged or paid in full prior
to the date of this  Agreement in the ordinary course of business consistent
with past practice or (v)  individually or in the aggregate (A) have not had
and would not reasonably be expected  to have a Company Material Adverse
Effect, or (B) would not reasonably be expected to  prevent or materially
delay the consummation of any of the transactions contemplated by  this
Agreement.

  



    

       

  

     |  

  13

    
---|--- 
   

  



     

       

  

     |  

  SECTION 3.12

     |  

  _Company  Property_.

    
---|---|--- 
   

  

  (a)   Section 3.12(a) of the Company Disclosure Schedule contains
a true and  complete list of all real property owned by the Company and its
Subsidiaries (the  " _Owned Real Property_ ")  as of the date hereof. Except
for matters that individually or in the aggregate have  not had or would not
reasonably be expected to have a Company Material Adverse Effect,  the
Company and its Subsidiaries have good, marketable and valid fee title to all
of  the Owned Real Property free and clear of Liens other than Permitted
Liens.

  

  (b)   Except for matters that individually or in the aggregate
have not had  and would not reasonably be expected to have a Company Material
Adverse Effect, the  Company or a Subsidiary enjoys peaceful and undisturbed
possession of the Leased Real  Property pursuant to the Leases.

  

  (c)   Except for matters that individually or in the aggregate
have not had  and would not reasonably be expected to have a Company Material
Adverse Effect, none of  the Company Property is subject to any option,
lease, sublease, license or other  agreement granting to any Person any right
to the use, occupancy or enjoyment of such  property or any portion thereof
or to obtain title to all or any portion of such  property.

  

  (d)   Except for matters that individually or in the aggregate
have not had  and would not reasonably be expected to have a Company Material
Adverse Effect, all  equipment and machinery located in the Company's
manufacturing facility in  Quebec, Canada are in good operating condition and
repair and generally suitable in all  respects for the present and continued
use, operation and maintenance thereof as now  used, operated or maintained.

  

  SECTION  3.13 _Assets of the  Company and its Subsidiaries_. (a)
The Company or a Subsidiary  of the Company has good title, free and clear of
any Liens (other than Permitted  Liens), to, or a valid leasehold interest
under enforceable leases in, all material  furniture, fixtures, equipment,
operating supplies and other personal property  necessary to conduct the
business of the Company as conducted immediately prior to the  date of this
Agreement and (b) there are no material assets, properties, rights or 
interests of any kind or nature that the Company or any of its Subsidiaries
has been  using, holding or operating in their business prior to the Closing
that will not be  held or owned by each of the Company or its Subsidiaries
immediately following the  Closing.

  

       

  

     |  

  SECTION 3.14

     |  

  _Intellectual  Property_.

    
---|---|--- 
   

  

  (a)   Section 3.14(a) of the Company Disclosure Schedule sets
forth a complete  and current list of all issued patents and patent
applications, registered trademarks  and service marks, trademark and service
mark applications, domain names, and copyright  registrations and
applications that, in each case, are owned by or licensed to the  Company or
any of its Subsidiaries (" _Registered  Intellectual Property_ "). The
Company and its  Subsidiaries also own or license from third parties certain
works of authorship in  various media, trade names, confidential or
proprietary information, trade secrets or  know how rights, intellectual
property rights in computer programs or software  (including without
limitation source code and object code), confidential information,  database
rights, or other types of intellectual property or proprietary

  



    

       

  

     |  

  14

    
---|--- 
   

  



     

rights  that are material to the conduct of the business of the Company or
its Subsidiaries as  currently conducted (" _Material Unregistered
Intellectual  Property_ "). The Registered Intellectual Property and  the
Material Unregistered Intellectual Property are collectively referred to
herein as  " _Intellectual Property_ ".  The Intellectual Property
constitutes all intellectual property necessary to conduct of  the business
of the Company and its Subsidiaries as currently conducted. To the  Knowledge
of the Company and its Subsidiaries and except as would not be reasonably 
expected to have a Company Material Adverse Effect, the Intellectual Property
is valid,  subsisting, and enforceable. To the Knowledge of the Company and
its Subsidiaries as of  the Closing Date, except as set forth on Section 3.14
of the Company Disclosure  Schedule, no governmental or administrative agency
fees, office action responses,  maintenance filings, or other required
actions with respect to the Registered  Intellectual Property fall due within
30 days of the Closing Date.

  

  (b)   Except as set forth in Section 3.14(b) of the Company
Disclosure  Schedule or in Section 3.14(f) of the Company Disclosure
Schedule, the Company or one  of its applicable Subsidiaries is the sole
owner of all right, title, and interest in  and holds good title to the
Intellectual Property, free and clear of all Liens other  than Permitted
Liens, or holds a valid and enforceable license to use the Intellectual 
Property. Except as set forth in Section 3.14(b) of the Company Disclosure
Schedule or  in Section 3.14(f) of the Company Disclosure Schedule or Section
3.20 of the Company  Disclosure Schedule, the Company and its Subsidiaries
are not restricted from assigning  their rights in any Intellectual Property.

  

  (c)   Except as set forth in Section 3.14(c) of the Company
Disclosure  Schedule, to the Knowledge of the Company and except as would not
be reasonably  expected to have a Company Material Adverse Effect, no third
party (including any  current or former employee or consultant of the Company
or any of its Subsidiaries) is  infringing or has misappropriated any
Intellectual Property. Neither the Company nor  any of its Subsidiaries has
made any claim of any infringement or misappropriation by  any third party of
rights to any Intellectual Property, which claim is pending as of  the
Closing Date.

  

  (d)   Except as set forth in Section 3.14(d) of the Company
Disclosure  Schedule, to the Knowledge of the Company: (i) the conduct of the
business of the  Company and its Subsidiaries as conducted on the Closing
Date does not infringe or  misappropriate any intellectual property or
proprietary right of any third party; and  (ii) there are no claims pending
or, to the Knowledge of the Company, threatened  against the Company or any
of its Subsidiaries with regard to the rights of the Company  or any of its
Subsidiaries in any Intellectual Property. To the Knowledge of the  Company,
the Company and its Subsidiaries are in material compliance with all
relevant  agreements governing the use or exploitation of any Intellectual
Property.

  

  (e)   Except as set forth in Schedule 3.14(e) the consummation by
the Company  of the transactions contemplated by this Agreement will not (i)
alter, impair or result  in the termination of any Intellectual Property or
(ii) result in the creation of any  Lien (other than a Permitted Lien) with
respect to any of the Intellectual  Property.

  

  (f)   Section 3.14(f) of the Company Disclosure Schedule sets
forth, as of the  date hereof, a list of the written agreements under which
the Company or any of its  Subsidiaries is obligated to make payments to
third parties for use of any Intellectual  Property with respect to the
commercialization of any products that are, as of the date  hereof, being
sold, manufactured

  



    

       

  

     |  

  15

    
---|--- 
   

  



     

by or  under development by the Company or any of its Subsidiaries and for
which such payments  are in excess of $100,000 per year for any single
product.

  

  (g)   Except as set forth on Section 3.14(g) of the Company
Disclosure  Schedule or as, individually or in the aggregate, has not had and
would not reasonably  be expected to have a Company Material Adverse Effect,
all current officers, senior  directors, engineers, and research and
development (R and D) employees of the Company  or its Subsidiaries, and all
former officers, senior directors, engineers, and research  and development
(R and D) employees who left the employment of the Company or its  Subsidiaries
within the ten-year period prior to the Closing Date, and all contractors 
and consultants engaged by the Company or its Subsidiaries within the ten-year
period  prior to the Closing Date and involved in the creation of
Intellectual Property have  executed written agreements (i) requiring them to
maintain the confidentiality of such  Intellectual Property to the extent
that it consists of confidential information and/or  trade secrets and (ii)
assigning to the Company or its Subsidiaries, as applicable, all  right,
title and interest in and to any inventions and any other Intellectual
Property  created by such officers, senior directors, engineers, research and
development (R  and D) employees, contractors, or consultants in conjunction
with their work for or  on behalf of the Company within the ten-year period
prior to the Closing  Date.

  

  (h)   The Company and its Subsidiaries do not own, use, or
distribute any  software that incorporates or uses any "free software" or
"open  source software" in a manner that would require that the Company or
any of its  Subsidiaries : (i) disclose any source code to third parties; or
(ii) license to third  parties any source code for the purpose of making
derivative works thereof; or (iii)  make available any source code for
redistribution by any third party.

  

       

  

     |  

  SECTION 3.15

     |  

  _Licenses and  Permits_.

    
---|---|--- 
   

  

  (a)   Except as provided in Section 3.16 or for matters that
individually or  in the aggregate (x) have not had and would not reasonably
be expected to have a  Company Material Adverse Effect or (y) would not
reasonably be expected to prevent or  materially delay the consummation of
any of the transactions contemplated by this  Agreement, (i) the Company and
its Subsidiaries have, and are in compliance with, all  licenses, permits,
franchises, registrations, authorizations and approvals issued or  granted by
any Governmental Entity for the conduct of their respective businesses (the 
" _Licenses and Permits_ ")  and have taken all necessary action to maintain
such Licenses and Permits and (ii) the  Licenses and Permits are sufficient
and adequate to permit the continued lawful conduct  of the business of the
Company and its Subsidiaries, and none of the operations of the  Company or
its Subsidiaries are being conducted in a manner that violates any of the 
terms or conditions under which any License and Permit was granted.

  

  (b)   Except for matters that individually or in the aggregate
have not had  and would not reasonably be expected to have a Company Material
Adverse Effect, each  License and Permit is valid and in full force and
effect, and no petition, action,  investigation, notice of violation or
apparent liability, notice of forfeiture, order  to show cause, complaint, or
administrative or judicial proceeding seeking to revoke,  reconsider the
grant of, cancel, suspend, declare invalid or modify any of the Licenses  and
Permits is pending or, to the Knowledge of the Company, threatened before
any  Governmental Entity. As of the date hereof, no notices have

  



    

       

  

     |  

  16

    
---|--- 
   

  



     

been  received by, and, to the Knowledge of the Company, no claims have been
filed against,  the Company or its Subsidiaries alleging a failure to hold
any Licenses or  Permits.

  

       

  

     |  

  SECTION 3.16

     |  

  _Regulatory  Matters_.

    
---|---|--- 
   

  

  (a)   The Company and its Subsidiaries manufacture, market, test
and  distribute and, since June 3, 2004, have manufactured, marketed, tested
and distributed  their own products in compliance with the Federal Food,
Drug, and Cosmetic Act (the  " _FDCA_ ") and all  applicable rules and
regulations of the FDA or similar applicable Laws in any state or  foreign
jurisdiction, including, but not limited to, current "Good Manufacturing 
Practices," "Quality System Regulation," "Adverse Event  Reporting," "Medical
Device Reporting" and those Laws related to  investigational use of drugs and
medical devices, marketing medical devices and drugs,  and marketing
unapproved "grandfathered drugs," regulations regarding  labeling,
advertising and record-keeping, in compliance with the Company's and  its
Subsidiaries' quality control procedures in effect at the time of 
manufacture, where the failure to be in such compliance has, individually, or
in the  aggregate, had or would reasonably be expected to have a Company
Material Adverse  Effect. All of the products currently sold by the Company
and its Subsidiaries have  been approved or cleared for marketing by the FDA,
unless approval or clearance is not  required, as the case may be, and all
other applicable Governmental Entities performing  functions similar to those
performed by the FDA. Neither the Company nor any of its  Subsidiaries
promotes or, to the Knowledge of the Company, has promoted any  "off-label"
use for such products in violation of existing Law or current  regulatory
interpretations, or received any notice in writing from the FDA or any 
Governmental Entity performing functions similar to those performed by the FDA
alleging  such illegal promotion. Neither the Company nor any Subsidiary has
received any written  notice or other communication from the FDA, or any
other Governmental Entity, that has  not been fully and satisfactorily
responded to and resolved, questioning its  manufacturing, distribution or
reporting practices or threatening to revoke or curtail  any product
clearance or approval or otherwise alleging any violation of the FDCA, its 
regulations or Law applicable to any products of the Company or its
Subsidiaries.  Except as set forth in Section 3.16(a) of the Company
Disclosure Schedule, none of the  products of the Company or its Subsidiaries
has been recalled, withdrawn, suspended or  discontinued by the Company or
its Subsidiaries in the United States or outside the  United States, whether
voluntary or involuntary. As of the date hereof, to the  Knowledge of the
Company, there exists no basis for any action by it, the FDA or any  other
applicable Governmental Entity performing functions similar to those performed
by  the FDA to revoke, recall, suspend, cancel or withdraw any product, or
product  approval, clearance, registration, license or other authorization or
permit with  respect to any product of the Company or its Subsidiaries. All
United States and  international regulatory approvals or pre-market
notifications therefor are owned  either by and registered in the name of the
Company or one of its Subsidiaries, or in  the name of a licensed
distributor, and are in full force and effect.

  

  (b)   Neither the Company nor any of its Subsidiaries has failed
to file with  the FDA or any applicable Governmental Entity performing
functions similar to those  performed by the FDA any material required
filing, declaration, listing, registration,  report or submission; all such
filings, declarations, listings, registrations, reports  or submissions were
to the Knowledge of the Company in compliance with applicable Laws  when
filed, and no unresolved deficiencies have been asserted by any applicable 
regulatory authority with respect to any such filings,

  



    

       

  

     |  

  17

    
---|--- 
   

  



     

  declarations, listing, registrations, reports or submissions which, 
individually or in the aggregate, have had or could be reasonably expected to
have a  Company Material Adverse Effect.

  

  (c)   Any clinical, pre-clinical and other studies and tests
conducted by or  on behalf of or sponsored by the Company or its Subsidiaries
were and, if still  pending, are to the Knowledge of the Company being
conducted in accordance in all  material respects with "Good Clinical
Practices" and all United States and  foreign Laws, as applicable, including
the Laws of those States that address clinical  trials. As of the date
hereof, the Company has no Knowledge of other studies or tests  the results
of which contain any significant or material inconsistencies with the 
Company's or its Subsidiaries' studies or tests or otherwise call into 
question the safety or efficacy of the Company's or its Subsidiaries' 
products. Neither the Company nor any of its Subsidiaries has received any
written  notices or other correspondence from an institutional review board
or study site, the  FDA or any other applicable Governmental Entity
performing functions similar to those  performed by the FDA with respect to
any of these ongoing clinical or pre-clinical  studies or tests requiring the
termination, suspension or material modification of such  studies or tests.

  

  (d)   To the Knowledge of the Company, neither the Company, nor
any of its  Subsidiaries, nor any employee of the Company, nor any of its
Subsidiaries or any  Person retained by the Company or any of its
Subsidiaries, has made on behalf of the  Company or any of its Subsidiaries
any false statement or material omissions in any  application or other
submission relating to products governed by the Department of  Health and
Human Services or other Governmental Entity.

  

  (e)   To the Knowledge of the Company, all of the manufacturing
facilities and  operations of the Company and its Subsidiaries of finished
products sold in the United  States are in material compliance with
applicable FDA regulations, including current  Good Manufacturing Practices,
when applicable, and meet quality standards set by the  FDCA, except where
the failure to be in such compliance or to meet such standards has  not,
individually or in the aggregate, had and would not reasonably be expected to
have  a Company Material Adverse Effect.

  

  (f)   The products sold by the Company and its Subsidiaries in
the United  States are generally classified either as over-the-counter drugs
under 21 U.S.C.   353(b)(i), "grandfathered drugs" under 21 U.S.C. 
321(p)(1), or as  Class I and Class II Medical Devices (as defined in 21
U.S.C.  360c(a)(1)(A) and  (B) and the applicable rules thereunder). The
Company and its Subsidiaries, and the  products sold by the Company and its
Subsidiaries, are in compliance in all material  respects with all current
and otherwise applicable Laws administered or issued by the  FDA and any
other applicable Governmental Entity performing functions similar to those 
performed by the FDA, except where the failure to be in such compliance has
not,  individually or in the aggregate, had and would not reasonably be
expected to have a  Company Material Adverse Effect.

  

  (g)   The Company has made available to Parent all material
complaints  maintained by the Company and its Subsidiaries (as required by 21
C.F.R. Parts 211 and  820) and all Product Adverse Event Reports or Medical
Device Reports received or  compiled by the Company and its Subsidiaries
since June 3, 2004. To the Knowledge of  the Company, all such

  



    

       

  

     |  

  18

    
---|--- 
   

  



     

  complaints that it was required to report to the FDA or comparable 
Governmental Entity it reported as required by Law.

  

  (h)   Except as noted in Schedule 3.16(h), to the Knowledge of
the Company  neither the Company nor any of its Subsidiaries has committed
any act, made any  statement or failed to make any statement that would
violate the FDA's policy  with respect to "Fraud, Untrue Statements of
Material Facts, Bribery, and Illegal  Gratuities" set forth in 56 Fed. Reg.
46191 (September 10, 1991) or any similar  laws, rules or regulations,
whether under the jurisdiction of the FDA or any  Governmental Entity, and
any amendments thereto. Neither the Company nor any of its  Subsidiaries, nor
to the Knowledge of the Company, any officer, employee, or third  party
vendors of any of the Company or its Subsidiaries, has been convicted of any 
crime or engaged in any conduct that would reasonably be expected to result
in  (i) debarment under 21 U.S.C.  335a or any similar state or foreign law
or  regulation or (ii) exclusion under 42 U.S.C.  1320a-7 or any similar
state  or foreign law or regulation.

  

  (i)   To the Knowledge of the Company, neither the Company nor
any of its  Subsidiaries is being investigated by the Office of Inspector
General of the Department  of Health and Human Services with respect to any
matter arising under titles XI, XVIII,  or XIX of the Social Security Act, or
the implementing regulations. Neither the Company  nor any of its
Subsidiaries (i) has been excluded from participating in any federal  health
care program, (ii) has paid a civil money penalty under Title XI of the
Social  Security Act, or (iii) employs any individual who has been excluded
from participating  in any federal health care program.

  

       

  

     |  

  SECTION 3.17

     |  

  _Certifications; Product  Safety_.

    
---|---|--- 
   

  

  (a)   All operations of the Company and its Subsidiaries have
achieved and  substantially maintained all required ISO (International
Organization for  Standardization) and quality certifications and are
compliant, in all material  respects, with the applicable FDA Good
Manufacturing Practice and Quality System  Regulations. There are no Actions
pending or, to the Knowledge of the Company,  threatened in writing, to
audit, repeal, fail to renew or challenge any such  certification. Each
product distributed, sold, or leased, or service rendered, by the  Company
and its Subsidiaries complies in all respects with all product safety
standards  of each applicable product safety Governmental Entity having
jurisdiction over the  Company, except where the failure to so comply has
not, individually or in the  aggregate, had and would not reasonably be
expected to have a Company Material Adverse  Effect. The Company and its
Subsidiaries, or an agent of the Company or its  Subsidiaries, manufactures
each product of the Company and its Subsidiaries in  compliance with each
device master record (as such terms are defined in the FDA Good 
Manufacturing Practice and Quality System Regulations) maintained by the
Company and  its Subsidiaries, or an agent of the Company or its
Subsidiaries, for each product of  the Company and its Subsidiaries, except
when the failure to be in such compliance has  not, individually or in the
aggregate, had and would not reasonably be expected to have  a Company
Material Adverse Effect.

  

  (b)   As of the date hereof, no unresolved product liability
claims remain  pending related to the Company or its Subsidiaries or any of
the Company's or its  Subsidiaries' products.

  



    

       

  

     |  

  19

    
---|--- 
   

  



     

       

  

     |  

  SECTION 3.18

     |  

  _Compliance with Law; Sarbanes-Oxley  Act_.

    
---|---|--- 
   

  

  (a)   Each of the Company and its Subsidiaries is in compliance
with all  applicable Laws, including compliance with the listing and
governance rules and  regulations of NASDAQ, except where such noncompliance
individually or in the aggregate  (x) has not had and would not reasonably be
expected to have a Company Material Adverse  Effect or (y) would not
reasonably be expected to prevent or materially delay the  consummation of
any of the transactions contemplated by this Agreement or the Voting 
Agreement. This Section 3.18 shall not apply to the Laws that are expressly
the subject  of Sections 3.08, 3.10, 3.16, 3.17, 3.21, 3.25, 3.26 and 3.33.

  

  (b)   Except as permitted by the Exchange Act, including Sections
13(k)(2) and  (3) or rules of the SEC, since the enactment of the Sarbanes-
Oxley Act, neither the  Company nor any of its Affiliates has made, arranged
or modified (in any material way)  any extension of credit in the form of a
personal loan to any executive officer or  director of the Company.

  

  (c)   The Company maintains (i) disclosure controls and
procedures (as defined  in Rule 13a-15 or 15d-15, as applicable, under the
Exchange Act) designed to ensure  that information required to be disclosed
by the Company is recorded and reported on a  timely basis to the individuals
responsible for the preparation of the Company's  filings with the SEC and
other public disclosure documents and (ii) a system of  internal control over
financial reporting (as defined in Rule 13a-15 or 15d-15, as  applicable,
under the Exchange Act) designed to provide reasonable assurance regarding 
the reliability of financial reporting and the preparation of financial
statements for  external purposes in accordance with U.S. GAAP which includes
policies and procedures  that (i) pertain to the maintenance of records that
in reasonable detail accurately and  fairly reflect the transactions and
dispositions of the asset of the Company, (ii)  provide reasonable assurance
that transactions are recorded as necessary to permit  preparation of
financial statements in accordance with U.S. GAAP, and that receipts and 
expenditures of the Company are being made only in accordance with
authorizations of  management or the directors of the Company, and (iii)
provide reasonable assurance  regarding prevention or timely detection of
unauthorized acquisition, use or  disposition of the Company's assets that
could have a material effect on its  financial statements. The Company has
disclosed, based on the most recent evaluation of  its chief executive
officer and its chief financial officer prior to the date hereof,  to the
Company's auditors and the audit committee of the Company Board (x) any 
significant deficiencies in the design or operation of its internal controls
over  financial reporting that are reasonably likely to adversely affect the
Company's  ability to record, process, summarize and report financial
information (and has  identified for the Company's auditors and audit
committee of the Company Board  any material weaknesses in internal control
over financial reporting) and (y) any  fraud, whether or not material, that
involves management or other employees who have a  significant role in the
Company's internal control over financial  reporting.

  

  SECTION  3.19   _Litigation_. Other than the action  entitled
_Tyco Healthcare Group LP, Mallinckrodt Inc. and  Liebel-Flarsheim Company
vs. E-Z-EM, Inc._ Case no.  2-07CV-262, as amended through the date hereof,
(the  " _Tyco Litigation_ ") or as  set forth in Section 3.19 of the Company
Disclosure Schedule, there is no material  litigation, claim, action, suit,
arbitration, mediation, subpoena, investigation or  other proceeding
administrative, regulatory, judicial or other by or before a  Governmental
Entity or Person acting in a dispute resolution capacity (each,

  



    

       

  

     |  

  20

    
---|--- 
   

  



     

an  " _Action_ ") that is  pending or, to the Knowledge of the Company,
threatened, against, or brought by, any of  the Company or its Subsidiaries
or any of their officers or directors involving or  relating to the Company
or its Subsidiaries, the assets, properties or rights of any of  the Company
and its Subsidiaries or the transactions contemplated by this Agreement or 
the Voting Agreement. There is no Order of any Governmental Entity or before
any  arbitrator of any nature outstanding, or to the Knowledge of the
Company, threatened,  against either the Company or its Subsidiaries that
individually or in the aggregate  have had or would reasonably be expected to
have a Company Material Adverse  Effect.

  

       

  

     |  

  SECTION 3.20

     |  

  _Material  Contracts_.

    
---|---|--- 
   

  

  (a)   Section 3.20 of the Company Disclosure Schedule sets forth
a complete  and correct list of all Contracts as of the date hereof.

  

  (b)   Except for matters that individually or in the aggregate
(x) have not  had and would not reasonably be expected to have a Company
Material Adverse Effect or  (y) would not reasonably be expected to prevent
or materially delay the consummation of  any of the transactions contemplated
by this Agreement or the Voting Agreement, each  Contract is in full force
and effect, valid, binding and enforceable against the  Company or its
Subsidiaries and, to the Knowledge of the Company, against the other  parties
thereto in accordance with its terms, subject to (i) the effect of
bankruptcy,  fraudulent conveyance, reorganization, moratorium and other
similar laws relating to or  affecting the enforcement of creditors' rights
generally, (ii) general equitable  principles (whether considered in a
proceeding in equity or at law) and (iii) an  implied covenant of good faith
and fair dealing. Each of the Company and its  Subsidiaries has performed all
obligations required to be performed by it to date  under, and is not in
default or delinquent in performance, status or any other respect  (claimed
or actual) in connection with, any Contract, and, to the Knowledge of the 
Company, no event has occurred which, with due notice or lapse of time or
both, would  constitute such a default, except for matters that individually
or in the aggregate (r)  have not had and would not reasonably be expected to
have a Company Material Adverse  Effect or (s) would not reasonably be
expected to prevent or materially delay the  consummation of any of the
transactions contemplated by this Agreement or the Voting  Agreement. Except
for matters that individually or in the aggregate (I) have not had  and would
not reasonably be expected to have a Company Material Adverse Effect or (II) 
would not reasonably be expected to prevent or materially delay the
consummation of any  of the transactions contemplated by this Agreement or
the Voting Agreement, the Company  has sent no notices of default under any
Contract, which default remains uncured, and  to the Knowledge of the
Company, no other party to any Contract is in material default  in respect
thereof, and, to the Knowledge of the Company, no event has occurred which, 
with due notice or lapse of time or both, would constitute such a default. The
Company  has made available to Parent or its representatives true and
complete originals or  copies of all the Contracts.

  

  (c)   A  " _Contract_ " means any  binding agreement, contract
or commitment to which either the Company or any of its  Subsidiaries is a
party or by which it or any of its assets are bound  constituting:

  

  (i)   an agreement that would be required to be filed by the
Company as a  "material agreement" pursuant to Item 601(b)(10) of Regulation
S-K under  the Securities

  

  

    

       

  

     |  

  21

    
---|--- 
   

  



    

  

  Act or disclosed by the Company on a Current Report on Form 8-K or that 
if terminated or subject to a default by any party thereto individually or in
the  aggregate would reasonably be expected to have a Company Material
Adverse  Effect;

  

  (ii)   an agreement (A) with a customer of the Company or any of
its  Subsidiaries pursuant to which the Company or any of its Subsidiaries
has sold or will  sell goods and/or services and has derived, or expects to
derive, revenue of at least  $500,000 in any twelve (12) month period, or (B)
with any customer that contains  "most-favored nation," pursuant to which the
Company or any of its  Subsidiaries has sold or will sell goods and/or
services and derived, or expects to  derive, revenue of at least $500,000 in
any twelve (12) month period;

  

  (iii)   an agreement with a licensor, supplier or other vendor of
the Company or  any of its Subsidiaries pursuant to which the Company and its
Subsidiaries has paid or  is expected to pay at least $500,000 to such
licensor, supplier or other vendor in any  twelve (12) month period;

  

  (iv)   a mortgage, indenture, security agreement, guaranty, pledge
and other  agreement or instrument relating to the borrowing of money or
extension of credit  (other than accounts receivable or accounts payable in
the ordinary course of business  and consistent with past practice), in each
case having an aggregate principal amount  of at least $500,000;

  

  (v)   a written employment, change of control, retention or
severance  agreement or any consulting agreement pursuant to which the
Company has paid or is  expected to pay at least $100,000 in any twelve (12)
month period, or a collective  bargaining agreement or other material
agreement with any association representing  employees (other than customary
employment agreements entered into in the ordinary  course of business with
employees located in Europe);

  

  (vi)   any agreement with a group purchasing organization  ("
_GPO_ "), distributors  and independent hospital networks pursuant to which
the Company or any of its  Subsidiaries has sold or will sell goods and/or
services and has derived, or expects to  derive, revenue of at least $500,000
in any twelve (12) month period;

  

  (vii)   any joint venture, partnership or limited liability company
agreement  with third parties that is material to the business of the Company
and its  Subsidiaries, taken as a whole;

  

  (viii) any  non-competition agreement or any other agreement or
obligation which purports to  materially limit (A) the manner in which, or
the localities in which, the business of  the Company or its Subsidiaries may
be conducted or (B) the ability of either the  Company or its Subsidiaries to
provide any type of service presently conducted by the  Company or its
Subsidiaries;

  

  (ix)   (A) any leases, licenses (for real property), subleases
and occupancy  agreements, together with all amendments thereto, in which
either the Company or its  Subsidiaries has a leasehold interest or similar
occupancy rights, whether as lessor  or

  

  

    

       

  

     |  

  22

    
---|--- 
   

  



    

  

  lessee, and which involve payments by the Company or its Subsidiaries in 
excess of $250,000 per year (each, a  " _Lease_ " and  collectively, the  "
_Leases_ "; the property  covered by Leases under which either the Company or
its Subsidiaries is a lessee is  referred to herein as the " _Leased Real 
Property_ "; the Leased Real Property, together with the  Owned Real
Property, collectively being the " _Company  Property_ ") and (B) any lease
or sublease of personal  property to which the Company or any of its
Subsidiaries is party as either lessor or  lessee, that, in the case of (B),
is material to the business of the Company and its  Subsidiaries, taken as a
whole;

  

  (x)   an agreement limiting or restricting the ability of either
the Company  or its Subsidiaries to make distributions or declare or pay
dividends in respect of its  capital stock or membership interests, as the
case may be;

  

  (xi)   a distribution, dealership, representative, broker, sales
agency,  consulting or advertising contract that is material to the business
of the Company and  its Subsidiaries, taken as a whole;

  

  (xii) an  agreement requiring capital expenditures in excess of
$200,000 in any twelve (12) month  period;

  

  (xiii) an  agreement or offer to acquire all or a substantial
portion of the capital stock,  business, property or assets of any other
Person or sell, transfer or otherwise dispose  of a substantial portion of
the assets or capital stock of the Company or its  Subsidiaries;

  

  (xiv) any  agreement between the Company or any of its Subsidiaries
and any Governmental Entity  that is material to the business of the Company
and its Subsidiaries, taken as a  whole;

  

       

  

     |  

  (xv)

     |  

  any agreement relating to the supply of barium sulfate;  or

    
---|---|--- 
   

  

  (xvi) any  other material agreement not in the ordinary course of
the business of the Company and  its Subsidiaries that is material to the
business of the Company and its Subsidiaries,  taken as a whole.

  

       

  

     |  

  SECTION 3.21

     |  

  _Employee Plans_.

    
---|---|--- 
   

  

  (a)   Section 3.21(a) of the Company Disclosure Schedule sets
forth a list:  (i) all "employee benefit plans", as defined in Section 3(3)
of ERISA, and  all other employee benefit agreements, plans, programs,
policies or arrangements,  including, without limitation, any such
agreements, plans, programs, policies or  arrangements providing severance
pay, sick leave, employment, severance, retention,  change in control,
consulting, vacation pay, salary continuation for disability,  retirement
benefits, deferred compensation, bonus pay, incentive pay, stock options or 
stock awards, hospitalization insurance, medical insurance, life insurance,
cafeteria  benefits, dependent care reimbursements, prepaid legal benefits,
scholarships or  tuition reimbursements, maintained or sponsored by the
Company or any of its  Subsidiaries or to which the Company or any of its
Subsidiaries is obligated to  contribute thereunder for current or former
employees, officers, directors, agents,  consultants and independent
contractors of the Company

  



    

       

  

     |  

  23

    
---|--- 
   

  



     

and  its Subsidiaries (the " _Employee Benefit  Plans_ "), and (ii) all
"employee pension benefit  plans," as defined in Section 3(2) of ERISA,
maintained or sponsored by the  Company or any trade or business (whether or
not incorporated) which is under control  or treated as a single employer
with the Company under Section 414(b), (c), (m), or (o)  of the Code (a "
_ERISA  Affiliate_ ") or to which the Company or any ERISA  Affiliate has
contributed or has been obligated to contribute thereunder (the  " _Pension 
Plans_ ").

  

  (b)   True, correct and complete copies of the following
documents, with  respect to each of the Employee Benefit Plans and Pension
Plans, have been made  available to Parent, to the extent applicable: (i) all
plans and related trust  documents, and amendments thereto; (ii) Forms 5500
filed for the three most recent plan  years; (iii) the most recent IRS
determination letter, if any, regarding the  tax-qualified status of such
Employee Benefit Plan or Pension Plan; (iv) the most  recent summary plan
descriptions, annual reports and material modifications; (v) the  most recent
actuarial report, if any; (vi) written descriptions of the terms of all  non-
written agreements relating to the Employee Benefit Plans or Pension Plans;
and  (vii) the most recent written results of all compliance testing required
pursuant to  Sections 125, 401(a)(4), 401(k), 401(m), 410(b), 415 and 416 of
the Code.

  

  (c)   None of the Employee Benefit Plans or Pension Plans is a
multiemployer  plan, as defined in Section 3(37) of ERISA  (" _Multiemployer
Plan_ ")  or subject to Title IV or Section 302 of ERISA or Sections 412 or
4971 of the Code.  None of the Company or any ERISA Affiliate has withdrawn
at any time within the  preceding six years from any Multiemployer Plan or
incurred any withdrawal liability  which remains unsatisfied and no
circumstances have occurred or exist which could  reasonably be expected to
result in any such liability to the Company or any  Subsidiary.

  

  (d)   Each Pension Plan that is intended to qualify under Section
401(a) of  the Code has received a determination letter from the IRS or can
rely on an opinion  letter as to its qualification and the trust maintained
pursuant thereto is exempt from  federal income taxation under Section 501(a)
of the Code, and nothing has occurred with  respect to the operation of any
such Pension Plan that would reasonably be expected to  cause the loss of
such qualification or exemption or the imposition of any material  liability,
penalty or Tax under ERISA or the Code.

  

  (e)   All contributions (including all employer contributions and
employee  salary reduction contributions) and all premiums required to have
been paid under any  of the Employee Benefit Plans or Pension Plans or by Law
(without regard to any waivers  granted under Section 412 of the Code) to any
funds or trusts established thereunder or  in connection therewith have been
made by the due date thereof (including any valid  extension) and all
contributions for any period ending on or before the Closing Date  which are
not yet due will be paid or accrued prior to the Closing Date.

  

  (f)   To the Knowledge of the Company, there has been no
material violation of  ERISA or the Code with respect to the filing of
applicable reports, documents and  notices regarding the Employee Benefit
Plans with the Secretary of Labor or the  Secretary of the Treasury or the
furnishing of required reports, documents or notices  to the participants or
beneficiaries of the Employee Benefit Plans.

  



    

       

  

     |  

  24

    
---|--- 
   

  



     

  (g)   There are no pending Actions (other than claims for
benefits in the  ordinary course) which have been instituted or, to the
Knowledge of the Company,  asserted against the Employee Benefit Plans or
Pension Plans, the assets of any of the  trusts under such plans or the plan
sponsor or the plan administrator, or against any  fiduciary of the Employee
Benefit Plans or Pension Plans with respect to the operation  or
administration of such plans or the investment of the assets of such plans
(other  than routine benefit claims), nor does the Company have Knowledge of
facts which could  reasonably form the basis for any such claim or lawsuit.
No Employee Benefit Plan or  Pension Plan has been the subject of an audit,
investigation or examination by any  Governmental Entity to the Knowledge of
the Company.

  

  (h)   The Employee Benefit Plans and Pension Plans have been
maintained, in  all material respects, in accordance with their terms and
with all provisions of ERISA  and the Code (including rules and regulations
thereunder) and other applicable federal  and state laws and regulations.
None of the Company, its Subsidiaries, or, to the  Knowledge of the Company,
any "party in interest" or "disqualified  person" with respect to the
Employee Benefit Plans or Pension Plans, as  applicable, has engaged in a
non-exempt "prohibited transaction" within the  meaning of Section 406 of
ERISA or 4975 of the Code pursuant to which the Tax or  penalty could be
material. No stock or other security issued by the Company or any  Affiliate
forms or has formed a part of the assets of any Employee Benefit Plan or 
Pension Plan.

  

  (i)   None of the Employee Benefit Plans or Pension Plans
provide retiree  life, health or death benefits except as may be required
under COBRA or any similar  state or local Law at the retirees own expense.

  

  (j)   Except as set forth in Section 3.21(j) of the Company
Disclosure  Schedule, neither the execution and delivery of this Agreement
nor the consummation of  the transactions contemplated hereby will, either
alone or together with the occurrence  of subsequent events (i) increase any
benefits otherwise payable under any Employee  Benefit Plan or Pension Plan;
(ii) result in the acceleration of the time of payment or  vesting of any
benefits under any Employee Benefit Plan, Pension Plan or Contract to  any
current or former employee; or (iii) result in the payment of any amount
that  would, individually or in combination with any other such payment, fail
to be  deductible by reason of Section 280G of the Code.

  

  (k)   No Contract, Employee Benefit Plan, warrant or other
compensatory or  equity-based arrangement with any employee, officer or
director of the Company contains  any provision requiring the Company to pay
on behalf of, or otherwise reimburse, any  such individual for any income or
excise Taxes due by such individual upon payment of  any benefits by the
Company, other than any such obligations as required by applicable  laws or
regulations.

  

  (l)   Each "nonqualified deferred compensation plan" (as
defined  in Section 409A(d)(1) of the Code) of the Company has been operated
in good faith  compliance with Section 409A of the Code, IRS Notice 2005-1,
or the proposed  regulations or final regulations promulgated under Section
409A of the Code.

  

  (m)   All Company Employee Benefit Plans and all Company Pension
Plans subject  to the laws of any jurisdiction outside of the United States
(i) have been maintained  in material compliance with all applicable
requirements, (ii) if they are intended to  qualify for

  



    

       

  

     |  

  25

    
---|--- 
   

  



     

  special Tax treatment, meet all requirements for such treatment, and 
(iii) if they are intended to be funded and/or book-reserved, are fully funded
and/or  book reserved, as appropriate, based upon reasonable actuarial
assumptions.

  

  SECTION  3.22   _Insurance_. The Company has made available  to
Parent true, complete and accurate copies of all material surety bonds and
fidelity  bonds applicable to the Company or any of its Subsidiaries and all
material insurance  policies insuring each of the Company and its
Subsidiaries and their material assets,  properties and operations. All such
policies and bonds are in full force and effect in  all material respects.
None of the Company or its Subsidiaries is in material default  under any
provisions of any such policy of insurance nor has any of the Company or its 
Subsidiaries received written notice of cancellation of or cancelled any
such  insurance. For all material claims made under such policies and bonds,
the Company and  its Subsidiaries have timely complied in all material
respects with any applicable  notice provisions.

  

  SECTION  3.23 _Affiliate  Transactions_. There are no
transactions, agreements,  arrangements or understandings between the Company
or any of its Subsidiaries, on the  one hand, and any Affiliate of the
Company (other than any of the Subsidiaries of the  Company), on the other
hand, that would be required to be disclosed under Item 404 of  Regulation
S-K under the Securities Act and that are not disclosed in the  Company's
Annual Report on Form 10-K for the fiscal year ended June 2, 2007 or  any
Company SEC Reports filed with the SEC after August 16, 2007.

  

  SECTION  3.24 _GPOs,  Distributors and Independent Hospital
Networks._ None of the  Company's top ten (10) GPOs, top ten (10)
distributors or top ten (10)  independent hospital networks (in each case,
with "top" being determined by  revenues derived by the Company during the
last twelve (12) months) has expressed in  writing or, to the Knowledge of
the Company, verbally, to the Company or any of its  Subsidiaries its
intention to cancel, fail to renew or otherwise terminate or  materially
reduce purchases under agreements with the Company or any of its 
Subsidiaries.

  

       

  

     |  

  SECTION 3.25

     |  

  _Labor Matters_

    
---|---|--- 
   

  

  (a)   Except as set forth in Section 3.25(a) of the Company
Disclosure  Schedule, neither the Company nor any of its Subsidiaries is a
party to any collective  bargaining agreement or other labor union contract
or similar scheme or arrangement  applicable to its employees nor does the
Company have Knowledge of any activities or  proceedings of any labor union
to organize any such employees.

  

  (b)   Except for matters that individually or in the aggregate
have not had or  would not reasonably be expected to have a Company Material
Adverse Effect, each of the  Company and its Subsidiaries is in compliance
with all applicable Laws relating to  employment and employment practices,
the classification of employees, wages, hours,  collective bargaining,
unlawful discrimination, civil rights, safety and health,  workers'
compensation and terms and conditions of employment. Except as set forth  in
Section 3.25(b) of the Company Disclosure Schedule, to the Knowledge of the
Company,  (i) there are no charges with respect to or relating to either the
Company or its  Subsidiaries pending or threatened before the Equal
Employment Opportunity Commission  or any state, local or foreign agency
responsible for the prevention of

  



    

       

  

     |  

  26

    
---|--- 
   

  



     

  unlawful employment practices and (ii) neither the Company nor any of  its
Subsidiaries has received any notice from any national, state, local or
foreign  agency responsible for the enforcement of labor or employment laws
of an intention to  conduct an investigation of either the Company or its
Subsidiaries and no such  investigation is in progress.

  

  (c)   Except as set forth in Section 3.25(c) of the Company
Disclosure  Statement, since there has been no "mass layoff" or "plant 
closing" as defined by the Worker Adjustment and Retraining Notification Act
or  any similar state or local "plant closing" Law  (" _WARN_ ") with
respect to  the current or former employees of the Company or its
Subsidiaries since June 4,  2006.

  

       

  

     |  

  SECTION 3.26

     |  

  _Environmental  Matters_.

    
---|---|--- 
   

  

  (a)   To the Knowledge of the Company, each of the Company and
its  Subsidiaries is, and has since June 3, 2003 been, in compliance in all
material  respects with all applicable Environmental Laws.

  

  (b)   To the Knowledge of the Company, each of the Company and
its  Subsidiaries has in effect all material Licenses and Permits required
under all  Environmental Laws and all such Licenses and Permits and other
authorizations are in  full force and effect in all material respects and the
Company is in compliance in all  material respects with all such licenses,
permits and authorizations.

  

  (c)   There is no material Action pending, or to the Knowledge of
the Company,  threatened against the Company, any of its Subsidiaries or any
of their respective  properties under any applicable Environmental Law, and
since June 3, 2003, the Company  and its Subsidiaries have not received any
written notice of any material violation or  liability under any applicable
Environmental Laws from any Person or any Governmental  Entity or of an
inquiry, request for information, or demand letter under any  Environmental
Law relating to operations or properties of the Company or its  Subsidiaries.

  

  (d)   None of the Company, its Subsidiaries or their respective
properties or  operations is subject to any orders arising under
Environmental Laws nor are there any  Actions pending or, to the Knowledge of
the Company, threatened, against the Company or  its Subsidiaries under any
Environmental Law.

  

  (e)   To the Knowledge of the Company, there has been no release
or threatened  release of any Hazardous Material in violation of applicable
Environmental Laws, on, at  or beneath any of the Company Property or other
properties currently or previously  owned or operated by the Company or its
Subsidiaries.

  

  (f)   To the Knowledge of the Company, none of the Company or
its Subsidiaries  has sent or arranged for the disposal of any Hazardous
Material, or transported any  Hazardous Material in violation of applicable
Environmental Laws.

  

  (g)   The Company has made available to Parent copies of all
environmental  studies, investigations, reports or assessments in the
possession or under the control  of the Company or its Subsidiaries since
June 3, 2003.

  



    

       

  

     |  

  27

    
---|--- 
   

  



     

  (h)   To the Knowledge of the Company, none of the Company and
its  Subsidiaries is required to, or is reasonably expected to, incur
material costs or  expenses in order to cause their operations or properties
to comply with applicable  Environmental Laws.

  

  SECTION  3.27 _No  Brokers_. No broker, finder or similar
intermediary has acted  for or on behalf of, or is entitled to any broker's,
finder's or similar  fee or other commission from the Company or its
Subsidiaries in connection with this  Agreement or the transactions
contemplated hereby other than RBC Capital Markets  Corporation.

  

  SECTION  3.28 _State Takeover  Statutes_. Assuming the accuracy of
the representations and  warranties of Parent and Merger Sub in Section 4.09,
no "fair price",  "moratorium", "control share acquisition" or other
similar  anti-takeover statute or regulation, is, or at the Effective Time
will be, applicable  to the Company, the Merger or the other transactions
contemplated hereby or by the  Voting Agreement.

  

  SECTION  3.29 _Opinion of  Financial Advisor_. RBC Capital Markets
Corporation has  delivered to the Company Board its written opinion (or oral
opinion to be confirmed in  writing), dated as of the date hereof, that, as
of such date, the Merger Consideration  is fair, from a financial point of
view, to the holders of Company Common  Stock.

  

  SECTION  3.30 _Information  Supplied_. The information supplied or
to be supplied by the  Company for inclusion in the proxy statement or any
amendment or supplement thereto  (the " _Proxy Statement_ ")  and to be sent
to the stockholders of the Company in connection with the Company 
stockholders meeting to adopt this Agreement and the Merger (the  " _Company
Stockholders  Meeting_ ") shall not, on the date the Proxy Statement is 
first mailed to the stockholders of the Company or at the time of the
Company  Stockholders Meeting, contain any untrue statement of a material
fact or omit to state  any material fact required to be stated therein or
necessary in order to make the  statements therein, in light of the
circumstances under which they were made, not  misleading. The Proxy
Statement shall, at the time of the Company Stockholders Meeting,  comply as
to form in all material respects with the requirements of the Exchange  Act.

  

  SECTION  3.31 _Board  Approval_. The Company Board, at a meeting
duly called and  held, by unanimous vote of its independent members following
disclosure made pursuant  to Section 144 of the DGCL, (a) has determined that
this Agreement and the Merger are  advisable, and in the best interests of,
the Company and its stockholders, (b) has  approved and declared advisable,
the agreement of merger (within the meaning of Section  251 of the DGCL)
contained within this Agreement and the transactions contemplated by  this
Agreement and the Voting Agreement, including as necessary so that Parent
and  Merger Sub, and their respective Affiliates, will not be prohibited from
entering into  a "business combination" with the Company as an "interested 
stockholder" (in each case as such term is used in Section 203 of the DGCL)
and  (c) has resolved, subject to Section 7.04, to recommend that the holders
of the shares  of Company Common Stock vote in favor of the adoption of this
Agreement at the Company  Stockholder Meeting.

  



    

       

  

     |  

  28

    
---|--- 
   

  



     

  SECTION  3.32 _Vote  Required_. The affirmative vote of the
holders of a majority  of the outstanding shares of Company Common Stock
entitled to vote thereon (the  " _Company Stockholder  Approval_ ") is the
only vote of the holders of any class  or series of the Company's capital
stock necessary to adopt this Agreement and  approve the transactions
contemplated hereby, including the Merger, in accordance with  applicable Law
and the Company Organizational Documents.

  

  SECTION  3.33 _Foreign Corrupt  Practices and International Trade
Sanctions_. Except where  failure to comply individually or in the aggregate
has not had and would not reasonably  be expected to have a Company Material
Adverse Effect, neither the Company, nor any of  its Subsidiaries, nor any of
their respective Representatives has, in connection with  the operation of
their respective businesses, (a) used any corporate or other funds for 
unlawful contributions, payments, gifts or entertainment, or made any
unlawful  expenditures relating to political activity to government
officials, candidates or  members of political parties or organizations, or
established or maintained any  unlawful or unrecorded funds in violation of
Section 104 of the Foreign Corrupt  Practices Act or any other similar Law
applicable to the Company or any of its  Subsidiaries, (b) paid, accepted or
received any unlawful contributions, payments,  expenditures or gifts, or (c)
violated or operated in noncompliance with any export  restrictions, anti-
boycott regulations, embargo regulations or other similar Laws  applicable to
the Company or any of its Subsidiaries.

  



  

  SECTION  3.34   _Products_. Except for matters that  individually
or in the aggregate have not had and would not reasonably be expected to 
have a Company Material Adverse Effect, (a) there are no claims, statements
or  decisions by any Governmental Entity that any products sold, offered for
sale or  distributed by the Company or any of its Subsidiaries  ("
_Products_ ") is  defective or dangerous or fails to meet any standards
promulgated by any Governmental  Entity, (b) since June 3, 2004, there have
been no recalls ordered by any Governmental  Entity nor have there been any
voluntary recalls by the Company or any of its  Subsidiaries with respect to
any Product and (c) to the Knowledge of the Company, there  are no facts or
circumstances relating to any Products that would be reasonably likely  to
give rise to a requirement to recall any Products in accordance with
applicable  Law.

  

  

  

  SECTION  3.35 _No Other  Representations or Warranties_. Except
for the representations  and warranties contained in this Article 3, each of
Parent and Merger Sub acknowledges  that neither the Company nor any other
Person on behalf of the Company makes any other  express or implied
representation or warranty with respect to the Company or with  respect to
any other information provided to Parent or Merger Sub in connection with 
the transaction contemplated hereunder. Neither the Company nor any other
Person will  have or be subject to any liability or indemnification
obligation to Parent, Merger Sub  or any other person resulting from the
distribution to Parent or Merger Sub, or  Parent's or Merger Sub's use of,
any such information, including any  information, documents, projections,
forecasts or other material made available to  Parent or Merger Sub in
certain "data rooms" or management presentations in  expectation of the
transactions contemplated by this Agreement, unless any such  information is
expressly included in a representation or warranty contained in this  Article
3 or in the corresponding section of the Company Disclosure Schedule. 
Notwithstanding the foregoing, this

  



    

       

  

     |  

  29

    
---|--- 
   

  



     

  Section 3.35 shall not apply to any claim by Parent or Merger Sub  against
the Company based on fraud or intentional misrepresentation by the Company
or  its Affiliates or Representatives.

  

  ARTICLE 4

  

  REPRESENTATIONS AND WARRANTIES OF PARENT AND MERGER SUB

  

  Parent and Merger Sub hereby jointly and severally represent and warrant 
to the Company as follows:

  

  SECTION  4.01   _Organization_. Each of Parent and Merger Sub  is
duly organized, validly existing and in good standing under the laws of the 
jurisdiction of its organization, and has all requisite corporate power to own
its  properties and assets and to conduct its businesses as now conducted.

  

  SECTION  4.02 _No Conflict or  Violation_. The execution, delivery
and performance by Parent  and Merger Sub of this Agreement do not and will
not (a) violate or conflict with any  provision of any of Parent's
organizational documents or the organizational  documents of Merger Sub as
currently in effect, (b) violate any provision of applicable  Law, or any
order, judgment or decree of any Governmental Entity, (c) result in the 
creation or imposition of any Lien (other than any Permitted Lien) upon any of
the  assets, properties or rights of either Parent or Merger Sub or (d)
violate or result in  a breach of or constitute (with due notice or lapse of
time or both) a default under  any material contract, agreement or instrument
to which Parent or Merger Sub is a party  or by which it is are bound or to
which any of its properties or assets is subject,  except in each case as
would not, individually or in the aggregate, prevent or  materially delay the
ability of Parent and Merger Sub to perform their respective  obligations
under this Agreement.

  

  SECTION  4.03 _Consents and  Approvals_. No consent, waiver,
authorization or approval of  any Governmental Entity, and no declaration or
notice to or filing or registration with  any Governmental Entity, is
required in connection with the execution and delivery of  this Agreement by
Parent or Merger Sub or the performance by Parent or its Subsidiaries  or
Merger Sub of their obligations hereunder, except for (a) any antitrust,
competition  or other regulatory approvals and/or notifications required by
or of any Governmental  Entity in connection with the transactions
contemplated by the Agreement, including the  Required Approvals; (b)
applicable requirements of the Securities Act and of the  Exchange Act and
the rules and regulations of NASDAQ; (c) state securities, takeover  and
"blue sky" laws; (d) the filing of the Certificate of Merger with the 
Secretary of State of the State of Delaware; and (e) such other consents,
waivers,  authorizations, declarations, notices, filings and registrations
the failure of which  to be obtained or made individually or in the aggregate
would not reasonably be  expected to impair in any material respect the
ability of Parent or Merger Sub to  perform their respective obligations
under this Agreement or prevent or materially  impede, interfere with, hinder
or delay the consummation of any of the transactions  contemplated by this
Agreement.

  

  SECTION  4.04 _Authorization  and Validity of Agreement_. Parent
and Merger Sub have all  requisite corporate power and authority to execute,
deliver and perform their  obligations under this Agreement and to consummate
the transactions contemplated  hereby. The execution and delivery of this
Agreement by Parent and Merger Sub and the  performance by Parent and

  



    

       

  

     |  

  30

    
---|--- 
   

  



     

Merger  Sub of their obligations hereunder and the transactions contemplated
hereby have been  duly authorized by the Board of Directors of each of Parent
and Merger Sub (and, with  respect to Merger Sub, Parent as sole stockholder
of Merger Sub), and all other  necessary corporate action on the part of
Parent and Merger Sub, and no other corporate  proceedings on the part of
Parent and Merger Sub are necessary to authorize this  Agreement and the
transactions contemplated hereby. This Agreement has been duly and  validly
executed and delivered by Parent and Merger Sub and, assuming due execution
and  delivery by the Company, shall constitute their legal, valid and binding
obligation,  enforceable against them in accordance with its terms, subject
to (a) the effect of  bankruptcy, fraudulent conveyance, reorganization,
moratorium and other similar laws  relating to or affecting the enforcement
of creditors' rights generally, (b)  general equitable principles (whether
considered in a proceeding in equity or at law)  and (c) an implied covenant
of good faith and fair dealing.

  

  SECTION  4.05 _No  Brokers_. Except for Credit Suisse Securities
LLC and Evercore  Capital Partners, no broker, finder or similar intermediary
has acted for or on behalf  of, or is entitled to any broker's, finder's or
similar fee or other  commission from Parent in connection with this
Agreement or the transactions  contemplated hereby.

  

  SECTION  4.06 _Information  Supplied_. The information supplied or
to be supplied by  Parent specifically for inclusion in the Proxy Statement
shall not, on the date the  Proxy Statement is first mailed to the
stockholders of the Company or at the time of  the Company Stockholders
Meeting or at the Effective Time, contain any untrue statement  of a material
fact or omit to state any material fact required to be stated therein or 
necessary in order to make the statements therein, in light of the
circumstances under  which they were made, not misleading.

  

  SECTION  4.07 _Merger  Sub_. Merger Sub was formed solely for the
purpose of engaging  in the transactions contemplated by this Agreement. All
of the outstanding capital  stock of Merger Sub is directly owned of record
and beneficially by Parent. Except for  obligations or liabilities incurred
in connection with its incorporation or  organization and the transactions
contemplated by this Agreement, Merger Sub has not  and will not have
incurred, directly or indirectly, any obligations or liabilities or  engaged
in any business activities of any type or kind whatsoever or entered into
any  agreements or arrangement with any other Person. Merger Sub has no 
Subsidiaries.

  

  SECTION  4.08 _Sufficiency of  Funds_. Parent shall have, and
Bracco Imaging shall ensure  that Parent shall have, sufficient funds at the
Effective Time for the payment of the  Merger Consideration and to perform
its other obligations with respect to the  transactions contemplated by this
Agreement.

  

  SECTION  4.09 _Ownership of  Shares_. As of the date of this
Agreement, none of Parent,  Merger Sub or their respective controlled
Affiliates owns (directly or indirectly,  beneficially or of record) any
shares of Company Common Stock and none of Parent,  Merger Sub or their
respective controlled Affiliates holds any rights to acquire any  shares of
Company Common Stock except pursuant to this Agreement.

  

  SECTION  4.10 _Vote/Approval  Required_. No vote or consent of the
holders of any class or  series of capital stock of Parent is necessary to
approve this Agreement or the Merger  or

  



    

       

  

     |  

  31

    
---|--- 
   

  



     

the  transactions contemplated hereby. The vote or consent of Parent as the
sole stockholder  of Merger Sub (which shall have occurred prior to the
Effective Time) is the only vote  or consent of the holders of any class or
series of capital stock of Merger Sub  necessary to approve this Agreement or
the Merger or the transactions contemplated  hereby.

  

  SECTION  4.11 _No Other  Representations or Warranties_. Except
for the representations  and warranties contained in this Article 4, the
Company acknowledges that none of  Parent, Merger Sub or any other Person on
behalf of Parent or Merger Sub makes any  other express or implied
representation or warranty with respect to Parent or Merger  Sub or with
respect to any other information provided to the Company. Notwithstanding 
the foregoing, this Section 4.11 shall not apply to any claim by the Company
against  Parent or Merger Sub based on fraud or intentional misrepresentation
by Parent or its  Affiliates or Representatives.

  

  ARTICLE 5

  

  COVENANTS OF THE COMPANY

  

  The Company hereby covenants as follows:

  

       

  

     |  

  SECTION 5.01

     |  

  _Conduct of Business Before the Closing  Date._

    
---|---|--- 
   

  

  (a)   The Company covenants and agrees that, during the period
from the date  hereof to the earlier of the termination of this Agreement in
accordance with its terms  and the Effective Time (except as otherwise
expressly provided by the terms of this  Agreement or as set forth in Section
5.01(a) of the Company Disclosure Schedule or as  required by applicable
Law), unless Parent shall otherwise consent in writing: (i) the  businesses
of the Company and its Subsidiaries shall be conducted, in all material 
respects, in the ordinary course of business and in a manner consistent with
past  practice, and (ii) the Company shall use its commercially reasonable
efforts consistent  with the foregoing to preserve substantially intact the
business organization of the  Company and its Subsidiaries, to keep available
the services of the present officers  and key employees of the Company and
its Subsidiaries and to preserve, in all material  respects, the present
relationships of the Company and its Subsidiaries with Persons  with which
the Company or any of its Subsidiaries has significant business relations. 
Without limiting the generality of the foregoing, neither the Company nor any
of its  Subsidiaries shall (except as otherwise expressly provided by the
terms of this  Agreement, or as set forth in Section 5.01(a) of the Company
Disclosure Schedule or as  required by applicable Law), between the date of
this Agreement and the earlier of the  termination of this Agreement in
accordance with its terms and the Effective Time,  directly or indirectly do,
any of the following without the prior written consent of  Parent:

  

  (i)   make any change in any of the Company Organizational
Documents; issue,  sell, pledge, dispose of, grant or encumber, or authorize
the issuance, sale, pledge,  disposition, grant or encumbrance of, any shares
of capital stock (other than upon the  exercise of options to purchase shares
of Company Common Stock outstanding on the date  hereof in accordance with
the Company Plans or as set forth in Section 3.06(a) of the  Company
Disclosure Schedule) or other equity securities, restricted or performance 
stock award or grant any option, warrant, restricted stock or performance
unit, stock  appreciation or depreciation right or other right to acquire any
capital stock or  other

  

  

    

       

  

     |  

  32

    
---|--- 
   

  



    

  

  equity securities or issue any security convertible into or exchangeable 
for such securities or alter in any way any its outstanding securities or make
any  change in outstanding shares of capital stock or other ownership
interests or its  capitalization, whether by reason of a reclassification,
recapitalization, stock split  or combination, exchange or readjustment of
shares, stock dividend or  otherwise;

  

  (ii)   reclassify, combine, split, subdivide or redeem, or
purchase or  otherwise acquire, directly or indirectly, any of its capital
stock;

  

  (iii)   make any sale, assignment, transfer, abandonment, sublease,
assignment  or other conveyance of its material assets, Company Property,
Intellectual Property or  other material rights or any part thereof, other
than dispositions of worn-out or  obsolete equipment for fair or reasonable
value in the ordinary course of business and  consistent with past practice;

  

  (iv)   subject any of its or its Subsidiaries' material assets, 
properties or rights or any part thereof, to any Lien or suffer such to exist,
in each  case, other than Permitted Liens;

  

  (v)   redeem, retire, purchase or otherwise acquire, directly or
indirectly,  any shares of the capital stock, membership interests or
partnership interests or other  ownership interests of the Company and its
Subsidiaries or declare, set aside or pay  any dividends or other
distribution in respect of such shares or interests;

  

  (vi)   (A) acquire any corporation, partnership, other business
organization or  any division thereof in any transaction or series of related
transactions (including by  merger, consolidation or acquisition of stock or
assets or any other business  combination); (B) acquire assets outside of the
ordinary course of business  consistent with past practice from any Person
for consideration in excess of $500,000  individually or $1,000,000 in the
aggregate, other than any such acquisitions required  under the terms of any
Contract in effect as of the date hereof (including by merger, 
consolidation, or acquisition of stock or assets or any other business
combination);  (C) other than in the ordinary course of business consistent
with past practice,  incur any indebtedness for borrowed money or issue any
debt securities or assume,  guarantee or endorse, or otherwise become
responsible for, the obligations of any  Person, or make any loans or
advances; or (D) authorize, or make any commitment  with respect to any
capital expenditure that is in excess of the amounts included in  the budget
set forth in Section 5.01(a)(vi) of the Company Disclosure  Schedule;

  

  (vii)   amend or modify in any material respect or terminate or
(other than in  the ordinary course of business and consistent with past
practice) enter into any  Contract or cancel, modify in any material respect
or waive any debts or claims held by  it or waive any rights having in each
case a value in excess of $500,000;

  

  (viii) enter  into any new (or amend any existing to increase
benefits or otherwise) employee benefit  plan, program or arrangement or any
new (or amend any existing to increase benefits or  otherwise) employment,
severance, change of control or

  

  

    

       

  

     |  

  33

    
---|--- 
   

  



    

  

  consulting agreement, grant any general increase in the compensation of 
officers or employees (including any such increase pursuant to any bonus,
pension,  profit-sharing or other plan or commitment), grant any increase in
the compensation  payable or to become payable to any employee, except as
otherwise provided pursuant to  the terms of any plan or agreement, as
required by law, to the extent necessary to  avoid imposition of any Taxes
under Section 409A (but only to the extent such amendment  does not
materially increase the cost of such plan, program or arrangement to the 
Company, without regard to the time value of money) or for increases in
compensation to  employees as required under pre-existing contractual
provisions that have been  disclosed to Parent, or hire any additional
employees (except to fill current  vacancies) or terminate the employment of
any executive officer (other than for  "cause");

  

  (ix)   fail to keep in full force and effect insurance materially
comparable in  amount and scope to coverage maintained as of the date hereof;

  

  (x)   pay (other than with respect to compensatory payments to
current or  former employees, officers, consultants or directors, in each
case (A) in the ordinary  course of business consistent with past practice,
(B) as required under agreements in  effect as of the date hereof or (C)
which have been accrued for on the Company's  balance sheet), lend or advance
any amount to, or sell, transfer or lease any  properties or assets to, or
enter into any agreement or arrangement with, any of its  Affiliates (other
than wholly owned Subsidiaries);

  

  (xi)   make any change in any method of accounting or accounting
principle,  method, estimate or practice except for any such change required
by reason of a  concurrent change in U.S. GAAP or applicable Law, or write
off as uncollectible any  accounts receivable except in the ordinary course
of business and consistent with past  practice;

  

  (xii)   make or change any material Tax election, change an annual
accounting  period, adopt or change any accounting method, file any amended
Tax Return, enter into  any closing agreement, settle any material Tax claim
or assessment relating to the  Company or any of its Subsidiaries, surrender
any right to claim a refund of a material  amount of Taxes or consent to any
extension or waiver of the limitation period  applicable to any material Tax
claim or assessment relating to the Company or any of  its Subsidiaries;

  

  (xiii) settle,  release or forgive any material claim or litigation
(including the Tyco Litigation) or  waive any right thereto;

  

       

  

     |  

  (xiv)

     |  

  adopt, approve, or agree to adopt, a shareholder rights  plan;

    
---|---|--- 
   

  

       

  

     |  

  (xv)

     |  

  create any new Subsidiaries; or

    
---|---|--- 
   

  

  (xvi) announce  any intention, enter into any agreement or otherwise
make a commitment, to do any of  the foregoing.

  



    

       

  

     |  

  34

    
---|--- 
   

  



     

  (b)   Nothing contained in this Agreement shall give to Parent or
Merger Sub,  directly or indirectly, rights to control or direct the
operations of the Company or  its Subsidiaries prior to the Closing Date.
Prior to the Closing Date, the Company and  its Subsidiaries shall exercise,
consistent with the terms and conditions of this  Agreement, complete control
and supervision of its and its Subsidiaries'  operations.

  

  SECTION  5.02 _Notice of  Breach_. From and after the date hereof
and until the earlier  to occur of the Closing Date or the termination of
this Agreement pursuant to Article 9  hereof, the Company shall promptly give
Parent written notice with particularity upon  having Knowledge of the
occurrence of any Effect that would result in the failure of  any condition
to the Closing set forth in Sections 8.02(a), 8.02(b) or 8.02(f). 
Notwithstanding the above, the delivery of any notice pursuant to this Section
will not  limit or otherwise affect the remedies available hereunder to
Parent or the conditions  to Parent's obligation to consummate the Merger.

  

  SECTION  5.03 _FDA  Correspondence_. Subject to applicable Law and
applicable  confidentiality agreements with any Person, the Company shall
promptly provide Parent  with copies of any material correspondence with the
FDA and any material written  comments, notices, supplemental reports or
materials received from or provided to the  FDA and promptly advise Parent of
any oral communications with the FDA.

  

  SECTION  5.04 _Section  409A_. To the extent requested by Parent,
the Company will  work with Parent in good faith to amend each Company
Employee Benefit Plan and Company  Pension Plan to comply with or be exempt
from Section 409A of the Code (if  applicable).

  

  SECTION  5.05 _Exemption from  Liability Under Section 16(b)_. The
Company Board (or a  committee thereof) shall adopt a resolution in advance
of the Effective Time that  exempts the disposition of Company equity
securities by those officers and directors of  the Company who are subject to
the reporting requirements of Section 16(a) of the  Exchange Act pursuant to
the Merger from the short-swing profits liability provisions  of Section 16
of the Exchange Act by reason of Rule 16b-3.

  

  ARTICLE 6

  

  COVENANTS OF PARENT AND MERGER SUB

  

       

  

     |  

  SECTION 6.01

     |  

  _Employee  Benefits_.

    
---|---|--- 
   

  

  (a)   Employees of Company and its Subsidiaries who continue
their employment  with the Surviving Corporation or who become employees of
Parent or any subsidiary of  Parent (" _Continuing  Employees_ ") shall be
given credit for all service with  the Company and its Subsidiaries (and
their respective predecessors) (or service  credited by the Company and its
Subsidiaries for similar plans, programs or policies)  under all employee
benefit and fringe benefit plans, programs and policies of the  Parent or its
Affiliates in which they become participants for purposes of eligibility, 
vesting and level of benefits (except to the extent such service credit will
result in  benefit accrual under any defined benefit pension plans or
otherwise result in a  duplication of benefits).

  

  (b)   For a period of at least one year following the Closing,
Parent shall,  either (i) continue to maintain the Employee Benefit Plans and
Pension Plans and cause  the Continuing

  



    

       

  

     |  

  35

    
---|--- 
   

  



     

  Employees to be covered thereunder substantially to the same extent 
covered prior to the Closing; or (ii) provide compensation and employee
benefits that,  in the aggregate, are no less favorable to those provided
under the Employee Benefit  Plans and Pension Plans immediately preceding the
Closing. Parent shall cause any of  its medical, dental or other health plans
to (x) waive any preexisting condition  limitations for conditions covered
under the applicable medical, health or dental plans  of the Company (the "
_Company Welfare  Plans_ "); and (y) honor any deductible and out-of-pocket 
expenses incurred by such employee and his or her beneficiaries under the
Company  Welfare Plans during the portion of the applicable plan year
including the Closing. It  is expressly acknowledged and agreed that nothing
contained herein shall require a  Continuing Employee's participation in the
Bracco Retirement Income  Plan.

  

  (c)   To the extent that Parent is a "successor employer," as
such  term is defined in Section 54.4980B-9 of the Treasury Regulations,
Parent shall satisfy  and be fully responsible for any and all obligations
arising under Section 4980B of the  Code and the regulations promulgated
thereunder  (" _COBRA_ ") with respect  to such employees, former employees
and their respective spouses and dependents who  participate in any Employee
Benefit Plans that are group health plans (within the  meaning of Section
5000(b)(1) of the Code) and who are "MandA Qualified  Beneficiaries" (as such
term is defined in Section 54.4980B-9 of the Treasury  Regulations) with such
coverage provided through any health plan maintained by Parent  (if the
corresponding Employee Benefit Plan is terminated). Parent shall satisfy and
be  fully responsible for any and all COBRA obligations that arise with
respect to any  MandA Qualified Beneficiary (as such terms is determined in
Section 54.4980B-9)  entitled to elect continuation coverage pursuant to
COBRA as a result of a  "qualifying event" that occurred on or prior to the
Closing  Date.

  

  (d)   Except as provided in this Section 6.01, nothing in this
Agreement shall  limit or restrict the right of Parent or any of its
Subsidiaries to modify, amend,  terminate or establish employee benefit plans
or arrangements, in whole or in part, at  any time after the Effective Time.

  

  (e)   No provision of this Section 6.01 shall create any third
party  beneficiary rights in any Continuing Employee or any current or former
director or  consultant of the Company or its Subsidiaries located in the
United States in respect  of continued employment (or resumed employment) or
any other matter.

  

  SECTION  6.02   _Directors ' and Officers' Indemnification and 
Insurance_. (a) Without limiting any additional rights that  any employee,
officer or director may have under any employment agreement, Employee 
Benefits Plan, the Company Organization Documents, indemnification agreement
or  otherwise, after the Effective Time, Parent shall, and shall cause the
Surviving  Corporation to, indemnify and hold harmless each present (as of
immediately prior to  the Effective Time) and former officer or director of
the Company and its Subsidiaries  (collectively, the " _Indemnified 
Parties_ "), against all claims, losses, liabilities,  damages, judgments,
inquiries, fines and reasonable fees, costs and expenses,  including,
attorneys' fees and disbursements (collectively,  " _Costs_ "), incurred in 
connection with any Action, arising out of actions taken by them in their
capacity as  officers or directors at or prior to the Effective Time
(including with respect to this  Agreement and the transactions and actions
contemplated hereby), whether asserted or  claimed prior to, at or after the
Effective Time, to the fullest extent  permitted

  



    

       

  

     |  

  36

    
---|--- 
   

  



     

under  applicable Law for a period of six years from the Effective Time. Each
Indemnified  Party will be entitled to advancement of reasonably documented
expenses (including  reasonable attorney's fees) incurred in the defense for
any such Action from the  Surviving Corporation within ten (10) Business Days
of receipt by the Surviving  Corporation from the Indemnified Party of a
request therefor;  _provided_ that any Indemnified Party to whom  expenses
are so advanced provides an undertaking to repay such advances if it is 
ultimately determined that such person is not entitled to indemnification.
The  Surviving Corporation shall not be liable for any settlement effected
without its prior  written consent (which consent shall not be unreasonably
withheld or delayed). The  Surviving Corporation shall not settle, compromise
or consent to the entry of any  judgment in any pending or threatened Action
that names an Indemnified Party as a  defendant, unless (i) such settlement,
compromise or consent includes an unconditional  release of such Indemnified
Party from all liability arising out of such Action or (ii)  such Indemnified
Party otherwise consents. Notwithstanding the foregoing, to the extent  Costs
are covered by insurance and actually paid to the Indemnified Party pursuant
to  such insurance coverage (" _Insurance  Proceeds_ "), and either Parent
or the Surviving  Corporation has made a payment to the Indemnified Party in
connection with such Costs  under this Section 6.02, the Indemnified Party
shall promptly pay to Parent or the  Surviving Corporation, as the case may
be, an amount in cash equal to the excess amount  of Insurance Proceeds
received by such Indemnified Party over the amount of Costs that  have not
been reimbursed by the Surviving Corporation at the at the time of receipt
of  such Insurance Proceeds.

  

  (b)   The certificate of incorporation and by-laws of the
Surviving  Corporation shall contain provisions no less favorable with
respect to indemnification  than are set forth in the Company Organizational
Documents, which provisions shall not  be amended, repealed or otherwise
modified for a period of six years from the Effective  Time in any manner
that would affect adversely the rights thereunder of individuals  who, at or
prior to the Effective Time, were directors, officers, employees, 
fiduciaries or agents of the Company, unless such modification shall be
required by  applicable Law. The indemnification agreements between the
Company and its directors  and officers as in effect on the date thereof
shall not be amended, terminated or  otherwise modified by the Surviving
Corporation for a period of six years from the  Effective Date.

  

  (c)   The parties acknowledge and agree that the Company intends,
prior to the  Effective Time, to purchase directors' and officers' liability
insurance  coverage under a run-off or tail policy providing, for a period of
six years after  the Effective Time (and at a total cost currently estimated
not to exceed  $280,000), the same coverage amounts and terms and conditions
as those  in the policy of directors' and officers' liability  insurance
currently maintained by the Company. If such insurance policy is  in effect
at the Effective Time, the Surviving Corporation shall, and the Parent shall 
cause the Surviving Corporation to, maintain such insurance policy in effect
for a  period of six years after the Effective Time. The parties agree that,
if for any reason  such run-off or tail policy is not in effect at the
Effective Time, as  promptly as reasonably practicable thereafter Parent
shall, or shall cause the  Surviving Corporation to, obtain a commercially
available run-off or tail policy, which  shall (i) be for a term of six years
from the Effective Time, (ii) provide coverage for  each person covered by
the Company's current directors' and  officers' liability insurance policy in
effect on the date hereof, and (iii)  be no less favorable with respect to
coverage terms and amounts in any material  respect than the Company's
current directors' and officers' liability  insurance policy;  _provided_ ,

  



    

       

  

     |  

  37

    
---|--- 
   

  



     

  _however_ , that in no event shall Parent or  the Surviving Corporation be
obligated or required to pay premiums for such  policy under this Section
6.02(c) in excess of 200% of the amount of the  current net annual premiums
paid by the Company for such directors' and  officers' liability insurance
policy (which current net annual premiums are  hereby represented and
warranted by the Company to be $85,000).

  

  (d)   In the event the Company, the Surviving Corporation or
Parent or any of  their respective successors or assigns (i) consolidates
with or merges into any  other Person and shall not be the continuing or
surviving corporation or entity of such  consolidation or merger or (ii)
transfers all or substantially all of its  properties and assets to any
Person, then, and in each such case, proper provision  shall be made so that
the successors and assigns of the Company, the Surviving  Corporation or
Parent, as the case may be, or at Parent's option, Parent, shall  expressly
assume the obligations set forth in this Section 6.02.

  

  ARTICLE 7

  

  ADDITIONAL COVENANTS OF THE PARTIES

  

       

  

     |  

  SECTION 7.01

     |  

  _Preparation of Proxy Statement, Company Stockholders  Meeting_.

    
---|---|--- 
   

  

  (a)   As promptly as reasonably practicable after the date
hereof, the Company  shall prepare and file with the SEC the Proxy
Statement;  _provided_ that the Company shall consult  with Parent and
provide Parent and its counsel a reasonable opportunity to review and 
comment on such Proxy Statement (and any amendments or supplements thereto),
and shall  reasonably consider such comments, prior to filing. The parties
shall reasonably  cooperate with each other in the preparation of the Proxy
Statement and to have such  document cleared by the SEC as promptly as
reasonably practicable after such filing.  Parent shall furnish to the
Company the information relating to it and Merger Sub that  is required by
the rules and regulations promulgated by the SEC under the Exchange Act  for
inclusion in the Proxy Statement. The Proxy Statement shall include the 
recommendation of the Company Board in favor of the adoption of this Agreement
and the  approval of the transactions contemplated hereby at the Company
Stockholders Meeting  (the " _Company  Recommendation_ "), except to the
extent the Company  Board shall have withdrawn, amended or modified such
recommendation of this Agreement  to the extent such action is permitted by
Section 7.04. The Company shall use its  commercially reasonable efforts to
cause the Proxy Statement to be mailed to the  holders of Company Common
Stock as promptly as practicable upon the earlier of (x)  receiving
notification that the SEC is not reviewing the Proxy Statement and (y) the 
conclusion of any SEC review of the Proxy Statement. The Company shall
promptly provide  copies, consult with Parent and prepare written responses
with respect to any written  comments received from the SEC with respect to
the Proxy Statement and advise Parent of  any oral comments received from the
SEC. The Company shall cause the Proxy Statement to  comply as to form in all
material respects with the rules and regulations promulgated  by the SEC
under the Exchange Act and the rules and regulations of NASDAQ.

  

  (b)   The Company shall make all necessary filings with respect
to the Merger  and the transactions contemplated thereby under the Exchange
Act and the rules and  regulations thereunder. The Company will advise
Parent, promptly after it receives  notice thereof, of any request by the SEC
for any amendment of or supplement to the  Proxy Statement or comments

  



    

       

  

     |  

  38

    
---|--- 
   

  



     

  thereon and responses thereto or requests by the SEC for additional 
information. The Company shall provide Parent and its counsel a reasonable
opportunity  to review and comment on any such comments and any amendment or
supplement to the Proxy  Statement made in response thereto and the Company
shall reasonably consider  Parent's and its counsel's comments prior to
filing. If at any time prior  to the Effective Time, any information relating
to Parent or the Company, or any of  their respective Affiliates, officers or
directors, should be discovered by Parent or  the Company that should be set
forth in an amendment or supplement to the Proxy  Statement, so that such
documents would not include any misstatement of a material fact  or omit to
state any material fact necessary to make the statements therein, in light 
of the circumstances under which they were made, not misleading, the party
which  discovers such information shall promptly notify the other parties
hereto and an  appropriate amendment or supplement describing such
information shall be promptly filed  with the SEC and, to the extent required
by applicable Law, disseminated to the holders  of the Company Common Stock.

  

  (c)   Unless the Company Board makes an Adverse Recommendation or
terminates  this Agreement, in each case pursuant to and in accordance with
Section 7.04, the  Company (i) shall, acting through the Company Board, cause
the Company Stockholders  Meeting to be duly called and held as soon as
reasonably practicable following the  commencement of the mailing of the
Proxy Statement for the purpose of obtaining the  Company Stockholder
Approval and (ii) shall not, unless required under applicable Law,  postpone,
delay or adjourn the Company Stockholders Meeting without Parent's  prior
written consent. In connection with such meeting, the Company shall use its 
commercially reasonable efforts to obtain the Company Stockholder Approval
and  otherwise comply with all legal requirements applicable to such meeting.

  

  SECTION  7.02 _Access to  Information; Preparation of December 31
Financial Statements;  Confidentiality_.

  

  (a)   The Company shall, and shall cause each of its Subsidiaries
to, subject  to reasonable restrictions imposed from time to time upon advice
of counsel respecting  any applicable confidentiality agreement with any
Person (provided that the Company  discloses the existence of any such
agreement to Parent and uses its commercially  reasonable efforts to obtain
waivers under such agreements), afford to Parent and to  Parent's
Representatives, reasonable access during normal business hours at all  times
prior to the Effective Time to all their respective properties, assets,
books,  records, Contracts, Licenses and Permits, documents, information and
Representatives of  the Company and its Subsidiaries and records, and shall
cause each of its Subsidiaries  to make available to Parent, and provide to
Parent copies or originals if specifically  requested by Parent of, (i) each
report, schedule, form, statement and other document  filed or received by it
during such period pursuant to the requirements of any  applicable Law or
Order, (ii) all organizational documents, stock certificates and  other
evidences of equity interests and investments, stockholders' registers and 
other registers of equity interests, minute books, certificates of good
standing,  authorizations to do business and certified accounts of each
Subsidiary of the Company  and (iii) all other information concerning its
business, properties and personnel as  Parent reasonably may request. The
Company and Parent shall, and shall cause each of  their respective
Subsidiaries to, reasonably cooperate to obtain an orderly transition  and
integration process in connection with the Merger to minimize the disruption
to,  and preserve the value of, the business of the Surviving Corporation and
its  Subsidiaries during the period from

  



    

       

  

     |  

  39

    
---|--- 
   

  



     

and  after the Effective Time. Notwithstanding the foregoing, neither the
Company nor any of  its Subsidiaries shall be required to provide access to
or disclose information where  such access or disclosure would jeopardize the
attorney-client privilege of the Company  or any of its Subsidiaries or
contravene any applicable Law or binding agreement  entered into prior to the
date of this Agreement.

  

  (b)   In furtherance of, but without limitation to, the other
provisions of  this Section 7.02, after the date hereof, the Company shall,
and shall cause its  Subsidiaries and their respective directors, officers
and employees to, reasonably  cooperate, taking into consideration the
Company's periodic reporting obligations  under the Exchange Act, and request
the auditors of the Company to reasonably  cooperate, including by (i)
responding to questionnaires and participating in meetings  with
Representatives of Parent, in order to enable Bracco Imaging to prepare in 
accordance with IFRS, and have available on or before February 29, 2008, any
historical  or pro-forma financial statements, includingany audited
consolidated balance sheets and  statements of income, changes in
stockholders' equity and cash flow as of and for  the twelve (12) months
ended December 31, 2007 for the Company and its Subsidiaries  (together with
the notes thereto) and (ii) making accounting arrangements to enable  Parent
and Bracco Imaging to separately account for the Company's injector  business
commencing January 1, 2007. Parent shall reimburse the Company for all  out-
of-pocket expenses incurred by the Company or any of its Subsidiaries in
connection  with this Section 7.02(b).

  

  (c)   All information obtained by Parent, Merger Sub or the
Company pursuant  to this Section 7.02 shall be kept confidential in
accordance with the  confidentiality agreement, dated February 26, 2007
(the  " _Confidentiality  Agreement_ "), between Parent and the Company.

  

       

  

     |  

  SECTION 7.03

     |  

  _Commercially Reasonable  Efforts_.

    
---|---|--- 
   

  

  (a)   Subject to the other terms and conditions of this
Agreement, and except  in connection with any action required to be taken or
prohibited from being taken under  this Agreement where a different standard
is expressly set forth in this Agreement,  each party shall use its
commercially reasonable efforts to take, or cause to be taken,  all actions
and to do, or cause to be done, all things necessary, proper or advisable 
under applicable Law to consummate the Merger and the other transactions
contemplated  by this Agreement as soon as reasonably practicable after the
date hereof. In  furtherance and not in limitation of the foregoing, if
applicable, each party hereto  agrees to make any filing required to be made
by it by any applicable Regulatory Law  with respect to the transactions
contemplated hereby as promptly as reasonably  practicable, and to supply as
promptly as reasonably practicable any additional  information and
documentary material that may be requested pursuant to such applicable 
Regulatory Law and to take all other actions necessary to cause the expiration
or  termination of the applicable waiting periods under such applicable
Regulatory  Law.

  

  (b)   Each of Parent and the Company shall, in connection with
the efforts  referenced in Section 7.03 to obtain all requisite approvals and
authorizations for the  transactions contemplated by this Agreement under any
Regulatory Law, including the  Required Approvals, use its commercially
reasonable efforts to, to the extent permitted  under applicable Law, (i)
cooperate in all respects with each other in connection with  any filing or
submission and in connection with any investigation or other inquiry, 
including any proceeding initiated by a

  



    

       

  

     |  

  40

    
---|--- 
   

  



     

  private party; (ii) promptly inform the other party of any communication 
received by such party from, or given by such party to any Governmental Entity
and of  any material communication received or given in connection with any
proceeding by a  private party, in each case regarding any of the
transactions contemplated hereby, and  (iii) permit the other party (or their
external counsel in respect of competitively  sensitive, privileged or
confidential matters) to review any communication given by it  to, and
consult with each other in advance of any meeting or conference with, any 
Governmental Entity or, in connection with any proceeding by a private party,
with any  other Person, and to the extent permitted by the applicable
Governmental Entity or  other Person, give the other party the opportunity to
attend and participate in such  meetings and conferences. In furtherance and
not in limitation of the covenants of the  parties contained in this Section
7.03(b), each party hereto shall use its commercially  reasonable efforts to
resolve objections, if any, as may be asserted with respect to  the
transactions contemplated by this Agreement under any Regulatory Law.

  

  (c)   In furtherance of, but without limitation of, subsections
(a) and (b) of  this Section 7.03:

  

  (i)   _HSR Act_. As promptly as practicable after  the date
hereof, each of the Company and Parent shall prepare and file Notification
and  Report Forms under the HSR Act with the Unites States Federal Trade
Commission (the  " _FTC_ ") and the Antitrust  Division of the United States
Department of Justice (the  " _DOJ_ ") and provide all  supplemental
information in connection therewith required to be provided pursuant to  the
HSR Act. Each of Parent and the Company shall (A) furnish to the other party
such  necessary information and assistance as the other reasonably may
request in connection  with its preparation of any filing with, or submission
or response to inquiries from,  the FTC or the DOJ, (B) keep the other party
apprised promptly of the status of all  inquiries and requests (if any) for
additional information from the FTC or the DOJ, (C)  respond as promptly as
practicable to all inquiries and requests received from the FTC  or the DOJ
for additional information or documentation, (D) participate in interviews 
or meetings reasonably requested by the FTC or the DOJ in connection with
the  consummation of the Merger and the other transactions contemplated by
this Agreement,  and (E) not extend any waiting period under the HSR Act or
enter into any agreement  with the FTC or the DOJ not to consummate the
transactions contemplated by this  Agreement, except with the prior written
consent of the other parties  hereto;

  

  (ii)   _German Act Against Restraints of  Competition_. As
promptly as practicable after the date  hereof, the Company and Parent shall
notify the German Federal Cartel Office concerning  the Merger and the other
transactions contemplated by this Agreement. Each of Parent  and the Company
shall (A) furnish to the other party such necessary information and 
assistance as the other reasonably may request in connection with its
preparation of  any filing with, submission or response to inquiries from, or
negotiations with, the  German Federal Cartel Office, (B) keep the other
party apprised promptly of the status  of all inquiries and requests (if any)
for additional information from the German  Federal Cartel Office, (C)
respond as promptly as practicable to all inquiries and  requests received
from the German Federal Cartel Office for additional information or 
documentation, and (D) participate in interviews or meetings reasonably
requested by  the German Federal Cartel Office;

  



    

       

  

     |  

  41

    
---|--- 
   

  



     

  (iii)   _Exon-Florio Provision_. As promptly as  practicable after
the date hereof, the Company and Parent shall submit a joint filing  and any
requested supplemental information (collectively, the  " _Joint Filing_ ") to
CFIUS  pursuant to 31 C.F.R. Part 800 with regard to the Merger and the other
transactions  contemplated by this Agreement. Each of Parent and the Company
shall (A) furnish to the  other party such necessary information and
assistance as the other reasonably may  request in connection with its
preparation of any filing with, submission or response  to inquiries from, or
negotiations with, CFIUS in connection with the Joint Filing, (B)  keep the
other party apprised promptly of the status of all inquiries and requests
(if  any) for additional information from CFIUS in connection with the Joint
Filing, (C)  respond as promptly as practicable to all inquiries and requests
received from CFIUS  for additional information or documentation in
connection with the Joint Filing, and  (D) participate in interviews or
meetings reasonably requested by CFIUS in connection  with the Joint Filing;
and

  

  (iv)   _ITAR_. As promptly as practicable after the  date hereof,
the Company shall notify DDTC with respect to the transactions  contemplated
by this Agreement.

  

  (d)   Notwithstanding anything in this Agreement to the contrary,
it is hereby  expressly agreed that in no event shall Parent or any of its
Affiliates be required by  this Section 7.03 to take, or commit or agree to
take, any action (i) the effectiveness  or consummation of which is not
conditional on the consummation of the Merger, (ii)  that requires the
divestiture, licensing or separate holding of (A) any asset of Parent  or its
Affiliates or (B) any material asset of the Company or its material 
Subsidiaries, (iii) that imposes any limitation, burden or restriction on the
ability  of Parent or its Affiliates (A) except as permitted by Section
7.03(d)(ii)(B), to  operate the business of the Company from and after the
Effective Time in the same  manner, in all material respects, as the business
of the Company was operated  immediately prior to the date hereof, or (B) to
have or exercise, in each case from and  after the Effective Time, full
rights and incidents of beneficial ownership of all of  the outstanding
shares of capital stock of and in the Surviving Corporation and each of  its
material Subsidiaries, including with respect to dividends, voting and
dispositive  power, or (iv) imposes or requires any material limitation,
burden or restriction on  the ability of Parent, from and after the Effective
Time, to designate nominees to, or  otherwise to select the composition of,
the Board of Directors of the Surviving  Corporation and its Subsidiaries, or
to appoint or cause the employment of the  executive officers, senior
management personnel or key policy-making employees of the  Surviving
Corporation and its Subsidiaries (each of the effects referred to in clauses 
(i) through (iv) above, a " _Materially Burdensome  Condition_ ").

  

  

  

  (e)   The parties shall use their commercially reasonable efforts
to obtain  all consents, waivers, authorizations and approvals of all third
parties, including  Governmental Entities, necessary, proper or advisable for
the consummation of the  transactions contemplated by this Agreement or the
Voting Agreement and to provide any  notices to third parties required to be
provided prior to the Effective Time;  _provided_ that the Company shall not
incur  any significant expense or liability or agree to any significant
modification to any  contractual arrangement to obtain such consents or
certificates without the prior  written consent of Parent, such consent not
to be unreasonably withheld or  delayed.

  



    

       

  

     |  

  42

    
---|--- 
   

  



     

       

  

     |  

  SECTION 7.04

     |  

  _Acquisition  Proposal_.

    
---|---|--- 
   

  

  (a)   The Company shall, and shall cause its Subsidiaries to, and
its and  their respective Representatives to, immediately cease any existing
solicitations,  discussions or negotiations with any Person (other than
Parent and its Affiliates) that  has made or indicated an intention to make
an Acquisition Proposal. The Company shall  use commercially reasonable
efforts to have all copies of all non-public information it  or its
Subsidiaries or their respective Representatives have distributed since 
February 26, 2007 to Persons who have executed a confidentiality agreement
in  connection with such Persons' consideration of an Acquisition Proposal
(other  than with respect to Parent and its Affiliates), destroyed or
returned to the Company  as soon as possible.

  

  (b)   Except as set forth in this Section 7.04, the Company shall
not, and  shall cause its Subsidiaries not to, and shall not permit their
respective  Representatives to, directly or indirectly, (i) solicit, initiate
or knowingly  encourage or facilitate (including by way of furnishing non-
public information) any  Acquisition Proposal or the making or receipt
thereof, including approving any  transaction (or any Person (other than
Parent and its Affiliates) becoming an  "interested stockholder") under
Section 203 of the DGCL, or (ii) initiate,  participate in or knowingly
encourage or facilitate any discussions or negotiations  regarding, furnish
to any Person (other than Parent and its Affiliates) any information  with
respect to, assist or participate in any effort or attempt by any Person (or
any  Person (other than Parent and its Affiliates) with respect to, or
otherwise cooperate  in any way with, any Acquisition Proposal or the making
or receipt thereof;  _provided_ ,  _however_ , that, at any time prior to
the  Company Stockholder Approval, if the Company receives a bona fide
written Acquisition  Proposal that did not result from a breach of this
Section 7.04, the Company may  furnish, or cause to be furnished, non-public
information with respect to the Company  and its Subsidiaries to the Person
who made such proposal  ( _provided_ that all such information  has
previously been provided to Parent or is provided to Parent prior to or 
substantially concurrent with the time it is provided to such Person) and
may  participate in discussions and negotiations regarding such proposal if
(x) the  Company Board determines in good faith (after receiving the advice
of its outside legal  counsel and financial advisor), that (A) the failure to
take such action would  reasonably be likely to result in a breach of its
fiduciary duties under applicable Law  and (B) such Acquisition Proposal
either constitutes a Superior Proposal or is  reasonably likely to result in
a Superior Proposal, and (y) prior to taking such  action, the Company enters
into a confidentiality agreement with respect to such  proposal that contains
confidentiality and standstill provisions no less restrictive  than the
Confidentiality Agreement. Without limiting the generality of the foregoing, 
it is agreed that any violation of the restrictions set forth in this Section
7.04(b)  by any Representative of the Company or any of its Subsidiaries
shall be deemed a  breach of this Section 7.04(b) by the Company. The Company
shall promptly advise Parent  orally (with written confirmation to follow
within 24 hours) after receipt by the  Company of any Acquisition Proposal,
including the material terms and conditions  thereof and the identity of the
Person making any such Acquisition Proposal (attaching,  if available, a true
and complete copy thereof). The Company shall keep Parent  reasonably
informed on a prompt basis of the status and material terms (including all 
changes to the status and material terms) of any such Acquisition Proposal.
From and  after the date hereof, the Company shall not and shall cause its
Subsidiaries not to  enter into any confidentiality or other agreement with
any Person or group that  restricts or prohibits the Company or any of its
Subsidiaries from providing to Parent  the foregoing information regarding

  



    

       

  

     |  

  43

    
---|--- 
   

  



     

  (including the identity of the Person submitting) an Acquisition  Proposal
or which provides for any exclusive right of negotiation or dealing. The 
Company agrees not to release any third party from, or waive any provisions
of, any  confidentiality or standstill agreement to which the Company is a
party and shall use  its commercially reasonable efforts to enforce any such
agreement at the request of or  on behalf of Parent, unless the Company Board
determines in good faith (after receiving  the advice of its outside legal
counsel and financial advisor) that such action (or  inaction, in the case of
failing to provide any such release or waiver) would be  inconsistent with
its fiduciary duties under applicable Law.

  

  (c)   Prior to the Company Stockholder Approval, neither the
Company Board nor  any committee thereof shall (r) withdraw or qualify or
modify in a manner adverse to  Parent or Merger Sub or propose (publicly or
otherwise) to withdraw or to qualify or  modify in a manner adverse to Parent
or Merger Sub, the Company Recommendation, (s)  approve, adopt or recommend,
or propose (publicly or otherwise) to approve, adopt or  recommend, an
Acquisition Proposal to holders of the Company Common Stock (any of (r)  and
(s), an " _Adverse  Recommendation_ ") or (t) cause or permit the Company
or  any of its Subsidiaries to enter into any letter of intent, memorandum
of  understanding, agreement in principle, acquisition agreement, merger
agreement, option  agreement, joint venture agreement, partnership agreement
or similar agreement (x)  constituting or relating to, or that is intended or
would reasonably be expected to  lead to, any Acquisition Proposal, other
than a confidentiality agreement referred to  in Section 7.04(b) entered into
in the circumstances referred to in such Section  7.04(b), or (y) requiring
the Company to abandon, terminate or fail to consummate the  Merger or any
other transaction contemplated by this Agreement (any of (x) and (y), an  "
_Acquisition  Agreement_ "). Notwithstanding the foregoing, but subject  to
the Company's compliance at all times with the provisions of Section 7.04,
(I)  if a written Acquisition Proposal is made prior to the Company
Stockholder Approval,  the Company Board may make an Adverse Recommendation,
if (but only if):

  

  (i)   the Company Board has determined in good faith (after
receiving the  advice of its outside legal counsel and financial advisor)
that (A) it is required to  make such Adverse Recommendation in order to
comply with its fiduciary duties under  applicable Law, and (B) such
Acquisition Proposal constitutes a Superior  Proposal;

  

  (ii)   the Company shall have provided Parent five (5) Business
Days'  prior notice (the " _Notice  Period_ ") following Parent's receipt of
written  notice (a " _Notice of Superior  Proposal_ ") from the Company (A)
representing to Parent  that the Company Board has received a Superior
Proposal not in violation of the  provisions of Section 7.04, (B) specifying
the material terms and conditions of such  Superior Proposal (and attaching,
if available, the most current and complete version  of any written agreement
or offer relating thereto), (C) identifying the Person making  such Superior
Proposal and (D) stating that the Company Board intends to make an  Adverse
Recommendation; it being understood and agreed that, prior to any such
Adverse  Recommendation occurring, any amendment to the consideration to be
paid in connection  with such Superior Proposal or material amendment to such
Superior Proposal shall  require a new Notice of Superior Proposal with
respect to such amendments (a  " _Subsequent Notice_ ") and  a new three (3)
Business Day Notice Period (a  " _Subsequent Notice  Period_ ");

  



    

       

  

     |  

  44

    
---|--- 
   

  



     

  (iii)   during such Notice Period or Subsequent Notice Period, as
the case may  be, if requested by Parent, the Company shall have engaged in
good faith negotiations  with Parent and its Representatives so as to permit
Parent to propose to amend this  Agreement in such a manner that the
Acquisition Proposal that was determined to  constitute a Superior Proposal
is no longer determined to constitute a Superior  Proposal; and

  

  (iv)   at the end of the Notice Period or any Subsequent Notice
Period, as the  case may be, such Acquisition Proposal has not been withdrawn
and continues to  constitute a Superior Proposal,

  

and  (II) after an Adverse Recommendation is made in accordance with the
foregoing clause  (I), the Company shall be entitled to enter into a
definitive and binding Acquisition  Agreement providing for a Superior
Proposal if (but only if) this Agreement is  terminated by the Company
pursuant to Section 9.01(e) and, concurrently with and as a  condition to the
effectiveness of any such termination by the Company, the Company  shall,
concurrently with entering into such definitive and binding Acquisition 
Agreement, have paid all amounts due to Parent pursuant to Section 9.02. The
Company  agrees that it will not enter into an Acquisition Agreement
providing for a Superior  Proposal referred to in this Section 7.04(c) until
at least the sixth (6th)  Business Day after it has provided the Notice of
Superior Proposal or until at least  the third (4th) Business Day after it
has provided a Subsequent Notice, as  the case may be.

  

  (d)   Nothing contained in this Section 7.04 shall prohibit the
Company  from at any time taking and disclosing to its stockholders a
position contemplated by  Rule 14d-9 or Rule 14e-2(a) promulgated under the
Exchange Act or making any disclosure  required by Rule 14a-9 promulgated
under the Exchange Act, Rule 14e-2(b)  promulgated under the Exchange Act or
Item 1012(a) of Regulation M-A or from  making any other disclosure to its
stockholders or in any other regulatory filing if,  in the good faith
judgment of the Company Board (after receiving the advice of its  outside
legal counsel and financial advisor), failure to so disclose would be 
inconsistent with its obligations under applicable Law;  _provided_ , 
_however_ , that (solely except in the case of  a "stop-look-and-listen"
communication pursuant to Rule 14d-9(f) under the  Exchange Act) if any such
disclosure does not concurrently and expressly reaffirm the  Company
Recommendation or if it has the effect of withdrawing or qualifying or 
modifying in a manner adverse to Parent or Merger Sub the Company
Recommendation, then  such disclosure shall be deemed to be an Adverse
Recommendation for all purposes of  this Agreement and Parent shall have the
right to terminate this Agreement as set forth  in Section 9.01(f) and
receive the Break-Up Fee in accordance with Sections 9.02 and  9.03.

  

  SECTION  7.05 _Stockholder  Litigation_. The Company shall keep
Parent informed of, and  Parent shall reasonably cooperate with the Company
in connection with, any stockholder  litigation or claim against the Company
and/or its directors or officers relating to  the Merger or the other
transactions contemplated by this Agreement;  _provided_ ,  _however_ , that
no settlement in connection  with such stockholder litigation shall be agreed
to without Parent's prior  written consent, such consent not to be
unreasonably withheld or delayed.

  

  SECTION  7.06 _Public  Announcements_. The initial press release
relating to this  Agreement shall be a joint release the text of which has
been agreed to by each of  Parent and the

  



    

       

  

     |  

  45

    
---|--- 
   

  



     

  Company. Thereafter, each of the Company, Parent and Merger Sub agrees 
that no public release or announcement concerning the transactions
contemplated hereby  shall be issued by any party without the prior written
consent of the Company and  Parent (which consent shall not be unreasonably
withheld or delayed), except as such  release or announcement may be required
by applicable Law or the rules or regulations  of any applicable securities
exchange, in which case the party required to make the  release or
announcement shall use its commercially reasonable efforts to allow each 
other party reasonable time to comment on such release or announcement in
advance of  such issuance; _provided_ ,  _however_ , that upon prior
consultation with  the other party, each of the parties may make statements
that are not inconsistent with  previous press releases, public disclosures
or public statements made by any of the  parties in compliance with this
Section 7.06.

  

  SECTION  7.07 _Tyco  Litigation_. After the date hereof, the
Company shall, to the  full extent permitted by Law and (to the extent
necessary to preserve the  attorney-client privilege) subject to a customary
joint defense agreement, (a) promptly  inform Parent orally (with written
confirmation to follow within two (2) Business Days)  of all material
developments relating to the Tyco Litigation, (b) consult with Parent  with
respect to any material action it intends to take in connection with the
Tyco  Litigation prior to taking such action, (c) provide, or cause to be
provided, to Parent  copies of all pleadings, responses, analyses, opinions,
correspondence and other  documents related to the Tyco Litigation
(collectively,  " _Tyco Litigation  Documents_ "), (d) give Parent
reasonable opportunity (at  least two (2) Business Days) to comment on any
Tyco Litigation Document that is  prepared by or on behalf of the Company or
any of its Affiliates prior to the delivery  of such Tyco Litigation Document
to or filing with a Governmental Entity or other third  party and (e) give
Parent the opportunity to participate in the defense or settlement, 
compromise or resolution of the Tyco Litigation, in whole or in part. The
Company shall  not, and shall cause its Affiliates and Representatives not
to, take any action  intended to settle, compromise or resolve the Tyco
Litigation, in whole or in part,  without Parent's prior written consent.

  

  SECTION  7.08 _J.D. Edwards  ERP Implementation Project._ As
promptly as practicable after the date hereof, the  Company shall cause those
of its Representatives who are responsible for the J.D.  Edwards ERP
Implementation Project to meet with Representatives of Parent and engage in 
good faith discussions and negotiations regarding the timing of, and capital 
expenditures associated with, the J.D. Edwards ERP Implementation Project.

  

  SECTION  7.09 _Credit  Facility._ After the date hereof, Bracco
Imaging shall use its commercially  reasonable efforts to, on or prior to
November 15, 2007, obtain from a reputable  financial institution aggregate
financing in the amount of at least $200,000,000, all  of which shall be
available to Bracco Imaging for use in connection with Parent's  and Merger
Sub's payment obligations under this Agreement.  

  

  SECTION  7.10 _Cimbar  Agreement._ Parent hereby agrees that, at
the Effective Time, it shall accept and  assume (or cause any of its
Affiliates to accept and assume) all of the Company's  right, title and
interest in and to the Manufacturing and Supply Agreement, dated as of  April
30, 2007 (the "Cimbar Agreement"), by and among the Company, E-Z-EM  Canada,
Inc., and will agree (or cause such Affiliate) to be bound by all of the
terms  and conditions of, the Cimbar Agreement.

  



    

       

  

     |  

  46

    
---|--- 
   

  



     

  ARTICLE 8

  

  CONDITIONS PRECEDENT

  

  SECTION  8.01 _Conditions to  the Merger_. The obligations of each
party to effect the  Merger shall be subject to the satisfaction, at or prior
to the Effective Time, of the  following conditions:

  

  (a)   _HSR Act_. The waiting period applicable to  the
consummation of the Merger under the HSR Act shall have expired or been 
terminated.

  

  (b)   _German Antitrust Approval_. One of the  following events
shall have occurred (the earliest of which to occur being  decisive):

  

  (i)   receipt by the Company or Parent of a written notification
or  unconditional decision of the German Federal Cartel Office that the
Merger does not  fulfill the prohibition requirements of the German Act
Against Restraints of  Competition; or

  

  (ii)   expiry of a period of one month after the German Federal
Cartel  Office's receipt of the complete notification of the Merger, unless
the German  Federal Cartel Office shall have informed the Company or Parent
prior to the expiry of  such period that an examination of the Merger has
been initiated (Section 40 paragraph  1 sentence 1 of the German Act Against
Restraints of Competition) or has prohibited the  Merger.

  

  (c)   _Exon-Florio Provision_. The period of time  for any
applicable review process by CFIUS under the Exon-Florio Provision
(including,  if applicable, any investigation commenced thereunder) shall
have expired or been  terminated, CFIUS shall have provided a written notice
to the effect that review of the  transactions contemplated by this Agreement
has been concluded and that a determination  has been made that there are no
issues of national security sufficient to warrant  investigation under the
Exon-Florio Provision, or the President of the United States  shall have made
a decision not to block the transaction.

  

  (d)   _Other Required Approvals_. All other  Required Approvals
shall have been obtained.

  

  (e)   _Stockholder Approval_. The Company shall  have obtained
the Company Stockholder Approval.

  

  (f)   _Proxy Statement_. No Order suspending  the use of the
Proxy Statement shall have been issued and be in effect and no  proceeding
for that purpose shall have been initiated by the SEC and be  continuing.

  

  (g)   _No Order_. No Governmental Entity of  competent
jurisdiction shall have enacted or issued an order, decree, judgment, 
injunction or taken any other action (whether temporary, preliminary or
permanent) that  is in effect (collectively, an  " _Order_ ") and
restrains,  enjoins or otherwise prohibits or makes illegal the consummation
of the Merger;  _provided_ ,  _however_ , that the party claiming the 
failure of the condition set forth in this Section 8.01(g) shall have used
commercially  reasonable efforts to have such Order vacated.

  



    

       

  

     |  

  47

    
---|--- 
   

  



     

  SECTION  8.02 _Conditions to  the Obligations of Parent and Merger
Sub_. The obligations of  Parent and Merger Sub to consummate the Merger are
subject to the satisfaction or  waiver (where legally permissible), on or
prior to the Effective Time, of the following  additional conditions:

  

  (a)   _Representations and Warranties_. The  representations and
warranties of the Company contained in this Agreement shall be true  and
correct as of the date hereof and as of the Effective Time as though made on
and as  of the Effective Time (except to the extent expressly made as of an
earlier date, in  which case as of such earlier date), except (in the case of
representations and  warranties other than those contained in Section
3.09(b)) for failures to be true and  correct that individually or in the
aggregate would not have or be reasonably likely to  have a Company Material
Adverse Effect;  _provided_ , that for purposes of determining  whether the
condition in this Section 8.02(a) is satisfied, references to  "Company
Material Adverse Effect" and any other materiality qualification  contained
in such representations and warranties (other than those contained in
Section  3.09(b)) shall be ignored.

  

  (b)   _Agreements and Covenants_. The Company shall  have
performed or complied in all material respects with all agreements and
covenants  required by this Agreement to be performed or complied with by it
on or prior to the  Effective Time.

  

  (c)   _Officer Certificate_. The Company shall have  delivered
to Parent a certificate, dated the date of the Closing, signed by the Chief 
Executive Officer and Chief Financial Officer of the Company, certifying as to
the  satisfaction of the conditions specified in Sections 8.02(a) and
8.02(b).

  

  (d)   _Third Party Consents_. The Company shall  have obtained
(i) all consents and approvals of third parties listed on Section 8.02(d)  of
the Company Disclosure Schedule and (ii) any other consent or approval of any
third  party (other than a Governmental Entity), required in connection with
this Agreement  and the transactions contemplated hereby, other than consents
or approvals which if not  obtained would not, individually or in the
aggregate, reasonably be expected to result  in a Company Material Adverse
Effect.

  

  (e)   _No Materially Burdensome Condition_. No  Governmental
Entity of competent jurisdiction shall have enacted or issued an Order  that
would reasonably be expected to result in a Materially Burdensome  Condition.

  

  (f)   _No Company Material Adverse Effect_.   Since the date of
this Agreement, there shall not have occurred any Effect that,  individually
or in the aggregate, has had, or would reasonably be expected to have, a 
Company Material Adverse Effect.

  

  (g)   _Appraisal Rights_. Holders of no more than  ten percent
(10%) of the number of shares of Company Common Stock outstanding 
immediately prior to the Effective Time shall have exercised their appraisal
rights in  the Merger in accordance with Section 262.

  

  (h)   _Action Taken Under Section 5.01 to Comply with  Laws_. No
action taken by the Company or any of its  Subsidiaries pursuant to Section
5.01(a) to comply with applicable Law without  Parent's consent (as required
by such Section) shall have otherwise resulted in  any material non-
compliance by the Company with any covenant contained in Section  5.01(a) (it

  



    

       

  

     |  

  48

    
---|--- 
   

  



     

being  understood and agreed, however, that the Company shall not be deemed
to be in breach of  any representation or warranty relating to such Law if
Parent refuses to provide such  consent).

  

  SECTION  8.03 _Conditions to  the Obligations of the Company_. The
obligations of the  Company to consummate the Merger are subject to the
satisfaction or waiver (where  permissible) of the following additional
conditions:

  

  (a)   _Representations and Warranties_. The  representations and
warranties of Parent and Merger Sub contained in this Agreement  shall be
true and correct in all material respects as of the date hereof and as of
the  Effective Time, as though made on and as of the Effective Time (except
to the extent  expressly made as of an earlier date, in which case as of such
earlier date), except  for failures to be true and correct that individually
or in the aggregate would not  prevent or materially delay the ability of
Parent and Merger Sub to perform their  respective obligations under this
Agreement;  _provided_ , that for purposes of determining  whether the
condition in this Section 8.03(a) is satisfied, references to any 
materiality qualification contained in such representations and warranties
shall be  ignored.

  

  (b)   _Agreements and Covenants_. Parent and Merger  Sub shall
have performed or complied in all material respects with all agreements and 
covenants required by this Agreement to be performed or complied with by it on
or prior  to the Effective Time.

  

  (c)   _Officer Certificate_. Parent shall have  delivered to the
Company a certificate, dated the date of the Closing, signed by the  Chief
Executive Officer or Chief Financial Officer of Parent, certifying as to the 
satisfaction of the conditions specified in Sections 8.03(a) and 8.03(b).

  

  SECTION  8.04 _Frustration of  Closing Conditions_. No party may
rely on the failure of any  condition set forth in this Article 8 to be
satisfied if such party's failure to  comply with any provision of this
Agreement in a material respect has been the  proximate cause of, or resulted
in, the failure of the condition.

  

  ARTICLE 9

  

  TERMINATION

  

  SECTION  9.01   _Termination_. This Agreement may be 
terminated and abandoned, whether before or after receipt of the Company
Stockholder  Approval (except as set forth in this Section 9.01), prior to
the Effective Time, by  action taken by the Board of Directors of the
terminating party, only as  follows:

  

       

  

     |  

  (a)

     |  

  by the mutual written consent of Parent and the  Company;

    
---|---|--- 
   

  

       

  

     |  

  (b)

     |  

  by either the Company or Parent by written notice to the  other:

    
---|---|--- 
   

  

    (i)   if at the Company Stockholders Meeting (or at any
adjournment or  postponement thereof permitted by this Agreement) the Company
Stockholder Approval is  not obtained (provided that the right to terminate
this Agreement under this Section  9.01(b)(i) shall not be available to the
Company if at such time the Company is in  material breach this Agreement);

  



    

       

  

     |  

  49

    
---|--- 
   

  



     

  (ii)   if any Governmental Entity of competent jurisdiction shall
have enacted,  issued, promulgated, enforced or entered any Order that is in
effect and restrains,  enjoins or otherwise prohibits or makes illegal the
consummation of the Merger, and  such Order shall have become final and non-
appealable; or

  

  (iii)   if the consummation of the Merger shall not have occurred
on or before  April 30, 2008 (the " _Outside  Date_ ");  _provided_ , 
_however_ , that the Outside Date shall be  extended to and be deemed to be
July 31, 2008 if (but only if) on April 30, 2008, all  of the conditions to
Closing set forth in Article 8 shall have been satisfied, other  than the
conditions set forth in Sections 8.01(a), 8.01(b), 8.01(c), 8.01(d), 8.02(c) 
and 8.03(c);

  

  (c)   by written notice from Parent to the Company, if the
Company breaches or  fails to perform any of its representations, warranties
or covenants contained in this  Agreement, which breach or failure to perform
would give rise to the failure of a  condition set forth in Section 8.02(a)
or 8.02(b), and such condition is  incapable of being satisfied by the
Outside Date or such breach has not been cured by  the Company within thirty
(30) days after the Company's receipt of written notice  of such breach from
Parent;

  

  (d)   by written notice from the Company to Parent if Parent or
Merger Sub  breaches or fails to perform any of its representations,
warranties or covenants  contained in this Agreement, which breach or failure
to perform would give rise to the  failure of a condition set forth in
Section 8.03(a) or 8.03(b) and such  condition is incapable of being
satisfied by the Outside Date or such breach has not  been cured by Parent or
Merger Sub within thirty (30) days after Parent's receipt  of written notice
of such breach from the Company;

  

  (e)   by written notice from the Company to Parent, at any time
prior to the  Company Stockholder Approval, in accordance with, and subject
to the terms and  conditions of, Section 7.04(c)(II);

  

  (f)   by written notice of Parent to the Company, if (i) the
Company Board (or  any committee thereof) shall (A) fail to include the
Company Recommendation in the  Proxy Statement, (B) make an Adverse
Recommendation or resolve to do so, (C) fail  to reconfirm the Company
Recommendation within five days after Parent so requests in  writing (which
five day period will be extended for one additional five day period if  the
Company certifies to Parent prior to the expiration of the initial five day
period  that the Company Board is in good faith seeking to obtain additional
information  regarding its decision to reconfirm the Company Recommendation),
or (D) if a tender  offer or exchange offer for any of the outstanding shares
of Company Common Stock has  been publicly disclosed (other than by Parent or
an Affiliate of Parent) and, the  Company Board (or any committee thereof)
recommends that the stockholders of the  Company tender their shares in such
tender or exchange offer or (ii) (A) the Company  breaches or fails to
perform in any material respect any of its obligations under  Section 7.04,
(B) the Company Stockholder Approval is not obtained at the Company 
Stockholders Meeting (or at any adjournment or postponement thereof permitted
by this  Agreement) and (C) on or after the date of this Agreement and on or
prior to the date  of the Company Stockholders Meeting (or any adjournment or
postponement thereof  permitted by this Agreement), an Acquisition Proposal
shall have been publicly  announced by any Person or group (other than Parent
or any of its

  



    

       

  

     |  

  50

    
---|--- 
   

  



     

  Affiliates) or publicly disclosed by the Company and remains outstanding 
at the time of such termination; or

  

  (g)   by written notice of Parent to the Company, if a
Governmental Entity of  competent jurisdiction shall have enacted or issued a
final and non-appealable Order  that would reasonably be expected to result
in a Materially Burdensome  Condition.

  

       

  

     |  

  SECTION 9.02

     |  

  _Effect of  Termination_.

    
---|---|--- 
   

  

  (a)   Subject to the remainder of this Section 9.02 and to 
Section 9.03, in the event of the termination of this Agreement pursuant to 
Section 9.01, this Agreement shall forthwith become null and void and have
no  effect, without any liability on the part of Parent, Merger Sub or the
Company and each  of their respective directors, trustees, officers,
employees, partners, stockholders or  stockholders and all rights and
obligations of any party hereto shall cease, except for  the agreements
contained in Sections 7.02(c) (Confidentiality), 7.06 (Public 
Announcements), this 9.02 (Effect of Termination), 9.03 (Fees and Expenses)
and  Article 10 (Miscellaneous), which shall remain in full force and effect
and  survive any termination of this Agreement;  _provided_ ,  _however_ ,
that nothing contained in this  Section 9.02(a) shall relieve any party
hereto from liabilities or damages  arising out of any fraud or willful
breach by such party of any of its representations,  warranties, covenants or
other agreements contained in this Agreement.

  

  (b)   The Company shall pay to Parent an amount in cash equal to
$9,000,000  (the " _Break-Up Fee_ ")  if:

  

  (i)   this Agreement is terminated by the Company pursuant to
Section  9.01(e);

  

  (ii)   this Agreement is terminated by Parent pursuant to Section
9.01(f)(i);  or

  

  (iii)   this Agreement is terminated by the Company or Parent
pursuant to  Section 9.01(b)(iii), without the Company Stockholder Meeting
having occurred, or  Section 9.01(b)(i), or by Parent pursuant to Section
9.01(c) or Section 9.01(f)(ii),  if, in any such case (x) at any time after
the date of this Agreement and before such  termination (or in the case of a
termination pursuant to Section 9.01(f)(ii), on or  after the date of this
Agreement and on or prior to the date of the Company Stockholder  Meeting (or
any adjournment or postponement thereof permitted by this Agreement)), an 
Acquisition Proposal shall have been publicly announced by any Person or group
(other  than Parent or any of its Affiliates) or publicly disclosed by the
Company, and remains  outstanding at the time of such termination and (y)
within 12 months of such  termination the Company shall have entered into a
definitive agreement with respect to,  or shall have consummated, any
Acquisition Proposal (substituting 60% for 20% in the  definition thereof)
(which need not be the same Acquisition Proposal made prior to  termination).

  

  (c)   Any fee due under Section 9.02(b) shall be paid by the
Company by  wire transfer of same-day funds:

  



    

       

  

     |  

  51

    
---|--- 
   

  



     

  (i)   in the case of Section 9.02(b)(i), concurrently with (and
as condition  to the effectiveness of) such termination;

  

  (ii)   in the case of Section 9.02(b)(ii), within one Business
Day of such  termination; and

  

  (iii)   in the case of Section 9.02(b)(iii), concurrently with the
consummation  of such Acquisition Proposal (including any such consummation
occurring after the  twelve (12) month period referred to in such Section
with respect to any definitive  agreement referred to therein entered into
during such twelve (12) month  period).

  

       

  

     |  

  SECTION 9.03

     |  

  _Fees and  Expenses_.

    
---|---|--- 
   

  

  (a)   Except as set forth in Section 9.02 and this Section 9.03,
whether or  not the Merger is consummated, all fees, costs and expenses
incurred in connection with  the preparation, execution and performance of
this Agreement and the transactions  contemplated hereby, including all fees,
costs and expenses of agents, representatives,  financial advisors, counsel
and accountants shall be paid by the party incurring such  fees, costs or
expenses.

  

  (b)   If this Agreement is terminated by Parent pursuant to
Section 9.01(c) or  Section 9.01(f)(ii), the Company shall pay to Parent
within five Business Days after  the date of termination all documented,
reasonable out-of-pocket costs and expenses,  including the reasonable fees
and expenses of lawyers, accountants, financial advisors  and investment
bankers, incurred by Parent in connection with the entering into of this 
Agreement and the carrying out of any and all acts contemplated hereunder,
provided  that such fees and expenses to be paid by the Company hereunder
shall not exceed  $2,000,000; _provided_ ,  _however_ , that if a Break-Up
Fee is payable  by the Company pursuant to Section 9.02(b)(iii), then the
Company may reduce the amount  to be paid by it pursuant to such Section by
the amount of any expense reimbursement  paid by the Company to the Buyer
pursuant to this Section 9.03(b).

  

  (c)   If this Agreement is terminated by the Company pursuant
to  Section 9.01(d), Parent shall pay to the Company within five Business
Days after  the date of termination all documented, reasonable out-of-pocket
costs and expenses,  including the reasonable fees and expenses of lawyers,
accountants, financial advisors  and investment bankers, incurred by the
Company in connection with the entering into of  this Agreement and the
carrying out of any and all acts contemplated hereunder,  provided that such
fees and expenses to be paid by Parent hereunder shall not exceed 
$2,000,000.

  

  (d)   The parties acknowledge that the agreements contained in
Sections 9.02  and 9.03 are an integral part of the transactions contemplated
by this Agreement, and  that, without these agreements, the parties would not
enter into this Agreement. If one  party fails to promptly pay to the other
any expense reimbursement or fee due under  Sections 9.02 or 9.03, the
defaulting party shall pay the costs and expenses (including  reasonable
legal fees and expenses) in connection with any action, including the filing 
of any Action, taken to collect payment, together with interest on the amount
of any  unpaid fee at the publicly announced prime rate of Citibank N.A. plus
five percent (5%)  per annum, compounded quarterly, from the date such
expense reimbursement or fee was  required to be paid.

  



    

       

  

     |  

  52

    
---|--- 
   

  



     

  (e)   The parties further acknowledge and agree that (i) damages
attributable  to a termination of this Agreement as referenced in Sections
9.02 and 9.03 are  uncertain in amount, (ii) the fees provided in Sections
9.02 and 9.03 are a reasonable  fee and estimate of such damages at the time
the parties hereto executed and delivered  this Agreement and (iii) the
amounts to be paid pursuant to this Section 9.03  constitute liquidated
damages negotiated at arm's-length and do not constitute,  and are not
intended by the parties to operate as, a penalty.

  

  SECTION  9.04   _Amendment_. This Agreement may be amended by  the
parties hereto, by action taken or authorized by their respective Boards of 
Directors, at any time before or after approval of the matters presented in
connection  with the Merger by the stockholders of the Company, but, after
any such approval, no  amendment shall be made which by applicable Law
requires further approval by such  stockholders without such further
approval. This Agreement may not be amended except by  an instrument in
writing signed on behalf of each of the parties hereto.

  

  SECTION  9.05 _Extension;  Waiver_. At any time prior to the
Effective Time, the parties  hereto, by action taken or authorized by their
respective Boards of Directors, may, to  the extent legally allowed, (a)
extend the time for the performance of any of the  obligations or other acts
of the other parties hereto, (b) waive any inaccuracies in  the
representations and warranties contained herein or in any document delivered 
pursuant hereto and (c) waive compliance with any of the agreements or
conditions  contained herein. Any agreement on the part of a party hereto to
any such extension or  waiver shall be valid only if set forth in a written
instrument signed on behalf of  such party. The failure of any party to this
Agreement to assert any of its rights  under this Agreement or otherwise
shall not constitute a waiver of those  rights.

  

  ARTICLE 10

  

  MISCELLANEOUS

  

  SECTION 10.01   _Non-Survival of Representations, Warranties and 
Agreements_. None of the representations, warranties,  covenants and other
agreements in this Agreement or in any instrument delivered  pursuant to this
Agreement, including any rights arising out of any breach of such 
representations, warranties, covenants and other agreements, shall survive
the  Effective Time, except for those covenants and agreements contained
herein and therein  that by their terms apply or are to be performed in whole
or in part after the  Effective Time.

  

  SECTION 10.02   _Successors and Assigns_. No party hereto  shall
assign this Agreement or any rights or obligations hereunder without the
prior  written consent of the other parties hereto and any such attempted
assignment without  such prior written consent shall be void and of no force
and effect;  _provided_ , that, without the prior consent  of the Company,
each of Parent and Merger Sub may assign any of its rights hereunder to  its
Affiliates (but shall remain liable for all of its obligations under this 
Agreement). Any attempted assignment in violation of this Section 10.02 shall
be void.  This Agreement shall inure to the benefit of and shall be binding
upon the successors  and permitted assigns of the parties hereto.

  

       

  

     |  

  SECTION 10.03

     |  

  _Governing Law; Jurisdiction;  Remedies_.

    
---|---|--- 
   

  

       

  

     |  

  (a)

     |  

  This Agreement shall be construed, performed and  enforced in accordance

    
---|---|--- 
   

  



    

       

  

     |  

  53

    
---|--- 
   

  



     

with,  and governed by, the laws of the State of Delaware without giving
effect to any choice  or conflict of law provision or rule (whether of the
State of Delaware or any other  jurisdiction). The parties hereto irrevocably
elect as the sole judicial forum for the  adjudication of any matters arising
under or in connection with this Agreement, and  consent to the jurisdiction
of, the courts of the State of Delaware.

  

  (b)   Each party hereto irrevocably submits to the exclusive
jurisdiction of  (i) the Chancery Court of the State of Delaware (or other
appropriate state court in  the State of Delaware), and (ii) the United
States District Court for the District of  Delaware, for the purposes of any
Action arising out of this Agreement or any  transaction contemplated hereby.
Each party hereto agrees to commence any Action  relating hereto in the
Chancery Court of the State of Delaware or, if such Action may  not be
brought in such court for reasons of subject matter jurisdiction in the
United  States District Court for the District of Delaware. Each party hereto
irrevocably and  unconditionally waives any objection to the laying of venue
of any Action arising out  of this Agreement or the transactions contemplated
hereby in (A) the Chancery Court of  the State of Delaware, or (B) the United
States District Court for the District of  Delaware, and hereby further
irrevocably and unconditionally waives and agrees not to  plead or claim in
any such court that any such Action brought in any such court has  been
brought in an inconvenient forum. Each party hereto further irrevocably
consents  to the service of process out of any of the aforementioned courts
in any such Action by  the mailing of copies thereof by mail to such party at
its address set forth in this  Agreement, such service of process to be
effective upon acknowledgment of receipt of  such registered mail; provided
that nothing in this Section 10.03 shall affect the  right of any party to
serve legal process in any other manner permitted by applicable  Law. The
consent to jurisdiction set forth in this Section 10.03 shall not constitute
a  general consent to service of process in the State of Delaware and shall
have no effect  for any purpose except as provided in this Section 10.03. The
parties hereto agree that  a final judgment in any such Action shall be
conclusive and may be enforced in other  jurisdictions by suit on the
judgment or in any other manner provided by applicable  Law. Without limiting
the foregoing, each party agrees that service of process on such  party as
provided in Section 10.05 as to giving notice thereunder shall be deemed 
effective service of process on such party.

  

  (c)   Each party acknowledges and agrees that the other parties
would be  damaged irreparably if any provision of this Agreement were not
performed in accordance  with its specific terms or were otherwise breached.
Accordingly, the parties will be  entitled to an injunction or injunctions to
prevent breaches of the provisions of this  Agreement and to enforce
specifically this Agreement and its provisions in any Action  instituted in
any state or federal court sitting in the State of Delaware having 
jurisdiction over the parties and the matter, in addition to any other remedy
to which  they may be entitled, at Law or in equity. Except as expressly
provided herein, the  rights, obligations and remedies created by this
Agreement are cumulative and in  addition to any other rights, obligations or
remedies otherwise available at Law or in  equity. Except as expressly
provided herein, nothing herein will be considered an  election of remedies.

  

  (d)   _WAIVER OF JURY TRIAL_. EACH OF THE PARTIES  HEREBY WAIVES
TRIAL BY JURY IN ANY JUDICIAL PROCEEDING INVOLVING, DIRECTLY, IN ANY  MATTERS
(WHETHER SOUNDING IN TORT, CONTRACT OR OTHERWISE) IN ANY WAY ARISING OUT OF, 
RELATED TO, OR CONNECTED WITH, THIS

  



    

       

  

     |  

  54

    
---|--- 
   

  



     

  AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY. EACH OF THE PARTIES 
HERETO HEREBY WAIVES TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW ANY
RIGHT IT MAY  HAVE TO A TRIAL BY JURY WITH RESPECT TO ANY LITIGATION DIRECTLY
OR INDIRECTLY ARISING  OUT OF, UNDER OR IN CONNECTION WITH THIS AGREEMENT OR
THE TRANSACTIONS CONTEMPLATED BY  THIS AGREEMENT. EACH OF THE PARTIES HERETO
(A) CERTIFIES THAT NO REPRESENTATIVE, AGENT  OR ATTORNEY OF ANY OTHER PARTY
HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER  PARTY WOULD NOT, IN
THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER AND  (B)
ACKNOWLEDGES THAT IT AND THE OTHER PARTIES HERETO HAVE BEEN INDUCED TO ENTER
INTO  THIS AGREEMENT AND THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT, AS
APPLICABLE, BY,  AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN
THIS SECTION  10.03(D).

  

       

  

     |  

  Section 10.04

     |  

  _Severability;  Construction_.

    
---|---|--- 
   

  

  (a)   Any term or provision of this Agreement that is invalid or
unenforceable  in any situation in any jurisdiction shall not affect the
validity or enforceability of  the remaining terms and provisions hereof or
the validity or enforceability of the  offending term or provision in any
other situation or in any other jurisdiction. If the  final judgment of a
court of competent jurisdiction declares that any term or provision  hereof
is invalid or unenforceable, the parties hereto agree that the court making
such  determination shall have the power to limit the term or provision, to
delete specific  words or phrases, or to replace any invalid or unenforceable
term or provision with a  term or provision that is valid and enforceable and
that comes closest to expressing  the intention of the invalid or
unenforceable term or provision, and this Agreement  shall be enforceable as
so modified. In the event such court does not exercise the  power granted to
it in the prior sentence, the parties hereto agree to replace such  invalid
or unenforceable term or provision with a valid and enforceable term or 
provision that shall achieve, to the extent possible, the economic, business
and other  purposes of such invalid or unenforceable term.

  

  (b)   This Agreement has been freely and fairly negotiated among
the parties.  If an ambiguity or question of intent or interpretation arises,
this Agreement will be  construed as if drafted jointly by the parties and no
presumption or burden of proof  will arise favoring or disfavoring any party
because of the authorship of any provision  of this Agreement. Any reference
to any applicable Law will be deemed to refer to such  Law as in effect on
the date hereof and all rules and regulations promulgated  thereunder, unless
the context requires otherwise. The words "include,"  "includes," and
"including" will be deemed to be followed by  "without limitation." Pronouns
in masculine, feminine, and neuter genders  will be construed to include any
other gender, and words in the singular form will be  construed to include
the plural and vice versa, unless the context otherwise requires.  The words
"this Agreement," "herein," "hereof,"  "hereby," "hereunder," and words of
similar import refer to  this Agreement as a whole and not to any particular
subdivision unless expressly so  limited. The parties intend that each
representation, warranty, and covenant contained  herein will have
independent significance. Time is of the essence in the performance of  this
Agreement.

  

  SECTION 10.05   _Notices_. All notices and other  communications
provided for herein shall be in writing and shall be deemed to have been 
duly given, delivered and received (a) if

  



    

       

  

     |  

  55

    
---|--- 
   

  



     

  delivered personally or (b) if sent by facsimile, registered or  certified
mail (return receipt requested) postage prepaid, or by courier guaranteeing 
next day delivery, in each case to the applicable party to whom it is directed
at the  addresses indicated below:

  

  If to the Company:

  

  E-Z-EM, Inc.

  

  1111 Marcus Avenue

  

  Suite LL-26

  

  Lake Success, New York 11042

  

  Attention: Anthony Lombardo

  

       

  

     |  

  Peter Graham, Esq.

    
---|--- 
   

  

  Tel: (516) 333-8230

  

  Fax: (516) 302-2918

  

  

  

  Copy to (such copy not to constitute notice):

  

  Davies Ward Phillips and Vineberg LLP

  

  625 Madison Avenue, 12th Floor

  

  New York, New York 10022

  

  Attention: Steven H. Levin, Esq.

  

       

  

     |  

  Gerald D. Shepherd, Esq.

    
---|--- 
   

  

  Tel: (212) 588-5500

  

  Fax: (212) 308-0132

  

  

  

  If to Parent or Merger Sub:

  

  Bracco Diagnostics, Inc.

  

  107 College Road East

  

  Princeton, NJ 08540

  

  Attention: Carlo Medici

  

  Tel: (609) 514-2200

  

  Fax: (609) 514-2424

  

  

  

  Copy to (such copy not to constitute notice):

  

  

  

  Greenberg Traurig, LLP

  

  The Met Life Building

  

  200 Park Avenue

  

  New York, New York 10166

  

  Attention: Lorenzo Borgogni, Esq.

  

  Tel: (212) 801-9200

  

  Fax: (212) 801-6400

  

  

  

or, as  to each of the foregoing, at such other address as shall be
designated by such party in  a written notice to other parties complying as
to delivery with the terms of this  Section 10.05. Notices delivered
personally shall be effective on the day so delivered,  notices sent by
registered

  



    

       

  

     |  

  56

    
---|--- 
   

  



     

or  certified mail shall be effective five (5) days after mailing, notices
sent by  facsimile shall be effective when receipt is acknowledged, and
notices sent by courier  guaranteeing next day delivery shall be effective on
the day of actual delivery by the  courier.

  

  SECTION 10.06   _Entire Agreement_. This Agreement and the 
Confidentiality Agreement contain the entire understanding among the parties
hereto  with respect to the transactions contemplated hereby and supersede
and replace all  prior and contemporaneous agreements and understandings,
oral or written, with regard  to such transactions. All Exhibits and
Schedules hereto and any documents and  instruments delivered pursuant to any
provision hereof are expressly made a part of  this Agreement as fully as
though completely set forth herein.

  

  SECTION 10.07   _Parties in Interest_. Except for the rights  to
continued indemnification and insurance pursuant to Section 6.02 hereof (of
which  the Persons entitled to indemnification or insurance, as the case may
be, are the  intended beneficiaries following the Effective Time), nothing in
this Agreement is  intended to confer any rights or remedies under or by
reason of this Agreement on any  Persons other than the parties hereto and
their respective successors and permitted  assigns. Nothing in this Agreement
is intended to relieve or discharge the obligations  or liability of any
third Persons to the Company or Parent. No provision of this  Agreement shall
give any third parties any right of subrogation or action over or  against
the Company or Parent.

  

  SECTION 10.08   _Section and Paragraph Headings_. The section  and
paragraph headings in this Agreement are for reference purposes only and shall
not  affect the meaning or interpretation of this Agreement.

  

  SECTION 10.09   _Counterparts_. This Agreement may be  executed in
two or more counterparts, each of which will be deemed an original but all 
of which together will constitute one and the same instrument, and delivered
by means  of a facsimile or portable document format (pdf) transmission. This
Agreement will  become effective when one or more counterparts have been
signed by each of the parties  and delivered to the other parties. For
purposes of determining whether a party has  signed this Agreement or any
document contemplated hereby or any amendment or waiver  hereof, only a
handwritten original signature on a paper document or a facsimile copy  of
such a handwritten original signature shall constitute a signature,
notwithstanding  any applicable Law relating to or enabling the creation,
execution or delivery of any  contract or signature by electronic means.

  

  SECTION 10.10   _Company Disclosure Schedule_. There may have  been
included in the Company Disclosure Schedule items which are not  "material"
and such inclusion shall not be deemed to be an agreement by the  Company
that such items are "material" or to further define the meaning of  such term
for purposes of this Agreement.

  

  SECTION 10.11   _Bracco Imaging_. Bracco Imaging agrees to  take all
action necessary to cause Parent and Merger Sub to perform all of their 
respective agreements, covenants and obligations under this Agreement,
including by  providing Parent or Merger Sub, as the case may be, with all
necessary funds to enable  Parent or Merger Sub, as the case may be, to
comply with its obligations under this  Agreement.

  



    

       

  

     |  

  57

    
---|--- 
   

  



     

       

  

     |  

  SECTION 10.12

     |  

  _Definitions_. (a) As used in  this Agreement:

    
---|---|--- 
   

  

  " _Acquisition  Proposal_ " means any oral or written inquiry, proposal, 
indication of interest or offer from any Person or group (other than Parent,
Merger Sub  or any of their respective Affiliates), whether in one
transaction or a series of  transactions, relating to, or that would
reasonably be expected to lead to, (a) any  direct or indirect acquisition by
any means of (i) 20% or more of the consolidated  revenues, net income, cash
flows or assets of the Company and its Subsidiaries, taken  as a whole, or
(ii) 20% or more of the equity securities of the Company (including by 
issuance thereof by the Company) then outstanding; (b) any tender offer or 
exchange offer, as defined under the Exchange Act, that, if consummated, would
result  in any Person or group beneficially owning 20% or more of the equity
securities of the  Company then outstanding; or (c) any merger,
consolidation, business combination,  recapitalization, reorganization, share
exchange, split-off, spin-off, liquidation,  dissolution or similar
transaction involving the Company or any of its Subsidiaries, in  each case
other than the Merger and the other transactions contemplated  hereby.

  

  " _Affiliate_ "  shall mean, with respect to any Person, any other Person
that directly, or through one  or more intermediaries, controls or is
controlled by or is under common control with  such Person.

  

  " _Board of  Directors_ " shall mean the Board of Directors of any 
specified Person.

  

  " _Business  Day_ " shall mean any day on which banks are not required 
or authorized to close in New York, New York or Milan, Italy.

  

  " _Company Material Adverse  Effect_ " means any Effect that is materially
adverse to  (i) the business, financial condition or results of operations of
the Company and its  Subsidiaries taken as a whole or (ii) the ability of the
Company to consummate the  transactions contemplated by this Agreement; 
_provided_ ,  _however_ , that in no event shall any of the  following be
deemed to constitute a Company Material Adverse Effect: (a) any  Effect that
results from changes in general economic conditions or changes in  securities
markets in general, (b) any Effect that results from general changes in the 
industry in which the Company and its Subsidiaries operate, (c) any Effect 
(including the loss by the Company or any of its Subsidiaries of customers,
suppliers  or employees) arising out of to the public announcement of the
transactions  contemplated by this Agreement, (d) any Effect that results
from any action taken  by the Company at the written request of Parent, (e)
any change, in and of itself, in  the price or trading volume of the shares
of Company Common Stock (it being agreed that  this exception does not cover
the underlying reasons for such change), (f) in and of  itself, meeting, or
failing to meet, any internal or published projections, forecasts  or review
or earnings predictions for any period ending on or after the date of this 
Agreement (it being agreed that this exception does not cover the underlying
reasons  for such change), (g) any Effect arising out of the Tyco Litigation,
(h) any action or  change contemplated by the provisions of this Agreement
(other than as a result of the  Company's compliance with its obligation
under this Agreement to conduct its  business in the ordinary course), or (i)
any change in Laws;  _except_ in the case of clauses (a) and (b),  for any
Effect that has a significantly disproportionate adverse impact on the
Company  and its Subsidiaries compared to other companies of similar size
operating in the  industry in which the Company and its Subsidiaries operate.

  



    

       

  

     |  

  58

    
---|--- 
   

  



     

  " _Effect_ "  means any event, circumstance, change, development,
condition or effect.

  

  " _Environmental  Laws_ " shall mean any federal, state, local or
foreign,  statute, regulation, ordinance, order, decree, directive or other
requirement of Law  (including, without limitation, common law) relating to
human health, safety or  welfare, wildlife, natural resources, flora, fauna
or the environment (including,  without limitation, indoor or outdoor air,
water, water vapor, groundwater, drinking  water, surface or subsurface land,
noise and odor), or to the identification,  generation, use, labeling,
processing, control, transportation, handling, discharge,  emission,
treatment, storage, disposal, investigation, removal, remediation, 
import/export, or monitoring of, or exposure to, any pollutant, contaminant,
hazardous  or solid waste, or any hazardous or toxic substance, or material.

  

  " _ERISA_ "  shall mean the Employee Retirement Income Security Act of
1974, as amended.

  

  " _Governmental  Entity_ " shall mean any federal, state, local or
foreign  governmental, regulatory or administrative authority, branch, agency
or commission or  any court, tribunal, judicial or arbitral body.

  

  " _Hazardous  Material_ " shall mean any product, substance, gas, 
chemical, microbial matter, material or waste, whose presence, nature,
quantity or  concentration, either by itself or in combination with other
materials is (a)  potentially injurious to human health or safety, the
environment or natural resources  or (b) regulated, monitored or subject to
reporting by any Governmental Entity relating  to Environmental Laws.

  

  " _IFRS_ "  shall mean International Financial Reporting Standards.

  

  " _IRS_ "  shall mean the United States Internal Revenue Service.

  

  " _J.D. Edwards ERP Implementation  Project_ " shall mean the replacement
of MAPIC ERP  applications with J.D. Edwards ERP applications.

  

  " _Knowledge_ "  shall mean, with respect to the Company, the actual
knowledge of the officers of the  Company listed on _Schedule I_   (without
independent inquiry or investigation).

  

  " _Law_ "  means any federal, national, supranational, state, provincial,
local or similar  statute, law, ordinance, regulation, executive order, rule,
code, Order, requirement or  rule of law (including common law) of a
Governmental Entity.

  

  " _Lien_ "  shall mean any mortgage, pledge, security interest,
encumbrance or title defect, lease,  lien (statutory or other), conditional
sale agreement, claim, charge, limitation or  restriction.

  

  " _NASDAQ_ "  shall mean The NASDAQ Global Market, Inc.

  

  " _Permitted  Liens_ " shall mean (a) liens for utilities and current 
Taxes and assessments not yet due and payable and (b) mechanics',  carriers',
workers', repairers', materialmen's,  warehousemen's, and other similar liens
arising or incurred in the ordinary  course of business not yet due and
payable, if the same shall not at the time be  delinquent or thereafter can
be paid

  



    

       

  

     |  

  59

    
---|--- 
   

  



     

  without penalty or are being contested in good faith by appropriate 
proceedings and for which appropriate reserves have been included on the
balance sheet  of the applicable Person (provided that, in the case of assets
material to the business  of the Company or any of its Subsidiaries, taken as
a whole, such liens do not and  would not reasonably be expected to
materially impair the continued use or operation of  such assets or, in the
case of any real property, render the title to such real  property
unmarketable).

  

  " _Person_ "  shall mean an individual, corporation, limited liability
company, partnership,  association, trust, unincorporated organization, other
entity or group (as defined in  the Exchange Act).

  

  " _Regulatory  Law_ " means the Sherman Act, the Clayton Act, the HSR 
Act, the Federal Trade Commission Act, the German Act Against Restraints of 
Competition, in each case as amended, and all other federal, state and
foreign, if any,  statutes, rules, regulations, orders, decrees,
administrative and judicial doctrines  and other laws that are designed or
intended to prohibit, restrict or regulate actions  having the purpose or
effect of monopolization or restraint of trade or lessening of  competition
through merger or acquisition.

  

  " _Representative_ "  means, with respect to any Person, (i) such Person's
directors, officers,  employees or (ii) any investment banker, financial
advisor, attorney, accountant or  other advisor, agent representative of such
Person, when acting as such or (iii) any  controlled Affiliate of such
Person.

  

  " _Subsidiary_ "  when used with respect to any party shall mean any
corporation, partnership or other  organization, whether incorporated or
unincorporated, (i) of which such party or any  other Subsidiary of such
party is a general partner (excluding partnerships, the  general partnership
interests of which held by such party or any Subsidiary of such  party do not
have a majority of the voting interests in such partnership) or (ii) at 
least a majority of the securities or other interests of which having by their
terms  ordinary voting power to elect a majority of the Board of Directors or
others  performing similar functions with respect to such corporation or
other organization is  directly or indirectly owned or controlled by such
party or by any one or more of its  Subsidiaries, or by such party and one or
more of its Subsidiaries.

  

  " _Superior  Proposal_ " means any bona fide, written offer made (not  in
violation of Section 7.04) to the Company Board by any Person (other than
Parent and  its Affiliates) that if consummated would result in such Person
(or its stockholders,  partners, trustees or members) owning, directly or
indirectly, in a transaction or  series of transactions, more than 60% of the
shares of Company Common Stock then  outstanding (or of the shares of the
surviving entity in a merger or the direct or  indirect parent of the
surviving entity in a merger) or more than 60% of the assets of  the Company,
that, in each case, the Company Board determines in good faith (after 
receiving the advice of its outside legal counsel and financial advisor), is
(a)  reasonably capable of being consummated in accordance with its terms
(relative also to  the expected time of consummation of the transactions
contemplated by this Agreement),  taking into account all legal, financial
(including whether financing (to the extent  required) is then fully
committed), regulatory and other aspects of the offer and the  Person making
the offer and (b) more favorable to the holders of the Company Common  Stock
from a financial point of view than the Merger taking into account all the
terms  and conditions of such offer and this Agreement (including any

  



    

       

  

     |  

  60

    
---|--- 
   

  



     

  proposal by Parent to amend the terms of this Agreement pursuant to 
Section 7.04(c)).

  

  " _Tax  Return_ " shall mean any report, return, information  return,
filing, claim for refund or other information, including any schedules or 
attachments thereto, and any amendments to any of the foregoing required to be
supplied  to a taxing authority in connection with Taxes.

  

  " _Taxes_ "  shall mean all federal, state, local or foreign taxes,
including, without limitation,  income, gross income, gross receipts,
production, excise, employment, sales, use,  transfer, ad valorem, value
added, profits, license, capital stock, franchise,  severance, stamp,
withholding, Social Security, employment, unemployment, disability,  worker's
compensation, payroll, utility, windfall profit, custom duties, personal 
property, real property, taxes required to be collected from customers on the
sale of  services, registration, alternative or add-on minimum, estimated and
other taxes,  governmental fees or like charges of any kind whatsoever,
whether disputed or not,  including any interest, penalties or additions
thereto; and  " _Tax_ " shall mean any one  of them.

  

  " _U.S.  GAAP_ " shall mean United States generally accepted  accounting
principles as in effect from time to time.

  

       

  

     |  

  (b)

     |  

  The following terms have the meaning set forth in the  sections set forth

    
---|---|--- 
   

  

       

  

     |  

  below:

    
---|--- 
   

  



  

       

  _Defined Term_

     |  

  _Location of Definition_

    
---|--- 
      

  Action

     |  

  3.19

    
      

  Acquisition Agreement

     |  

  7.04(c)

    
      

  Adverse Recommendation

     |  

  7.04(c)

    
      

  Agreement

     |  

  Preamble

    
      

  Appraisal Shares

     |  

  1.08(e)

    
      

  Bracco Imaging

     |  

  Recitals

    
      

  Break-Up Fee

     |  

  9.02(b)

    
      

  Certificate

     |  

  1.08(a)

    
      

  Certificate of Merger

     |  

  1.03

    
      

  CFIUS

     |  

  3.04

    
      

  Cimbar Agreement

     |  

  7.10

    
      

  Closing

     |  

  1.02

    
      

  Closing Date

     |  

  1.02

    
      

  COBRA

     |  

  6.01(c)

    
      

  Code

     |  

  2.07

    
      

  Company

     |  

  Preamble

    
      

  Company Board

     |  

  3.05

    
      

  Company Common Stock

     |  

  Recitals

    
      

  Company Disclosure Schedule

     |  

  Article 3

    
      

  Company Option

     |  

  1.09(a)

    
      

  Company Option Plans

     |  

  3.06(a)(iv)

    
      

  Company Organizational Documents

     |  

  3.01

    
      

  Company Plans

     |  

  3.06(a)(v)

    
      

  Company Property

     |  

  3.20(c)(ix)

    
   

  



  



    

       

  

     |  

  61

    
---|--- 
   

  



     



  

       

  _Defined Term_

     |  

  _Location of Definition_

    
---|--- 
      

  Company Recommendation

     |  

  7.01(a)

    
      

  Company SEC Reports

     |  

  3.08(a)

    
      

  Company Stockholder Approval

     |  

  3.32

    
      

  Company Stockholders Meeting

     |  

  3.30

    
      

  Company Welfare Plans

     |  

  6.01(b)

    
      

  Confidentiality Agreement

     |  

  7.02(c)

    
      

  Continuing Employees

     |  

  6.01(a)

    
      

  Contract

     |  

  3.20(c)

    
      

  Costs

     |  

  6.02(a)

    
      

  Credit Facility

     |  

  7.09

    
      

  DDTC

     |  

  3.04

    
      

  DGCL

     |  

  1.01

    
      

  DOJ

     |  

  7.03(c)(i)

    
      

  Effective Time

     |  

  1.03

    
      

  Employee Benefit Plans

     |  

  3.21(a)

    
      

  ERISA Affiliate

     |  

  3.21(a)

    
      

  Exchange Act

     |  

  3.04

    
      

  Exchange Agent

     |  

  2.01

    
      

  Exchange Fund

     |  

  2.01

    
      

  Exon-Florio Provision

     |  

  3.04

    
      

  FDA

     |  

  3.04

    
      

  FDCA

     |  

  3.16(a)

    
      

  FTC

     |  

  7.03(c)(i)

    
      

  GPO

     |  

  3.20(c)(vi)

    
      

  HSR Act

     |  

  3.04

    
      

  Indemnified Parties

     |  

  6.02(a)

    
      

  Insurance Proceeds

     |  

  6.02(a)

    
      

  Intellectual Property

     |  

  3.14(a)

    
      

  ITAR

     |  

  3.04

    
      

  Joint Filing

     |  

  7.03(c)(iii)

    
      

  Lease

     |  

  3.20(c)(ix)(A)

    
      

  Leased Real Property

     |  

  3.20(c)(ix)(A)

    
      

  Licenses and Permits

     |  

  3.15(a)

    
      

  Materially Burdensome Condition

     |  

  7.03(d)

    
      

  Material Unregistered Intellectual Property

     |  

  3.14(a)

    
      

  Merger

     |  

  Recitals

    
      

  Merger Consideration

     |  

  Recitals

    
      

  Merger Sub

     |  

  Preamble

    
      

  Multiemployer Plan

     |  

  3.21(c)

    
      

  Notice of Superior Proposal

     |  

  7.04(c)(ii)

    
      

  Notice Period

     |  

  7.04(c)(ii)

    
      

  Order

     |  

  8.01(g)

    
      

  Outside Date

     |  

  9.01(b)(iii)

    
      

  Owned Real Property

     |  

  3.12(a)

    
   

  



  



    

       

  

     |  

  62

    
---|--- 
   

  



     



  

       

  _Defined Term_

     |  

  _Location of Definition_

    
---|--- 
      

  Parent

     |  

  Preamble

    
      

  Pension Plans

     |  

  3.21(a)

    
      

  Preferred Stock

     |  

  3.06(a)

    
      

  Products

     |  

  3.34

    
      

  Proxy Statement

     |  

  3.30

    
      

  Registered Intellectual Property

     |  

  3.14(a)

    
      

  Required Approvals

     |  

  3.04

    
      

  Sarbanes-Oxley Act

     |  

  3.08(a)

    
      

  SEC

     |  

  2.01

    
      

  Section 262

     |  

  1.08(e)

    
      

  Securities Act

     |  

  3.04

    
      

  Stockholders

     |  

  Recitals

    
      

  Subsequent Notice

     |  

  7.04(c)(ii)

    
      

  Subsequent Notice Period

     |  

  7.04(c)(ii)

    
      

  Surviving Corporation

     |  

  1.01

    
      

  Tyco Litigation

     |  

  3.19

    
      

  Tyco Litigation Documents

     |  

  7.07

    
      

  Treasury Regulations

     |  

  2.07

    
      

  Voting Agreement

     |  

  Recitals

    
      

  WARN

     |  

  3.25(c)

    
   

  

  

  



  

  **[** _ **Remainder of Page Intentionally Left  Blank]**_

  



    

       

  

     |  

  63

    
---|--- 
   

  



     

  IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be 
executed as of the date first above written.

  

  

  

  BRACCO DIAGNOSTICS, INC.

  

  

  

  By: /s/ Carlo Medici 
  ------------------------------------

  

       

  

     |  

  Name: Carlo Medici

    
---|--- 
   

  

       

  

     |  

  Title: President and CEO

    
---|--- 
   

  

  EAGLE ACQUISITION SUB, INC.

  

  By: /s/ Carlo Medici 
  ------------------------------------

  

       

  

     |  

  Name: Carlo Medici

    
---|--- 
   

  

       

  

     |  

  Title: President and CEO

    
---|--- 
   

  

  E-Z-EM, INC.

  

  By: /s/ Anthony A. Lombardo 
  ------------------------------------

  

       

  

     |  

  Name: Anthony A. Lombardo

    
---|--- 
   

  

       

  

     |  

  Title: President and CEO

    
---|--- 
   

  

  

  



  

  **Acknowledged and agreed solely with respect to Sections 4.08, 7.09 
10.11 and 10.03:**

  



  

BRACCO  IMAGING S.P.A.

  

By: /s/  Roberto Rettani 
  ------------------------------------

  

       

  

     |  

  Name: Roberto Rettani

    
---|--- 
   

  

       

  

     |  

  Title: Managing Director and CEO

    
---|--- 
   

  



  



  



    

       

  

     |  

  64

    
---|--- 
   

  



     

  _SCHEDULE I_

  



  

Joseph  A. Cacchioli

  

Peter  J. Graham

  

Anthony  A. Lombardo

  

Jeffrey  S. Peacock

  

Brad.  S. Schreck

  



  



    



 

       '

